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9Résumé destiné à un large public
Le système immunitaire associé aux muqueuses gastro-intestinales doit être capable de
protéger notre organisme contre l’invasion de pathogènes. Parallèlement, il doit identifier en
tant que tels, des composés inoffensifs comme la nourriture ou les milliards de bactéries qui
résident dans notre intestin. Le travail présenté ici aborde ces deux aspects essentiels au bon
fonctionnement de notre muqueuse intestinale.
Dans une première partie, la protéine nommée pièce sécrétoire a été étudiée pour ses
propriétés protectrices contre le pathogène viral rotavirus. Le rôle de la pièce sécrétoire est de
transporter les anticorps que nous produisons vers la surface des muqueuses. En dehors de
cette fonction bien connue, il se peut que cette protéine soit également capable de protéger
notre organisme contre certains virus. L’hypothèse de travail était donc que la pièce sécrétoire
se lie directement au virus, l’empêchant ainsi d’infecter des cellules épithéliales de l’intestin.
En utilisant différentes techniques biochimiques, cette hypothèse s’est révélée fausse car
aucune interaction entre la pièce sécrétoire et le virus n’a pu être observée, et logiquement,
aucune protection n’a pu prendre place. En revanche, la pièce sécrétoire se lie à d’autres
structures pathogéniques et permet ainsi de neutraliser leurs effets néfastes. La pièce
sécrétoire participe donc activement à la protection de nos muqueuses, en plus de son rôle de
transporteur.
La deuxième partie de ce travail avait pour sujet les réactions inappropriées que le système
immunitaire induit parfois contre un aliment, ou, autrement dit, les allergies alimentaires. Un
modèle d’allergie alimentaire à donc été développé chez la souris et a permis de mesurer
plusieurs symptômes et facteurs liés à l’allergie. Puis, ce modèle a été utilisé afin de tester les
effets bénéfiques d’une bactérie lactique, dite probiotique, sur le développement de l’allergie.
Il a été observé que, sous certaines circonstances, l’administration de la bactérie lactique
protégeait entièrement les souris contre les réactions allergiques. L’effet bénéfique dépend
donc du probiotique mais également d’autres facteurs encore inconnus à ce jour. Cette étude
ouvre la voie sur la compréhension des mécanismes liés aux allergies alimentaires et sur
l’impact que peuvent avoir les bactéries probiotiques sur cette maladie.
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Résumé
Le système immunitaire associé aux muqueuses intestinales doit être capable de
différencier les antigènes inoffensifs tels que la nourriture ou les bactéries commensales des
microorganismes potentiellement dangereux. Cet aspect est essentiel pour le maintien de
l’homéostase intestinale et fait l’objet du travail présenté ici.
Dans un premier projet, les propriétés protectrices de la protéine appelée pièce sécrétoire
(SC) ont été étudiées. SC est une protéine connue pour le transport des immunoglobulines à la
surface des muqueuses. Cette protéine est fortement glycosylée par des sucres complexes, ce
qui nous a mené à postuler que SC puisse interagir avec le pathogène rotavirus. Cette
hypothèse était soutenue par le fait que ce virus adhère aux cellules épithéliales par des
résidus glycosylés. Des analyses biochimiques et biologiques ont démontré qu’aucune
interaction entre SC et le virus ne prenait place, et que par conséquent SC n’offrait aucune
protection contre ce pathogène. En revanche, SC interagit avec d’autres structures
pathogéniques, comme la toxine A de Clostridium difficile, et la molécule d’adhésion
intimine de la bactérie entéropathogène Escherichia coli. La liaison se fait par l’intermédiaire
des sucres et confère ainsi une protection contre ces pathogènes. Ainsi, SC a été identifié
comme agent neutralisant au niveau de l’intestin.
La deuxième partie de ce travail abordait le sujet des allergies alimentaires, et avait pour
but de tester les effets bénéfiques potentiels d’une bactérie probiotique, Lactobacillus
paracasei NCC2461, contre les réactions allergiques. Un modèle murin d’allergie alimentaire
a été mis au point, permettant de mesurer des immunoglobulines E, des symptômes
allergiques, et la dégranulation de mastocytes. Lorsque le probiotique a été administré aux
souris, celles-ci ont été complètement protégées des réactions allergiques dans une première
expérience. Cependant, cette protection n’a pas été reproduite et suggère que des facteurs
environnementaux encore inconnus sont critiques pour que le probiotique agisse
positivement. Ce travail a permis de mettre en évidence la complexité de l’approche des
traitements liés aux probiotiques et ouvre la voie sur la compréhension des mécanismes liés à
l’allergie.
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Abstract
The mucosal immune system associated to the gastrointestinal mucosa must efficiently
distinguish between innocuous antigens, such as food proteins and commensal bacteria and
potentially infectious agents. The work presented here deals with these two essential aspects
guaranteeing intestinal homeostasis.
In the first part of this work, the protective properties of secretory component (SC) toward
the pathogen rotavirus were investigated. SC, which allows the transport of polymeric
immunoglobulins (Ig) to mucosal surfaces, is highly glycosylated with complex glycan
structures. The abundance and the nature of these carbohydrates led us to speculate that SC
might interact with rotavirus, which is known to bind target cells with glycan receptors. Using
various biological and biochemical techniques, we demonstrated that SC did not interact with
rotaviruses, nor protected epithelial cells from infection. However, SC was shown to bind to
Clostridium difficile toxin A and to the enteropathogenic Echerischia coli adhesion molecule
intimin in a glycan-dependent fashion. These interactions allow in vitro protection of
epithelial cells using physiological concentrations of SC. These data identify SC as a
microbial scavenger at mucosal surfaces, and in the context of secretory IgA, further enhance
the neutralising properties of the complex.
The second project was inscribed in the domain of food allergy and aimed to test the
modulatory functions of a probiotic strain of Lactobacillus paracasei toward allergic
reactions. A model of food-mediated allergy was developed in the mouse using mucosal
sensitisation. Several parameters associated to allergy were quantified after allergen
challenge, and included allergen-specific IgE, allergic signs like diarrhea and temperature
drop, and degranulation of mast cells. Administration of the probiotic strain was shown to
completely protect mice from allergic reactions. However, these data were not reproduced,
suggesting that unknown environmental factors are required so that protection mediated by
the probiotic strain occurs. This study paves the way to the understanding of the mechanisms
associated to allergy, and highlights the tremendous complexity that probiotic treatments will
have to face.
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Chapter 1                             
Introduction
1.1 The gastrointestinal tract
The gastrointestinal (GI) tract is a very complex ecosystem where multiple partners are
constantly interacting together. On one hand, the host and its mucosal immune system need to
acquire nutrients and to protect itself against toxins and invading organisms. On the other
hand, the residing intestinal microbiota are living and proliferating in the constantly renewed
environment of the GI. And finally, the ingested food comprising loads of antigens need to be
processed appropriately for the good functioning of both living partners. These latter have
evolved together to live side by side, and constitute a fascinating complex representing the
focus of this work.
1.1.1 Anatomy and functions of the GI tract
The primary function of the GI tract is to digest and absorb nutrients necessary for the
good functioning of the organism, and to finally excrete undigested components. The human
GI tract is divided in an upper and lower part represented in figure 1. The cavity of the GI
tract is covered by the single layer of epithelial cells, and together with the underlying tissues,
constitutes the gastrointestinal mucosa. The surface of the intestinal mucosa is very large, due
to the numerous intestinal villosities and the microvilli present on the apical side of epithelial
cells (also named brush border). The total surface of the intestinal tract is estimated to be
more than 300 m2 for an adult human1, and thus guarantees efficient absorption of nutrients.
The upper GI tract allows the first step of digestion needed to absorb nutrients. Within the
oral cavity, aliments are destroyed in smaller fragments, masticated and mixed with the saliva
to form a bolus easy to swallow. Saliva is secreted from salivary glands and contains
electrolytes, mucus, antimicrobial molecules and enzymes (α-amylase, lipases, lysozyme),
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which start the digestion of macromolecules. The bolus is subsequently swallowed through
the esophagus to reach the stomach via peristaltic movements. The stomach is a cavity where
food is stored and homogenised before it enters the duodenum. The pH of the stomach is
extremely acid; it ranges from 1-3 depending on the species, age, food intake, and drug
consumption. This acidity allows breakdown of macromolecules and has in itself a strong
antimicrobial effect, which protects efficiently the organism of ingested microorganisms.
Besides the HCl responsible for low pH, the gastric acid secretions produced by the stomach
epithelium contain pepsin, a protease efficient a low pH, which hydrolyses proteins into
polypeptides. The stomach epithelium is preserved from auto-digestion through the intensive
secretion of mucins, large glycoproteins forming a protective hydrophobic gel.
Figure 1: The human gastrointestinal (GI) tract and associated organs.
The upper GI part consists of the oral cavity, the pharynx, the esophagus and the
stomach. The lower part comprises the small intestine (duodenum, jejunum and
ileum), the colon, the rectum and the anus. Glands and organs producing digestive
secretions are also shown. Taken and adapted from wikipedia.
(http://en.wikipedia.org/wiki/Gastrointestinal_tract)
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Although amylase, lipase and subsequently pepsin allow the first steps of the digestion of
food products, the main digestion and absorption takes place within the lumen of the small
intestine. The acidic alimentary bolus enters the duodenum, where it is mixed with pancreatic
secretions and the bile produced in the gall bladder and the liver. In addition to HCO3-
allowing pH neutralisation, pancreatic secretions and the bile contain biliary salts and
enzymes (or their precursors), which hydrolyse carbohydrates, proteins and lipids into small
absorbable units (mono or disaccharides, amino acids, di- or tri-peptides, glycerol, cholesterol
and fatty acids). The majority of the absorption takes place in the jejunum and the ileum,
through specialised epithelial cells named enterocytes. The absorption of digested nutrients is
mediated by many distinct mechanisms; diffusion, symport, specific transporter-mediated
uptake and endocytose. Final digestion of the nutrients takes place in the endocytic vesicules,
which also contain digestive enzymes. The nutriment digests are then swept away via the
blood capillaries and converge to the hepatic vein. The nutrients are then processed in the
liver, the main organ for metabolic conversions. Undigested foods, on the other hand, are
pushed by peristaltic movements to the large intestine. The large intestine contains a very
large community of resident bacteria, which allows final digestion of products and production
of essential molecules. The nature and functions of the commensal microbiota will be
discussed in details in section 1.1.3. The major function of the colon is to re-absorb the
important liquid quantities that are produced throughout the GI tract. Together with the small
intestine, the colon re-absorbs 90% of the water that entered the GI tract (i.e. 1-2 l drink, 1.5 l
saliva, 2.5 l gastric secretions, 1.5 l pancreatic secretions, 0.5 l bile and 1 l intestinal solution;
daily values). The fecal content is little by little dehydrated to form faeces that will finally be
excreted through the rectum and anus.
1.1.2 The mucosal epithelium
The mucosal epithelium is constituted of a single layer of fragile epithelial cells joined
together by tight junctions (TJ), adherent junctions and desmosomes. TJ, the most apical
complex, tightly regulates paracellular permeability. The TJ complex comprise about 40
proteins including, for example, Zonula Occludens (ZO)-1, ZO-2, and ZO-3 proteins,
occludin, claudins, members of the membrane-associated guanylate kinase protein family, and
several unidentified phosphoproteins2. The regulation of paracellular permeability is a
dynamic process, which is flexible to environmental changes3.
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Epithelial cells are divided in two main cell lineages: the enterocyte or absorptive lineage
and the secretory lineage (figure 2). Enterocytes represent more than 80% of epithelial cells in
the small intestine, whereas secretory cells are more dispersed. To date, 3 types of secretory
cells have been identified; Goblet cells, distributed between enterocytes along the villi, are
secreting a vast variety of mucins4, constituting the mucus coat; Enteroendocrine cells are also
distributed between enterocytes and secrete hormones, e.g., serotonine, substance P, or
secretin; Paneth cells reside at the crypt bottom and secrete antimicrobial agents such as
cryptdins and defensins together with lysozyme to control the microbial content of the
intestine5. All these cells originate from stem cells present in the crypts6. Enterocytes, goblet
and endocrine cells migrate upwards to the villus tip during their differentiations7. Once at the
villous tip they undergo apoptosis and are exfoliated from the villous8. The epithelium of the
Figure 2: The mucosal epithelium renewal
Epithelial cells derives from stem cells (dark blue) located in the crypts. The
differentiation of enterocytes (light blue) and Goblet cells (orange) occurs during the
migration to the tip of the villus, where they undergo apoptosis after a few days and
are finally exfoliated. Goblet cells continuously secrete mucins, the constituent of
the mucus coat. Paneth cells, in contrast, differentiate downwards to the bottom of
the crypt and secrete antimicrobial peptides. Taken and adapted from Reya and
Clevers (2005).
19
villi is thus constantly renewed (every 3-4 days), what limits the entry of adherent
microorganisms. In contrast, Paneth cells differentiate during downwards migration to the
crypt base, where they reside for an average of 23 days before being removed by
phagocytosis9.
The intestinal epithelium is covered by discontinuous, thinner mucus layer, produced by
goblet cells. Mucus thicknesses differ in the large intestine, gradually increasing from the
colon to the rectum. The mucus coat is composed of large glycoproteins (named mucins) of
molecular weights ranging from one to several millions Daltons. Mucins are made up of
carbohydrate side chains (70-80%) bound to a protein skeleton. The mucus coat provides a
filter overlying the epithelium surfaces, which prevents large molecules and bacteria to reach
the epithelium surface, whereas small molecules (nutrients) can freely diffuse to reach the
apical membrane of enterocytes. The viscosity of the mucus layer decreases with the distance
to the membrane, due to the absorption of water by the enterocytes10. Mucus distant from the
villus offers an ecological niche for intestinal bacteria, providing them with anchor proteins,
as well as nutrients. The continuous release of mucus into the lumen, together with enterocyte
renewal, generates a stream that draws luminal contents away from the epithelium, and thus
confer an efficient defence mechanism toward pathogenic bacteria, viruses and toxins.
Besides the mucus secreted, microvilli of enterocytes contain large, negatively charged
membrane glycoproteins that form a continuous, filamentous brush border glycocalyx11. This
thick layer allows adsorption of pancreatic enzymes responsible for terminal digestion.
Furthermore, it limits the uptake of bacteria, viruses or macromolecular aggregates within the
enterocyte12.
Despite all measures taken to limit the access of microorganisms and large molecules at
the apical surface of cells and further entry inside the body, macromolecular transport of
protein can however take place through (transcellular transport) or between (paracellular
transport) enterocytes13. In parallel, pathogenic microorgansisms possess features to bypass
the intestinal barrier and are thus able to provoke infection.
1.1.3 Commensal microbiota of the GI tract
Like all other species on earth, humans have been associated with a complex bacterial
community throughout their evolution. The specialised microbes inhabiting the surface of our
GI tract outnumber human cells by a factor of ten14. It is estimated that 1014 microbes are
housed in every human being and this impressive quantity also confers a huge biodiversity, as
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these microbes are distributed within hundreds of species and thousands of strains15. These
estimations were based on 16srRNA sequence analyses, and although more than 400 species
can already be cultured in laboratories, they were estimated to represent only 50% of the total
resident community16. Bacteria dominate the human gastrointestinal population; however,
fungi and archaea are also resident, but comprise less than 0.05% and 1% of the community,
respectively. This community is not only a number of cells, but possesses and regulates a
tremendous amount of genes. Indeed the number of bacterial genes is about 100 times
numerically superior to ours. This genetic diversity offers therefore a metabolic richness of
which we benefit every day14. Commensal bacteria have been recognised to participate in the
degradation of indigestible nutrients, to produce vitamins (K and B), butyrate and
propionate17. Vitamins are essential in many metabolic pathways, such as coagulation process
and constitute essential co-enzyme factors. Commensals also contribute to the gut maturation
and regulation of epithelial proliferation18, and protect the host from pathogenic infection by
competition for resources19.
The distribution of the bacterial community is not homogenous along the GI tract. The
mouth is colonised by thousands of species, of which Streptococcus sp. are numerically
dominant. Multi-species biofilms are typically found in the mouth20. Esophagus and stomach
are not really colonised by bacteria, but species, probably ingested with food, can be detected.
Gastric acidity kills many ingested microbes and prevents most of bacterial colonisation. The
only convincing evidence of stomacal resident bacteria is the pathogenic strain Helicobacter
pylori. Within the small intestine, the population of resident bacteria increase from 104/mg
(wet content) in the duodenum to 107/mg in the ileum, with an increasing proportion of
anaerobic species. Lactobacilli, Coliforms, Enterococci and Bacteroides are the most
represented species. The highest diversity is however reached within the colon, where
populations get to 1010-11/mg due to the hydrolysis of polysaccharides and carbohydrate
fermentation favouring growth of bacteria. Actually, the time of residence is greater in the
colon than in the small intestine, as peristaltic movements are slow. More than 800 different
species reside in the colon, and most are obligate anaerobes of Bacteroides and Firmicutes
phyla21 or unknown species.
The establishment of the intestinal bacterial communities start after birth, and is a long
term process which require years to reach an adult-like microbiota22,23. From the sterile uterine
stage, the GI tract is rapidly colonised by vaginal and environmental microbiota, which differ
according to the way of delivery, feeding practice, antibiotic use and hygienic environment24.
Bifidobacteria and Bacteroides are numerically dominant in the gut of infants during the first
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months of life. Intestinal microbiota gets more and more complex with time; Lactobacilli,
Eubacteria, Clostridia, and Fusobacteria increase to finally reach an adult distribution25,26.
The composition of the predominant bacterial community is host-specific and stable over time
in healthy adult individuals27. However, differences in microbiota composition between
humans are more important than first expected as the biochemistry of the GI tract follows the
same patterns. Surprisingly, based on molecular biology analyses, it appears that the
communities are about 30 % dissimilar between humans of the same ethny28. As such
different microbiota confer the same functionality, this implies an extensive metabolic
redundancy in the bowel bacterial community; more than one species can carry out a
particular metabolic process23.
Many factors are know to influence the intestinal microbiota29; the host genotype is
crucial, if not the most influencing parameter, as monozygotic twins geographically separated
share a greater intestinal microbiota similarity than two independent persons living in the
same environment30,31. The diet also influences the intestinal microbiota by determining the
niche for bacterial species. Transitions from breast milk to formulae and finally to solid food
impact on the microbial community composition19. In addition, a carbohydrate-rich diet has
been shown to modify the composition of the microbiota32. Besides these “external” factors,
the intestinal community modulates its composition by itself through microbial interactions.
Interactions among bacteria can be either cooperative (hydrolysis of complex carbohydrates
and sequential fermentation or exchange of growth factors33,34) or competitive (resource
competition, itself shaped by the diet35,36 and the production of bacteriocins37). Moreover,
phages are abundant and diverse in human faeces and can promote population diversity38.
To conclude, the presence of this tremendous amount of commensal bacteria is
unavoidable and functionally essential, but must be however tightly regulated and restricted to
the luminal content of the GI to avoid spreading of bacteria within the body. The architecture
of the GI tract already prevents most of the interaction between commensal micorbiota and
epithelial cells. Nevertheless, the organism must be able to protect itself from the invasion of
commensals and also from pathogenic mircoorganisms, toxins and thus to induce an immune
response. The mucosal immune system has this difficult task to induce appropriate immune
responses toward pathogenic or invasive microorganisms, but without triggering a permanent
inflammation at mucosal surfaces, which are constantly exposed to foreign antigens.
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1.2 The mucosal immune system
The mucosal associated lymphoid tissues comprise all lymphoid structures associated with
mucosae (i.e. the GI tract, the naso-pharynx, the lungs, and the uro-genital tract). As this work
is restricted to the intestinal mucosa environment, the gastrointestinal associated lymphoid
tissue is described exclusively below.
1.2.1 Definition of gastrointestinal associated lymphoid tissues (GALT)
The mucosal immune system can be roughly divided in inductive and effector sites.
Sampling of antigens from mucosal surfaces and further presentation to cognate naïve T and
B lymphocytes take place in the inductive sites. Effector sites, on the other hand, consist of
areas where immune cells exert their protective functions such as, the production of cytokines
and polymeric IgA (pIgA). Inductive sites in the gastrointestinal tract are denoted as
gastrointestinal associated lymphoid tissues (GALT) and comprise the Peyer’s patches (PP),
isolated lymphoid follicles (ILF), and the appendix. Mesenteric lymph nodes (MLN), the
mucosa-draining nodes, are not comprised in the GALT as they do not directely sample
antigens39, but play a crucial role in the activation and amplification of the mucosal immune
response.
The lamina propria (LP) of the GI tract represents the major effector site of the intestinal
mucosal immune system and is sometimes considered to be part of the GALT40 and
sometimes not39 depending of the author’s opinion about the capacity of immunological cells
residing in the LP to initiate an immune response. The LP contains many immunological
cells; the majority of LP lymphocytes (LPL) are plasma cells, which secrete polymeric IgA
(IgA; 70-90% of the LP resident plasma cells). In addition, CD4+ T cell, CD8+ T cells, DCs,
macrophages, monocytes and mast cells are spread throughout the LP. An important
population of heterogeneous CD8+ T cells are also found between epithelial cells and are thus
named intraepithelial lymphocytes (IEL). The role of these cells remains unclear as they have
been shown to exert cytotoxic activity against infiltrating pathogens, to control the
proliferation of tumor cells41 and in parallel, they display regulatory functions42. Although
DCs were shown to extend their dendrites in the intestine to sample antigens43, the strict
demonstration that DCs together with T cells residing in the LP can initiate an immune
response remains to be done. It is clear however, that expansion and terminal differentiation
of immune cells take place in the LP.
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Peyer’s patches were first described in 1677 in the sheep by Peyer44, and are defined as
aggregates of lymphoid follicles dispatched along the small intestine (Figure 3A). PPs are
found in most mammalian species studied; mice harbor between 8 and 10 PPs, whereas
humans posses about 100 PPs along the ileum45. Development of PPs takes place during
embryogenesis, and further increase in size upon microbial stimulation after birth. These
organised lymphoid structures are covered by the follicular associated epithelium (FAE),
which derives from the stem cells of the crypts. In contrast to the absorptive and digestive
epithelium, FAE does not contain goblets cells and is therefore not covered by the mucus coat
described above46. Instead, FAE displays very specialised epithelial cells named microfold
(M) cells47, which constantly sample intestinal antigens by endocytosis48. The basolateral side
of these cells is deeply invaginated in order to form an intraepithelial pocket that rapidly
brings the absorbed antigen to the immune cells. Although necessary to sample antigens from
the lumen, M cells can be considered as the Achill’s heel of mucosal immune system, as
many pathogens such as Salmonella49 or Shigella50 species target these cells to infiltrate the
host.
Microscopic analyses of a lymphoid follicle reveals that it is composed of four distinct
Figure 3: Peyer’s patches (PP) organisation
A, Ileum cross section stained with eosine hematoxyline showing the organisation of
a PP. A single PP is constituted of several follicules. The follicule in the rectangle is
further enlarged schematically in B. Taken and adapted from the Histology learning
system (www.bu.edu/histology/m/index.htm). B, Schematic representation of a
transversal section of one follicule from a PP. The follicular-associated epithelium
(FAE) covers the surface of the follicule and contains microfold (M) cells. The four
regions constituting the follicule are depicted as the subepithelial dome (SED) region,
the germinal center (GC), the Corona, and the interfollicular region (IFR). Taken and
adapted form Kraehenbuhl and Neutra. (1992).
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zones named as the subepithelial dome (SED), the germinal center (GC), the corona and the
interfollicular region (IFR)51 (Figure 3B). Spatial distribution of the immune cells in PPs is
well defined. The SED region mainly contains immature dendritic cells (DCs) and
macrophages52, which are strategically positioned under M cells to capture antigens. IFRs are
composed of CD4+ and CD8+ T cells, plasma cells, macrophages and DCs52. The corona
surrounds the GC and is composed of DC and CD4+ T cells. GC situated in the middle of the
follicle contains mainly B cells, which are activated and undergo somatic hypermutation53.
ILFs display the same organisation pattern, but are smaller; the number of follicle per ILF
is reduced and can therefore not be seen macroscopically as PPs are54. In contrast to PP,
development of ILF takes place after birth upon microbial challenge. ILF are important for
antigen sampling and induction of immune response, as they have been estimated to be at
least 30’000 along the small intestine55,56.
Additional organised lymphoid structures have been described in the mouse, such as
cryptopatches (CP). CP are aggregates of undifferentiated immune cells in the crypts, which
were originally thought to be the origin of IEL, but recent data question this notion, and they
are currently thought to be precursor of ILF57. It is however clear that CPs do not generate and
activate B cells as PP and ILF do.
1.2.2 Induction of a specific mucosal immune response
The induction of specific immune responses in the intestinal mucosa can take place
through different routes, as depicted in figure 4. The original and extensively described
sampling way is through the M cells of PPs58. This concept is now extended to ILFs, which
display the same sampling and inductive properties. M cells, which cover PPs and ILFs,
continuously sample antigens from the lumen and transmit them to the underlying DCs. In
addition to this sampling mechanism, DCs residing in the LP can also sample antigens from
the lumen by extending their dendrites through the epithelium43,59. It is not clear yet whether
antigen-loaded LP DCs migrate to MLN to induce an immune response or whether they
remain in the LP and activate T and B cells residing there. However, DCs from inductive sites
loaded with food antigens60 or with commensal bacteria61 migrate from PPs to MLN via
lymphatic vessels.
Subsequent activation of T and B cells takes place directly in PPs but is thought to happen
preferentially in MLN. Mucosal DCs present antigens to T and B cells on major
histocompatibility complex class II (MHC II) molecules together with co-stimulatory
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molecules, such as CD80, CD86, OX40 and CD40, what results in the activation of
lymphocytes. The surrounding cytokines (IL-4, IL-5, IL-10 and TGF-β62) promote IgA class
switch in B cells. Moreover, imprinting mechanisms takes place in PPs and MLN in order to
allow lymphocytes to home back to mucosal tissues63. Expression of α4β7 integrins by
lymphocytes is induced exclusively by mucosal DCs, and was shown to rely on a retinoic
acid-dependent pathway64.
After being primed to become effector or memory cells, B and T cells migrate from the
PP, ILF and MLN to the thoracic duct via efferent lymph vessels and are subsequently
distributed throughout the body by peripheral blood vessels. Cells will then home back to
mucosal surfaces to exert their immune functions. Homing mechanisms rely on the interaction
of α 4β7 integrins on the surface of mucosally-primed cells with molecular addressin cell
adhesion molecule-1 (MadCAM-1) expressed on the intestinal endothelial cells65. Expression
of the chemokine receptor 9 (CCR9) on T cells is also critical for T cell homing in the small
intestine. CCR9 interacts with the chemokine (C-C motif) ligand 25 (CCL25, also known as
TREK) expressed by epithelial cells of the small intestine66.
Upon arrival in the effector sites, IgA class switching in B cells is further strengthened
through the cytokines present in the LP. IL-5, TGF-β67, IL-4 as well as IL-10 are produced by
DCs, macrophages and T cells and favour the production of pIgA. These cytokines, and more
especially IL-10 and TGF-β promote a “hyporesponsive” environment, which contributes to
maintenance of the intestinal homeostasis. Epithelial cells were also shown to play an indirect
role in the final differentiation of immune cells, by secreting factors influencing the immune
response. Thymic stromal lymphopoietin (TSLP)68 and a proliferation inducing ligand
(APRIL) are such factors that are produced by epithelial cells after bacterial stimulation
through toll-like receptors (TLR)69. APRIL was shown to direct IgA2 class switching in the
colon. Finally, pIgA molecules are transported from the LP to the lumen via the polymeric Ig
receptor (pIgR), to exert their neutralizing functions.
In addition to the two sampling pathways described above, enterocytes were also shown to
present antigens on MHC II molecules to CD4+ T cells70,71. However, under normal conditions
(i.e. without inflammation), enterocytes do not express co-stimulatory molecules such as
CD80 and CD86 and thus cannot activate naïve T cells. Anergy of the cognate T cell
preferentially takes place, what is required to induce oral tolerance13, the topic of the next
section.
26
 Besides the conventional IgA-secreting B cells, CD5+ cells named B1 cells were
identified in the peritoneal cavity. These cells seem to be the precursor of about 40% of the
IgA secreting cells present in the LP, at least in the mouse72. Further experiments revealed
that B1 cells are the major precursor of microbiota-specific IgA secreting cells, and that they
are induced “naturally” by the presence of the microbiota in a T cell independent-fashion73.
Thus, an alternative pathway also exists to induce the production of IgA.
To summarise, sampling of intestinal antigens can be performed via i) M cells, ii) LP DCs
and iii) enterocytes. Further activation of T and B cells takes place in PPs and MLN, and
Figure 4: Schematic representation of the induction of an immune response at
the intestinal level
Antigens are sampled by M cells of PPs and ILFs (1) or by DCs residing in the LP
(2). Subsequent presentation of the antigen on MHC II molecules to naïve T and B
cells takes place either in PPs or when cells have migrated via the lymph vessels, in
MLN. T and B cells receive stimuli in the MLN that promote the expression of the
adhesion molecule α4β7 integrin, which allows homing to mucosal tissues. Cells are
then spread throughout the body by peripheral blood and home back to the intestine.
Interaction between α4β7 integrin and MadCAM-1 (not represented in the scheme)
allows extravasation of lymphocytes to the LP. Terminal differentiation of
lymphocytes occurs in the LP and promotes the production of IgA by B cells and
generally a regulatory profile of T cells. Polymeric IgA and IgM are secreted to
mucosal surfaces after transport by polymeric Ig receptor (pIgR). In addition,
enterocytes also present antigens to the underlying lymphocytes (3), a process
important in the induction of oral tolerance. Taken and adapted from Brandtzaeg and
Pabst (2004).
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possibly in the LP directly. Then, lymphocytes home back to the intestinal mucosa where
final differentiation takes place so that they can exert their functions efficiently.
1.2.3 Oral tolerance versus immunity
Food antigens and commensal microbiota constitute the majority of the antigenic load in
the intestine. Thus, to avoid uncontrolled inflammation, the “default” reaction of the immune
system consist in systemic unresponsiveness, a phenomenon known as oral tolerance74.
Ignorance, on the other hand, describes the situation where the antigen is never seen by the
immune system. If the phenomenon of oral tolerance has been described more than 60 years
ago, the associated immunological mechanisms are not yet fully understood. Two major
mechanisms leading to oral tolerance have been described depending on the dose of antigen
administered orally. It was thus demonstrated that upon administration of a high dose (5-10
mg) of antigen, oral tolerance is induced by T cell deletion and T cell anergy75. On the other
hand, repetitive administrations of low dose (1 mg) favour active suppression mediated by
regulatory T cells76. T cell deletion and T cell anergy is mediated by the induction of
apoptosis in a Fas-dependent manner77. It is believed that presentation of the antigen by
antigen presenting cells (APC), such as DCs and enterocytes, in absence of co-stimulatory
molecules (inflammatory cytokines and CD80/86-CD28 interaction) leads to apoptosis of the
cognate T cell. Oral tolerance induced with low dose of antigen was demonstrated to generate
regulatory T cells, which can be divided roughly in 3 different subtypes, Th3 cells77, TR1
cells78 and CD4+CD25+ T cells, which express specifically the transcription factor forkhead
box protein 3 (FoxP3) abbreviated here as Treg79. To date, the signals required to induce
deletion or defined regulatory T subtype is largely unidentified in the intestinal mucosa,
except that absence of inflammatory co-stimulatory molecules is imperative. Recent papers
showed that mucosal CD103+ DCs convert T cells in Treg (FoxP3+) cells into a retinoic acid-
and TGF-β-dependent pathway80-82.
The different subsets of regulatory T cells all aim to suppress immune reactions but act in
distinct manners. Th3 cells secrete mainly TGF-β, which in turn helps B lymphocytes to
secrete IgA locally. Additionally, TGF-β inhibits the proliferation of Th1 and Th2 cells, and
also promotes the differentiation of another subset of regulatory T cells, the CD4+CD25+
FoxP3+ Treg. TR1 cells secrete IL-10, which suppresses antigen-specific immune responses.
Finally, CD4+CD25+ FoxP3+ Treg, are thought to suppress immune response by cell-cell
contact in a membranar TGF-β and CTLA-4-dependent fashion83.
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Although identified using different antigen doses, T cell deletion and induction of
regulatory T cells probably act simultaneously and contribute to the general state of
unresponsiveness critical for intestinal homeostasis. However, in case of pathogenic
infections or in the presence of toxin, the mucosal immune system needs to induce a
protective immune response. In such cases, activation is characterised by the induction of
Th1, Th2 or the recently described Th17 cells, depending on conditions and pathogens.
How does the immune system discriminate between innocuous and harmful antigens? It is
believed that intestinal DCs play a crucial role in the decision to induce either oral tolerance
or immunity. DCs residing in the intestinal mucosa (in inductive and effector sites) are in a
“quiescent” or “immature” state. They do not express CD80 and CD86 costimulatory
molecules needed to activate effector T cells, thus the “default” response is oral tolerance.
Different subsets of intestinal DCs have been described, but do probably not arise from
different cell lineages. It is more likely that the “quiescent” state of DCs is defined by the
intestinal micro-environnement84. High concentrations of regulatory cytokines (TGF-ß and
IL-10) are present in the LP and thus preserve DCs from activation. Epithelial cells also play
a central role in the education of DCs and thus the immune response subsequently generated.
TSLP, a cytokine produced by epithelial cells upon microbial stimulation, leads under defined
concentrations to non-inflammatory DCs68. This immature state does however not prevent
DCs to “sense” the environment via pattern recognition receptors, such as TLR, which
recognise the collectively named pathogen-associated molecular patterns. To date more than
10 TLRs have been identified and together with nucleotide-binding oligomerisation domain
(NOD) proteins, they recognise a large number of bacterial motifs. Upon activation of their
TLR, DCs start to express co-stimulatory molecules and inflammatory cytokines, what leads
to differentiation of naïve T cells into effector Th1, Th2 and Th17 cells. Factors expressed by
activated DCs that lead to differentiation of each subtype of T cell subsets remain poorly
defined. Moreover, the fact that commensal bacteria are also recognised by TLRs but, in
contrast to pathogenic bacteria, do not induce an inflammatory response, is still not
understood. Part of the answer might be that, for the most part, commensals do not gain
access to the intestinal mucosa due to the physical barrier mentioned previously, but the
explanation cannot lie simply in physical exclusion. This emphasises that others and still
unknown signals are involved in the tuning of the delicate balance between oral tolerance or
immunity. Indeed, defects in oral tolerance can lead to allergic disorders like food allergy, and
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similarly, an excessive pro-inflammatory immune response toward commensals is observed in
the case of inflammatory bowel diseases.
To conclude, whether the mucosal immune system deals with protection against
pathogens, or the limitation of the entry of commensal bacteria, or occasionally in the case of
oral tolerance85, it eventually induces the production of the effector molecule secretory IgA
(SIgA). SIgA properties and functions are discussed in the next section.
1.2.4 Structural properties and multi-functionality of SIgA
The specific immune response at mucosal surfaces is characterized by the production of
SIgA58, in contrast to the systemic compartment, where IgGs are dominantly produced.
Indeed, mucosal surfaces contain a predominance of 70-90% of IgA-secreting plasma cells86,
which under normal conditions produce mainly pIgA. Considering the area of intestinal
mucosal surfaces (300 m2) and the number of IgA-secreting cells, it was estimated that the
daily production of IgA in human reaches as much as 60 mg/kg87, and makes IgA the most
produced antibody isotype.
IgA molecules synthesised by B cells at mucosal surfaces are mainly produced in a
polymeric form composed of 2 or 4 IgA molecules (pIgA), covalently linked together with the
joining (J) chain88. The J chain is a small 15-kDa glycoprotein with 8 cysteine residues among
which, two (Cys 15 and Cys 69) are involved in the formation of disulfide bridges with the α-
chains89. The presence of the J chain allows formation of polymers of IgA, (although not
stricktly necessary90), and most importantly, mediates interaction of the macromolecule to its
transporter, the polymeric Ig receptor (pIgR). The pIgR is a transmembranar glycoprotein
expressed at the basolateral surface of enterocytes, which mediates selective transport of pIgA
from the LP to the lumen. Only polymeric Ig (mainly pIgA and, to a lesser extent, pIgM) can
bind pIgR. The complex resulting from this association is then transcytosed and delivered to
the apical surface. A non-identified protease cleaves the receptor and releases in secretion
SIgA constituted of the N-terminal extracellular part of the pIgR, referred as secretory
component (SC), in combination with pIgA. Ultimately, SIgA is thus composed of 2-4 IgA,
one J chain, and SC and is schematically represented in figure 5. The protein SC will be the
object of the next section.
Humans IgA are found in two different subclasses; IgA1, which displays a long flexible
hinge region91 and IgA2 whose short hinge region and glycosylation pattern makes it more
resistant to proteases92,93. Although more susceptible, IgA1 is predominantly secreted in the
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upper part of the GI tract; the ratio IgA1/IgA2 is however inverted in favor of IgA2 within the
colon94, where epithelial cells induce B cells to produce mainly IgA269. Much less IgA are
found in the circulation, where IgA1 is dominantly produced in its monomeric form. IgA is
considered as a “non-inlammatory” Ig in that it does not activate the complement through the
classical pathway94. However, it seems to be possible through the alternative pathways95, and
recent data demonstrated that the capacity of IgA to trigger inflammatory or inhibitory
responses through FcαRI relies on its aggregation state96.
SIgA molecules possess many protective roles at mucosal surfaces. SIgA neutralises
antigens within the lumen and thus prevents their interaction with mucosal surfaces, a process
known as immune exclusion97. The complex antigen-SIgA is trapped within the mucus coat
and subsequently degraded by proteases or washed out by peristaltic movements. The
neutralising properties of SIgA are very efficient due to the multivalency of the protein, which
displays at least 4 Fab sites. Moreover SIgA harbors glycan residues, which are also potential
Figure 5: Schematic representation of human dimeric SIgA
Human dimeric SIgA is composed of 2 IgA monomers (in green and yellow), a J
chain (blue box) and SC (in red). IgA monomers are depicted here in a tail-to tail
arrangement, where the J chain is covalently linked through disulfide bridges to the
tails of the heavy chains of the two monomers. SC is composed of five Ig-like
domains (DI-DV) and is covalently linked to one IgA monomer. Yellow dots
indicate N-glycosylation sites present on the tree molecular partners.
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binding sites for bacterial products98,99. In addition to the neutralising properties within the
lumen, it has also been reported that antigens present in the enterocyte can be neutralised
during the pIgR-mediated transport of pIgA, as for example during virus replication. In vivo
and in vitro studies with Sendai virus100 or rotavirus101,102 demonstrated that neutralisation with
pIgA is taking place within endocytic vesicles103. Moreover, antigens that entered the mucosa
can be neutralised in the LP by pIgA, and subsequently transported back to the luminal side
via the pIgR-mediated pathway104,105.
In addition to the conventional neutralising properties of SIgA, recent data also
demonstrate that SIgA can bind to M cells and gain access to the underlying immunological
cells present in PP106. SIgA binds selectively to DC and T cells107. Further analysis of the
potential biological function of such a mechanisms led to the discovery that antigenised SIgA
can induce an immunological response108, as adjuvants can do. The induced response is
however moderate and does not lead to an inflammatory response, thus further arguing for a
homeostasic role of SIgA at the level of the mucosa109. Additional work demonstrated that
bacteria-SIgA complexes can also gain access to PP via this route110. This raises interesting
questions regarding the role of SIgA toward the commensal microbiota. It was shown that
commensal bacteria reach MLN is association with DC, where the latter are supposed to
induce commensal-specific IgA61. The role of SIgA toward commensal microbiota is however
ambiguous. SIgA prevents the adhesion of the bacterial community to mucosal surfaces and
at the same time provides them adhesion site to reside in the GI tract. This is inscribed in the
concept of the continuous flow of mucins and enterocytes from the mucosal surfaces to the
centre of the lumen. It is interesting to note that SIgA does not influence the intestinal
microbiota quantitatively; in vivo studies with mice lacking antibodies did not present any
increase in the bacterial load111. However contradictory data are observed regarding the role of
SIgA toward the composition of the different bacterial species of the microbiota112-114. Mice
deficient in secreted antibodies, pIgR knockout mice (pIgR-/-), do not display any
modification of intestinal microbiota. However these mice were shown to have a leaky
epithelium and thus small amount of Ig are present in the lumen. In contrast, mice lacking
hypermutated antibodies due to the lack of mature T and B cells (RAG-2-/-) or activation-
induced cytidine deaminase enzyme (AID-/-) have a greater population of segmented
filamentous bacteria in the small intestine, which with time induce hypertrophy of mucosal
lymphoid structures113. This phenotype is abolished when mice are populated with functional
B cells, demonstrating that SIgA influences the composition of the microbial population, and
preserves the epithelium from a constant immune activation. Indeed, pIgR-/- mice induce a
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greater systemic response toward commensals than conventional mice115, what can be
interpreted as an intermediate phenotype. Altogether, these data suggest that commensal-
specific SIgA limits the access of bacteria to the mucosal surface and thus protect the host
from an exacerbated immune response at the GI level. Indeed in presence of functional SIgA,
commensal bacteria are restricted to the mucosal compartment and can only reach MLN with
DCs61. In conclusion, SIgA belongs to the numerous factors shaping the bacterial community
within the gut.
1.2.5 Properties of secretory component (SC)
As mentioned previously, SC is derived from the pIgR that ensures selective transport of
pIgA across the epithelium. Beyond its function of transporter, SC increases the resistance of
the antibody to proteolytic cleavage116 and governs anchoring of SIgA at mucosal surfaces117.
Human SC is about 85 kDa in size and consists of five Ig-like domains (DI-DV). Several IgA-
binding sites were identified on SC. DI displays 3 complementary determining region (CDR)-
like motifs, which are known to make the first contact between the pIgA molecule and
SC118,119. In addition, the cysteine (Cys) 502 of DV allows the covalent link between pIgA1
and SC through the Cys 311 of one Cα2 chain of pIgA120,121. Thus, several contact areas allow
the interaction between SC and pIgA, however, the exact interaction between SC and pIgA
remains to be clarified.
In secretions, SC can be found in association with pIgA but also as such, and can reach
µM concentrations in maternal milk122. SC is heavily glycosylated on seven asparagine (Asn)
residues; carbohydrates constitute about 20% of the molecular weight of the protein. The
glycosylation pattern includes bi- and triantennary or Lewis-typed structures constituting
binding epitopes for bacterial adhesins123. The presence of these glycans suggests that SC
might play a role in the protection of mucosal surfaces through non-specific interactions with
microbial pathogens. Initially, such a role was demonstrated with human SC purified from
colostrum. Ex vivo experiments showed that adherence of Clostridium difficile toxin A to
hamster brush border membranes was limited in the presence of SC124. Additionally, glycans
present on the complete SIgA molecule are crucial to block the interaction of Helicobacter
pylori with the stomach mucosa98. This suggests that beyond it properties of transport and
stabiliser of pIgA, SC has itself protective properties against microbial pathogenic motifs.
However, further analyses are required to define the precise nature of such interactions and
evaluate their consequences in terms of protection in vivo.
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1.3 Food allergy
1.3.1 Definition and prevalence of food allergy
Food allergy is defined as an abnormal or exaggerated immunological response to specific
food proteins that may be IgE or non-IgE-mediated125. Due to their comparable symptoms,
food allergy is often mixed up with food intolerance, which, in contrast to food allergy, is not
related to specific immunological mechanisms, and generally arises from deficiencies of
digestive enzyme126. Atopy is defined as a personal tendency to develop IgE antibodies, and
thus describes the genetic predisposition associated with allergy.
The manifestations of food allergy are multiple and various and include gastrointestinal
(abdominal pain, diarrhea and vomiting), cutaneous (urticaria and eczema), respiratory
(wheezing) and systemic signs (collapse due to hypotension), which sometimes lead to life-
threatening anaphylactic shock. The prevalence of food allergy, together with other types of
allergies, has increased in the past few decades in industrialised countries. The incidence of
self-reported food allergies ranges between 3% and 35%; however, this incidence is much
lower (2%-5%) when subjects were assessed for their sensitisation (quantification of allergen-
specific IgE) and signs127. To date, only few studies have employed the gold standard method
consisting of double blind placebo-controlled food challenges to diagnose food allergy. More
generally, this implies frequent inaccurate diagnosis and leads to inadequate treatment128.
Food allergy affects differentially children and adults; children are more affected than
adults (6-8% and 2-3% respectively). Most of allergies declared during childhood (80%)
spontaneously resolve at school age. Major allergens also differ with the age of the patient;
milk, eggs and peanut being more frequent in children, whereas shellfish, peanuts, fish, and
fruits and vegetables whose reactions are less severe, affect adults preferentially129.
Considering all protein ingested, allergens represent only a tiny part of it. However, no
common structural characteristics can be defined among them130, Allergens are generally
resistant, globular and water-soluble glycoproteins ranging from 10 to 70 kDa131. Beyond their
intrinsic properties, the matrix and composition of food both impact on their allergenicity132.
Currently, management of food allergy consists of the strict avoidance of the causal food
component. This strongly impacts on the quality of life of patient and patient’s parents. To
date, no treatment targets the cause of the disease, they thus remain therapeutic and not
curative.
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1.3.2 Mechanisms of food allergic reactions
Food allergy is thought to result from defect in oral tolerance toward food proteins. As
mentioned previously, food antigens are in their majority digested in amino acids and di-,
tripeptides; however, a small proportion of antigens reaches the epithelium and is processed
by DC or enterocytes and presented to T cells which induce, in normal conditions, a non-
inflammatory response leading to tolerisation. In the case of food allergy, for reasons that
remain largely unknown, a specific immune response is generated toward the antigen (in that
case named allergen) that leads to the activation of allergen-specific Th2 cells. Th2 cells
typically secrete IL-4, IL-5, and IL-13, what will favour the production of allergen-specific
IgE by B cells. IgE is the key antibody isotype responsible for triggering allergic reactions,
and binds to the high-affinity FcεRI present on eosinophils, basophils and mast cells
dispatched in mucosal tissues. These first steps are known as the sensitisation phase (figure
6A). Upon re-exposure to the allergen, i.e. the effector phase, the allergen binds to the IgE
present on the surface of eosinophils, basophils and mast cells and thus mediate IgE
crosslinking what leads to the degranulation of these cells (figure 6B). The granule of these
cells contain various chemical mediators with important biological effects: i) histamine, a
Figure 6: Immunological mechanisms of the allergic reaction
A, Sensitistion phase; under special conditions, B cell produce allergen-specific IgE,
which subsequently binds to the FcεRI receptor displayed at the surface of mast cells,
eosinophils and basophils. B, Effector phase; upon re-exposure to the allergen, this
latter binds to IgEs and thus triggers crosslinking of the receptor what leads to
degranulation of mast cells. Chemical mediators released are responsible for the
allergic manifestations.
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powerful vasodilatator, increases contraction of intestinal and bronchial smooth muscles,
vasopermeability and secretion of mucins by Goblet cells; ii) leukotrienes and prostaglandins
are both synthesised post-degranulation and have similar effect of histamine but act in a
prolonged manner; iii) proteases, which roles largely remains to be defined; and iv) cytokines
such as IL-4, IL-5, IL-6 and TNF-α, which recruit neutrophils and eosinophils, and further
promote production of IgE by B cells133. These first events are known as the acute phase of
allergy and can lead sometimes to anaphylactic shock. In some rare cases, food allergy can be
IgE-independent and is, in such cases, mediated directly by allergen-specific T cells125.
Mechanisms related to such type of allergy remain largely unestablished, although recent data
demonstrated that TSLP can activate mast cells in an IgE-independent manner134.
1.3.3 Potential factors initiating sensitisation instead of tolerance
The main challenge nowadays is to understand why in some cases oral tolerance is
abrogated, and why the immune system induces an inappropriate immune response toward
food antigens. Among the incriminated factors is an inappropriate digestion of food protein,
resulting in the presence of intact immunoreactive allergens that should normally be
degraded. Gastric acidity and digestive enzymes were shown to play an important role in the
prevention of food allergy. Mice fed with caviar extracts in combination with antacids
develop caviar-specific IgE and T cells activity135. Furthermore, this observation was
extended to humans, who were shown to develop food-specific IgE when treated with anti-
ulcers drugs136. Protection of allergens against digestive enzymes in microspheres also shows
an abrogated oral tolerance137. It must be noted that the site of entry differs when the allergen
is encapsulated what can lead to different immune responses. What so ever the integrity of the
allergen is required to induce an allergic immune response, as otherwise ignorance of
degraded proteins takes place as the default mechanism. Indeed, infant formulae composed of
digested or partially digested cow’s milk proteins were developed to bypass allergic reaction
triggered by undigested allergens and even to inhibit sensitisation in newborns138,139.
The genetic background of the host is critical for the outcome of allergy. In mice, the
effectiveness of oral tolerance varies in function of the strains140; moreover, incidence of food-
induced anaphylaxis fluctuates from strains to strains141. In humans, analysis of the human
leukocyte antigen (HLA) genes underscored the association of some genotypes with peanut
allergy142 but not with cow’s milk allergy143, suggesting that HLA genes are important, at least
for some allergens. In addition, TLRs were shown to influence the development of allergic
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reactions. Activation of TLR4 by LPS of commensal bacteria prevents peanut sensitisation of
mice in a model of food-mediated allergy144. Moreover, activation of TLR9 by CpG
oligodeoxynucleotides during the sensitisation prevents allergic signs in TLR4-deficient mice.
TLR2 might also be involved in the prevention of allergic disorders145. In humans, TLR
polymorphisms are associated with asthma146 and atopic dermatitis147, but not with atopic
eczema148.
Although many other genes can be associated to allergy predisposition, the current
increase of allergy occurrence in westernised countries cannot be accounted solely to genetic
derive. Therefore, epidemiological studies on environmental factors and life habits were
performed in regions strongly or less affected by allergy149. This led to the so called “hygiene
hypothesis” first mentioned by Strachan and which stresses that decreased infection and
microbial stimulation in childhood increases susceptibility to allergic diseases150. Many
studies demonstrated that exposition during childhood to endotoxins151, animal sheds152 and
consumption of fermented products153 reduced the risk of hay fever and atopic sensitisation in
childhood and later in life. However, the protective effect of microbial products is seen only
for atopic sensitisation as high endotoxin levels are correlated with non-atopic wheezing154.
If the hygiene hypothesis is widely accepted as explanation for the epidemy of allergy, the
immunological bases are still controversial. It was first postulated that the lack of microbial
stimulation prevents the skewing of the Th1/Th2 balance to the “protective” Th1 response;
the so called immune deviation theory155. The Th2 response responsible for the production of
IgE is inhibited by the Th1 response induced following infection or microbial stimulation.
However, conflicting data question this theory, as for example, the fact that parasitic
infections (characterised by a strong Th2 response) protect against allergic diseases156.
Moreover, westernised countries also suffer from an increase of Th1 disease such as Crohn’s
disease157. Thus, the theory of reduced suppression was proposed as a complementary
explanation to the hygiene hypothesis158. Decreased activity of regulatory T cells is thought to
be responsible for the emergence of allergic diseases. But here again, epidemiologic data
suggests that regulatory T cells are not the unique explanation, as asthma occurrence has been
shown to protect from other autoimmune disorders159.
An alternative view of the hygiene hypothesis was proposed by Noverr et al. who first
mentioned the possibility that aberrant immune responses might be the result of a perturbed
intestinal microbiota, the so called “microflora hypothesis”160. This hypothesis was based on
the observation that i) allergic people harbour a modified intestinal microbiota161,162 and that
ii) the actual lifestyle in industrialised countries affects the microbiota due to the improved
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hygienic environment, the diet, and the use of antibiotics. More importantly, prospective
studies showed that perturbation of the microbiota within the first months of age precede the
appearance of the allergic disease later in life163-165. These studies demonstrated that the
presence of Clostridia species (C. difficile or the Clostridum genus in general) increased the
risk of sensitisation and atopic dermatitis. Furthermore, in some studies, an increase in E. coli
predispose to eczema165 and Bifidobacteria, in contrast, prevent apparition of allergic signs164.
Although these studies are often based on cultured species from fecal samples collected from
a limited number of patients (except in one study165), these data indicate that a perturbed
microbiota can predispose to allergic diseases. How the intestinal microbiota can influence
the initiation of sensitisation or prevent the apparition of eczema remains largely unknown,
but hypotheses are based on the same two theories; immune deviation and/or reduced
suppression.
Altogether, the current knowledge indicates that a decreased microbial stimulation during
childhood, either by infectious strains or simply by surrounding bacteria or their products,
together with a perturbed intestinal microbiota can trigger allergic disorders in genetically
predisposed patients. With the aim to prevent and to treat allergic diseases, the concept of
administrating beneficial and safe bacterial strains (or products) to compensate for this
decreased microbial stimulation associated with the modern life style has emerged and is
developed in the next section.
1.4 Probiotic treatments in allergic diseases
1.4.1 Definition and approaches
Probiotics are dietary supplements containing live beneficial microorganisms that can, at
the right concentration, improve health of the host. Although seeking the same purpose,
probiotics need to be distinguished from prebiotics, which are indigestible food ingredients
(generally carbohydrates) that beneficially affect the host by selectively stimulating the
growth and/or activity of one or a limited number of bacteria166. The most commonly used
probiotics are lactic acid bacteria such as Lactobacillus and also Bifidobacterium167. Since a
long time, humanity has used lactic acid bacteria in its alimentation, as for example the
consumption of fermented milk products (yogurt, sour milk and cheese). Beneficial effects of
probiotic have been demonstrated to prevent infections by pathogenic agents (rotaviruses168,
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Clostridium difficile169, Helicobacter pylori170), to improve inflammatory bowl disease
symptoms171,  and to reduce the risk of allergic diseases (see below).
Probiotics are thought to act at various levels in the GI tract. Among other mechanisms,
probiotic bacteria might participate in degradation of protein antigens, enhance intestinal
barrier functions, promote the development of the mucosal immune system, or influence the
composition of the intestinal microbiota in a competitive or symbiotic manner. In addition to
the use of natural isolates bacteria, novel approaches were developed with genetically
engineered bacteria expressing either the regulatory cytokine IL-10172,173 or a defined allergen
in order to establish oral tolerance174,175. These animal studies are promising and open the path
to new therapeutic treatments of gastrointestinal diseases.
1.4.2 Allergy prevention and treatment with probiotics
Probiotic interventions early in life aimed to prevent atopic manifestations have been
conducted. In a randomized placebo-controlled study, Lactobacillus rhamnosus GG
administration before birth and during the 6 first month of life was effective in prevention of
atopic eczema in predisposed children176. Interestingly, the protection observed against atopic
eczema was extended beyond infancy at 4 years177 and 7 years178. In a double-blinded
placebo-controlled study, oral treatment of pregnant mothers and then newborns with a
probiotic cocktail containing Lactobacillus rhamnosus GG, Lactobacillus rhamnosus LC705,
Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp shermanii JS showed
a decrease of IgE-associated allergic diseases and atopic eczema179. In a similar study,
administration of Lactobacillus reuteri ATCC 55730 prevented the prevalence of IgE-
associated eczema and sensitiation180. In a therapeutic approach, probiotic treatment with
Lactobacillus fermentum VRI-003 PCC of young children with severe atopic dermatitis
showed an improvement in the severity of the allergic signs181. The effects of Bifidobacterium
longum BB536 toward signs of hay fever in Japanese people were studied in a randomised
double-blinded, placebo-controlled trial. Although the study was limited to a small number of
patients, clinical signs were shown to be significantly decreased and a trend toward the
reduction of serum IFN-γ was observed182.
However, additional studies also showed that defined probiotics lack benefical activity
against allergy induction. Indeed, Lactobacillus acidophilus LAVRI-A1 treatment during the
first 6 months of life did not reduce the prevalence of atopic dermatitis and even increased the
sensitisation to allergens183. Moreover, supplemented hydrolysed formulae with Lactobacillus
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rhamnosus or Lactobacillus GG given to allergic young (<5 months) children failed to reduce
atopic dermatitis after 3 months of treatment184.
Altogether, these data indicate that probiotic treatment with defined strains can decrease
the risk of developing allergic diseases and also the severity of the allergic signs. However,
beneficial effect is not always observed and the underlying mechanisms for protection remain
at the level of hypothesis. Moreover, the influence of the strain used is not known, and is
probably closely linked to its mechanism of action.
1.4.3 Lactobacillus paracasei NCC2461
Lactobacillus paracasei NCC2461 was isolated from faeces of a healthy baby. This gram
positive bacteria was shown to have beneficial properties against gut visceral sensitivity when
administered alive185. The protective effect might be linked to the capacity of the strain to
improve intestinal barrier in stressed conditions. Moreover, L. paracasei normalise visceral
sensitivity in mice post-treatment with antibiotics186. Regarding allergic disorders, interesting
data on the ability of L. paracasei to hydrolyse β-lactoglobulin (BLG) peptides in
immunomodulatory acidic peptides were shown in vitro187. L. paracasei-hydrolysed acidic
peptides induced IL-10 production by splenocytes, whereas non-hydrolysed peptides induced
the production of pro-inflammatory cytokine IFN-γ. These data, together with other
promising results, place L. paracasei NCC2461 as a good candidate for modulation of allergic
responses. This strain was therefore tested in a murine model of food-mediated allergy.
1.5 Aims of this work
The aims of this work are dual as two main topics were studied, and although both are
belonging to the field of mucosal immunology, they are completely independent of each
other. Therefore the results have been divided in two separate parts.
In the first part, protective mechanisms against intestinal pathogens were studied. The aim
was to evaluate the innate immune properties of human SC toward the viral pathogen
rotavirus. In addition, structural aspects of the protein have been studied in collaboration with
the laboratory of S. Perkins at the University College London. The results obtained within this
project are only summarised in the result section, and described in more details in the three
publications presented in the annexes 1, 2 and 3.
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The second part of this work is placed in the domain of food allergy. The aims were first
to develop a reliable model of food-mediated allergy in the mouse, and then to study the
potential modulatory functions of the probiotic strain Lactobacillus paracasei NCC2461
towards allergic reactions.
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Chapter 2
Material and methods
2.1 Analytical Methods
2.1.1 Enzyme linked immunosorbent assay (ELISA)
ELISA was used to measure antibody concentration in serum and secretions of mouse and
to determine de concentration of cytokines in supernatant of cultured cells. Capture and
detection antibodies as well as standard proteins (when available) are listed in table 1,
together with dilutions used. For IL-10 and IL-13 detection, buffers, blocking agents and
incubation times were performed following the instructions in the kit; otherwise the general
procedure described below was applied.
Wells of 96-micro-well plates (Nagle Nunc International, Wiesbader, DE, cat. no. 442404)
were coated with 50 µl of coating buffer (50 mM carbonate-bicarbonate buffer; pH 9.6)
containing appropriate diluted capture antibody and incubated O/N at 4°C. Plates were
washed once with 250 µl of PBS, 0.05% Tween-20 (PBS-T) and blocked with 100 µl of 1%
bovine serum albumin (BSA; Fluka, Buchs, CH, cat. no. 05477) in PBS-T for one hour at
37°C. After washing with 250 µl of PBS-T, 50 µl of diluted sera or pure culture supernatant
were incubated for one hour at 37°C. Wells were then washed three time with 250 µl of PBS-
T, and incubated with 50 µl of 0.5% BSA PBS-T containing detection antibody for one hour
at 37°C. After three washes with 250 µl of PBS-T, detection was directly performed for assay
with horseradish peroxidase (HRP)-coupled detection antibodies, or further incubated with 50
µl of 0.5% BSA PBS-T containing HRP-conjugated streptavidin (Upstate, Tamecula, US, cat.
no. 18-152, diluted 1/2000). Detection was performed with 50 µl of 0.1 M citrate solution (pH
5.0) containing 1 mg/ml O-phenylenediamine (Sigma, Buchs, CH, cat. no. P-1526) and 0.01%
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Molecule 
detected
Antibodies and 
standards
Concentra-
tion References
anti-mIL-5 4 µg/ml BD Pharmingen, cat. no. 554393
mIL-5 2 ng/ml BD Pharmingen, cat. no. 554581
Biot-anti-mIL-5 2 µg/ml BD Pharmingen, cat. no. 554397
anti-mIL-10 4 µg/ml R&D System, cat. no. MAB417
mIL-10 2 ng/ml BD Pharmingen, cat. no. 550070
Biot-anti-mIL-10 0.4 µg/ml R&D System, cat. no. BAF417
anti-mIL-13 4 µg/ml R&D System, cat. no. MAB413
mIL-13 10 ng/ml R&D System, cat. no. 413-ML
Biot-anti-mIL-13 0.1 µg/ml R&D System, cat. no. BAF413
anti-mIFN-γ 4 µg/ml BD Pharmingen, cat. no. 551216
mIFN-γ 50 ng/ml BD Biosciences, cat. no. 554587
Biot-anti-mIFN -γ 2 µg/ml BD Pharmingen, cat. no. 554410
anti-mIgE 2 µg/ml BD Pharmingen, cat. no. 553413
anti-OVA mIgE 1 µg/ml Abserotec, cat. no. MCA2259
OVA-biot 0.5 µg/ml Lab made, see 2.1.2
anti-mIgE 2 µg/ml BD Pharmingen, cat. no. 553413
mIgE 0.5 µg/ml BD Pharmingen, cat. no. 03131D
Biot-anti-mIgE 1 µg/ml BD Pharmingen, cat. no. 553419
OVA 10 µg/ml Fluka, cat. no. 05461
Biot-anti-mIgG1  1:3000 Caltag, cat. no. M32115
OVA 10 µg/ml Fluka, cat. no. 05461
Biot-anti-mIgG2a 0.1 µg/ml Caltag, cat. no. M32315
OVA 10 µg/ml Fluka, cat. no. 05461
HRP-anti-mIgA  1:2000 Cappel, cat. no. 55549
anti-mIgA 2 µg/ml Sigma, cat. no. 8769
purified mIgA 1 µg/ml Labmade
HRP-anti-mIgA  1:2000 Cappel, cat. no. 55549
anti-OVA
IgE
IL-5
IL-10
IL-13
IFN-γ
Total SIgA
Total IgE
anti-OVA
IgG1
anti-OVA
IgG2a
anti-OVA
IgA & SIgA 
Table 1: Antibodies and standard proteins used in ELISA
For each molecule detected by ELISA, the capture antibody appears in the first line,
standard molecule in the second (when available) and the detection antibody in the
third line. Concentrations or dilutions used are indicated; for standard proteins the
top concentration of the calibration curve is indicated. m, mouse.
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H2O2. The reaction was stopped with 50 µl of 2 M sulfuric acid and absorbance was measured
at 492 nm with 620 nm as reference.
Optimal dilutions for detection of seric and secreted antibodies were determined by
titration in preliminary experiments and found optimal as follow: 1/20 for anti-OVA IgE, 1/40
for total IgE and anti-OVA SIgA, 1/200 for anti-OVA IgA, 1/500 for total SIgA, 1/2000 for
anti-OVA IgG2a and 1/100'000 for anti-OVA IgG1.
Due to the very large amount of OVA-specific IgG present in sera of sensitised mice,
OVA-specific IgE were detected using an optimised protocol derived from Christensen &
al.188. The principle of the assay consisted of a capture of total mouse IgE with an anti-mouse
IgE, an incubation of sera, and then a detection with a biotinylated OVA, thus guaranteeing
antibody and antigen specificity.
Mouse mast cell protease-1 (MMCP-1) was quantified following the kit manufacturer’s
instructions (Moredun Animal Health, Penicuit, UK cat. no MS-RM3). ELISA used to
estimate intestinal permeability is described in details under section 2.2.8.
2.1.2 Biotinylation of OVA
2 ml of a 10 mg/ml OVA solution were mixed with 1 mg sulfo-LC-NHS-biotin
(Molecular Biosciences, Boulder, US, cat. no. 00598) and incubated on a rotating wheel for
one hour at RT to allow covalent link between amino residues of OVA and biotin. The
solution was then loaded on a PD-10 Sephadex G25M column (Amersham Biosciences,
Uppsala, SW, cat. no. 17-0851-01) to remove unbound biotin. OVA-containing fractions were
pooled, and protein concentration was determined. Biotinylation of OVA was verified by
western blot analysis.
2.1.3 Western blotting
SDS-PAGE and transfer onto polyvinylidine fluoride (PVDF) membranes (Millipore,
Billerica, US, cat. no. 888) was carried out as described189 using the Mini-Protean II system
(Bio-Rad, Reinach, CH). OVA was reduced in 0.1 M dithiothreitol (DTT; AppliChem,
Darmstadt, DE, cat. no. 27565-41-9) for 3 min at 95°C before loading onto a 12 %
polyacrylamide:bisacrylamide (PAA) gel to guarantee correct migration. The membranes
were blocked with 5% BSA in PBS-T for one hour at RT, and subsequently incubated with
either sensitised mouse serum diluted 1:1000, or streptavidin-HRP (1/2000) diluted in 0.5%
BSA PBS-T. Membranes were then washed three times with PBS-T and further incubated
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with HRP-conjugated goat anti-mouse IgG (Sigma, cat. no. 87699) diluted 1/3000 in
0.5%BSA PBS-T or directly used for detection, respectively. After final washes, immune
complexes on membranes were detected by chemiluminescence using the Uptilight detection
kit (Interchim, Montluçon, FR, cat. no. UP99619A) and exposed on autoradiographic films
(Konica, Hevac Product, Villeneuve, CH).
2.1.4 Bicinchoninic acid (BCA) protein dosage
Protein solutions were quantified by a chemical protein dosage. The BCA protein assay kit
from Pierce (Rockford, US, cat. no. 23225) was used with an adapted protocol. The principle
of the protocol relies on the reduction of Cu++ in Cu+ by proteins in alkaline buffer. Then, Cu+
forms a purple complex with BCA. Briefly, wells of 96-well plates were filled with serial
dilutions (in PBS, final volume of 50 µl) of proteins, as well as BSA as standard. 250 µl of
reagent containing Cu++ and BCA was added in the wells and the colorimetric reaction was
performed for 30 min at 50°C. Absorbance was measured at 590 nm.
2.2 In vivo Experiments
2.2.1 Animals
Three to four-week-old female BALB/cOlaHsd (ordered from Harland Netherlands,
Horst, NL) were housed in the animal facility of the CHUV under standard conditions (or
otherwise indicated) according to the institutional guidelines, under authorization numbers
1287.1 and 1287.2. Water and commercial OVA-free diet (Provini Kliba SA, Penthalaz, CH,
cat. no. 3200) were provided ad libitum. Experimental protocols were systematically initiated
three weeks after the arrival of mice in the animal facility in order to allow infection by, and
subsequent clearance, of mouse hepatitis virus (MHV) present in the animal facility. All
experimental groups were constituted of 10 mice, which were banded individually to be
clearly identified.
One experiment was conducted in the MHV-free animal facility of the Nestlé Research
Center following an identical procedure.
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2.2.2 Protein and Adjuvant
OVA (Fluka, crude powder, cat. no. 05461) was solubilised in PBS at high concentration
(>200 mg/ml) by gentle mixing with a Pasteur pipette, followed by a one-hour incubation on
a rotating wheel. The solution was then centrifuged 10 min at 1700 x g to discard undisolved
materials, and supernatant was used for BCA protein dosage. Concentration was adjusted to
100 mg/ml (sensitisation and tolerisation protocols) or 200 mg/ml (challenges) and aliquots
were frozen at –20°C until further use.
Before administration, cholera toxin (Calbiochem, Darmstadt, DE, cat. no. 227035) was
mixed to OVA (sensitisation) or PBS (negative control) adjusted to a dose of 10 µg CT /
mouse.
2.2.3 Protocols for sensitisation, tolerisation and negative control groups
Seven to eight-week-old mice were administered intragastrically 20 mg OVA mixed with
10 µg CT in a final volume of 200 µl of PBS. Intragastric gavages (IG) were performed with
a feeding needle (Harvard Apparatus, 22 gauge, 38.1 mm, cat. no BS4 52-4025). The optimal
sensitisation protocol was established as seven successive administrations of OVA + CT once
a week, for seven weeks. Tolerisation and negative control protocols followed the same
schedule except that mice were given 20 mg OVA alone or 10 µg CT alone, respectively.
2.2.4 Treatment of allergic mice with a probiotic strain
Mice were treated intragastrically with Lactobacillus paracasei NCC 2461 (obtained from
the Nestlé Culture Collection) produced in Konolfingen (Nestlé Suisse, SA). Viable counts of
the bacteria was verified before, during and at the end of the sensitisation procedure to ensure
that mice received the correct dose of bacteria. Treatment consisted of intragastric
administration of 109 CFU of the probiotic strain (in PBS without glycerol) every 2 or 3 days
from the beginning of the sensitisation procedure to the end of the experiment. The whole
procedure consisted of 23 probiotic administrations.
2.2.5 Recovery of biological fluids
Biological fluids were recovered before, during and after the sensitisation, at indicated
time points, to test their antibody content. Blood (<150 µl) was recovered by performing a
small incision in the tail of the mice. Samples were then incubated for 20 min at 37°C and for
30 min at 4°C in order to trigger clotting. Serum was collected and transferred to a fresh tube,
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centrifuged for 10 min at 10'000 x g to pellet residual red cells. Clear sera were finally
collected and frozen at –20°C until further use.
Faeces of mice were freshly collected, solubilised in PBS containing protease inhibitors
(Complete™, Roche Applied science, Rotkreuz, CH, cat. no. 11836153001) and 0.001%
sodium azide, and adjusted to a 100 mg/ml concentration. Faeces were homogenized,
incubated for 1 hour at RT, centrifuged for 10 min at 10'000 x g at 4°C to remove solid
material, and finally frozen at –20°C until use.
2.2.6 Challenge and evaluation of the allergic reaction
Allergic reactions were provoked in all groups of mice by a single intragastric challenge
one week after the end of the experimental procedure (sensitisation, tolerisation and negative
control groups) Two hour-starved mice were given intragastrically 100 mg OVA (in a final
volume of 500 µl), and allergic reactions were observed during the first hour following
challenge. Rectal temperature was recorded before and 30 min after challenge using a baby
thermometer (Omron, Hoofddorp, NL, cat. no. 15446). Signs of allergic reaction (scratching,
bristled fur, diarrhea, laborious wheezing and abnormal immobility) were observed 30-60 min
post-challenge. Mice were observed in a blind fashion by one independent observor who was
asked to fill the form presented in annex 4. Allergic scores were subsequently graded
Score Signs
0 Mice behave normally, they are active and do not scratch more than 3 times during 15 min. 
1 Mice are scratching between 4-10 times during 15 min, but otherwise no strong signs.
2
Mice are scratching more then 10 times during 15 min, or 
display reduced activity or bristled fur, generally 
accompanied with puffiness around the mouth and eyes. 
3
Mice have a strongly reduced activity, display liquid diarrhea, 
have difficulties to walk normally, bristled fur and sometimes 
labored respiration.
4
Signs of degree 3 are stronger, mice display cyanosis 
around the mouth and tail. They remain immobile even after 
prodding.
5 Death.
Table 2: Definition of allergic scores
Allergic scores (0-5) were given following this scale; signs observed during the
allergic reaction are indicated in the right column.
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following a pre-established scale (see Table 2).
2.2.7 Organ collection
Three to four hours post-challenge, mice were sacrificed upon intraperitonal injection of
150-200 µl Trapanal (Altana Pharam, Konstanz, CH, cat. no. 800322). Cardiac blood was
collected by intracardiac perforation, and MLN and SPL were then removed and kept at 4°C
in 0.5 - 1 ml complete medium until processing. Complete medium consist of DMEM (1g/l
glucose; Gibco Invitrogen, Basel, CH, cat. no. 21885) containing 10% foetal bovine serum
(FBS; Sigma, cat. no. F7527), 10 mM Hepes (Amimed, Allschwil, CH, cat. no. 5-31F00-H), 2
mM glutamine (Sigma, cat. no. G7513), 100 units/ml of penicillin and 0.1 mg/ml
streptomycin (Gibco, cat. no. 4633), non-essential amino acid (Gibco, cat. no. 1140-035) and
50 µM ß-mercaptoethanol (Sigma, cat. no. M-7522). Small intestine was carefully unrolled by
cutting the mesenteric connections and intestinal secretions were collected by flushing 3 ml
PBS containing protease inhibitors through the intestine. Secretions containing the intestinal
content were then processed like faeces (see section 2.2.5). A piece of jejunum was then
collected at a distance of 10 cm away from the stomach and kept in PBS containing 4% PFA
at 4°C (Fluka, cat. no. 76240) for at least 24 hours to allow fixation.
2.2.8 Measurement of intestinal permeability
Intestinal permeability was assessed in vivo by quantifying seric OVA which has been
translocated through the intestinal epithelium of intragastrically-administred-OVA mice.
Two-hour-starved mice were given 50 mg or 100 mg OVA intragastrically, and blood was
collected before, 15 min, 1, 3 hours by tail incision. Finally, mice were sacrificed 6 hours
post-administration, and cardiac blood was collected. All blood samples were processed as
indicated in section 2.2.5. Free OVA or antibody-complexed OVA present in the serum were
then quantified by the following ELISA.
ELISA to quantify seric OVA was developed to ensure low background and good
sensitivity. Wells of 96-well plates were coated with 50 µl coating buffer containing 10 µg/ml
rabbit anti-OVA (Abcam, Cambridge, UK, cat. no. 1221) O/N at 4°C. After one wash with
250 µl of PBS-T, wells were blocked with 150 µl of 5% non-fat dry milk (NFDM; Migros,
Rapilait) in PBS-T for 2 hours at 37°C. Following a single wash with 250 µl PBS-T, sera
diluted 1:3 in 0.5 % NFDM PBS-T and standard (OVA diluted in serum) were incubated for 2
hours at 37°C. Due to the large amount of OVA-specific antibodies present in the sera of
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sensitised mice, different calibration curves were used to ensure comparison. Standard curves
for naïve, tolerised and negative control mice were obtained in pre-immune serum diluted 1:3
in 0.5 % NFDM PBS-T, with 50 ng/ml OVA as top concentration. When sera of sensitised
mice were analysed, standard curve was performed in pooled sera of sensitised but
unchallenged mice also diluted 1:3 in 0.5 % NFDM PBS-T with OVA concentrated at 100
ng/ml as top concentration. Wells were then washed extensively and incubated with 50 µl of
0.5 % NFDM PBS-T containing mouse antibodies anti-OVA (pooled sera of unchallenged
mice, diluted 1:1000) for 1 hour at 37°C. After 3 washing with 250 µl of PBS-T, final
incubation with HRP-conjugated-anti mouse IgG (Sigma, cat. no. A-2554) diluted 1:2000 in
50 µl 0.5 % NFDM PBS-T was performed for 45 min at 37°C. After final washes, detection
was performed as in section 2.1.1.
2.3 Ex vivo Analysis
2.3.1 Organ processing
After collection, MLN and SPL were scratched on a 40-µm cell strainer (BD Falcon,
Allschwil, CH, cat. no. 352340) with a plunger of a syringe, resuspended in 10 ml of
complete medium, and centrifuged for 10 min at 300 x g at 4°C. MLN cells were resuspended
in 5 ml complete medium and directly counted on a Neubauer slide, whereas SPL cells were
resuspended in 2 ml lysis buffer (0.1 mM EDTA, 155 mM NH4Cl, 10 mM KHCO3) and
incubated for 5 min at RT, to allow the lysis of red blood cells. Then, SPL cells were washed
twice with 10 ml of complete medium and centrifuged for 10 min at 300 x g at 4 °C. Finally,
cells were resuspended in 10 ml of complete medium and counted on a Neubauer slide.
2.3.2 Ex vivo stimulation
Allergen stimulation of MLN and SPL cells were performed ex vivo to determine the
cytokine profile of immune cells. Briefly, 500'000 MLN or SPL cells were plated on 96 flat
bottom micro-well culture plates (Costar®, Sigma, cat. no. 3596) and stimulated in a final
volume of 200 µl of complete medium. Stimulation was performed with 250 µg/ml OVA
(Fluka, crude powder, cat. no. 05461) or 2 µg/ml Concanavalin A as positive control, or
remained unstimulated for 5 days. Supernatant were then collected and frozen at –20°C until
use. To test the influence of “contaminating” LPS during stimulation, LPS-free OVA
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(Worthington, Lakewood, US, cat. no. 3056) was used once in comparison to conventional
OVA.
2.3.3 Histology and mast cells staining
Jejunum samples were embedded in paraffin and cut with a microtome in 4 µm cross-
sections. Two different mast cell stainings were used to visualise mast cells in connective
tissues (toluidine blue) or mast cells in lamina propria (fuchsine).
• Toluidine blue: The staining principle relies on the formation of a purple complex
between azure A (product of toluidine blue) and sulfate radicals from heparin present
in the granules. Slides were re-hydrated and incubated for 10 min in methanol
containing 1% toluidine blue, washed, dehydrated and mounted with Eukitt quick
hardening mounting medium (Fluka, cat. no. 03989).
• Fuchsine: The staining principle relies on the presence of esterases in the granules of
mast cells that hydrolyze a specific substrate, which turns fuchsine into purple
color190,191. All solutions were prepared freshly; 1 ml of 4% new fuchsine (Fluka, cat.
no. 72200) solution was mixed with 1 ml of 4% aqueous sodium nitrite (Riedel-
deHaën, Seelze, DE cat. no. 31443) and added to 300 ml 0.07 mM phosphate buffer
(pH 6.5). Substrate solution consisting of 0.1 g Naphtol AS-D chloroacetate (Sigma,
cat. no. N0758) in 10 ml N,N-dimethylformamide (Sigma, cat. no. D4254) was
subsequently added to the fuchsine solution, mixed and filtered. Slides were re-
hydrated, incubated for 15-30 min in fuchsine solution, dehydrated and mounted with
Eukitt quick hardening mounting medium.
Mast cells were counted under the microscope (Leica DM 1000, magnification: 400 x).
Three to four cross sections per mice were counted and presented as means for each mouse.
2.4 Microbiology Analysis
2.4.1 Detection of Lactobacillus paracasei NCC2461 strain in faeces
Persistence time of L. paracasei NCC2461 in the gastrointestinal tract of mice was
evaluated post-administration of 109 CFU. Faeces of mice were freshly collected before, one,
two and three days post-administration and kept at 4°C. Every day, fresh faeces (1-2 pieces)
were resuspended in 3 ml PBS, dilution of this solution was plated on Mann Rogosa Sharpe
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(MRS) lacto-plates and grown for 2 days at 37°C under anaerobic conditions. The lawn was
scraped, resuspended in 10 ml PBS, washed twice and used for DNA extraction (Qiagen,
Hombrechtikon, CH, BioRobot EZ1 and EZ1 DNA Tissue kit, cat. no. 953934). L. paracasei
NCC2461 was then detected by polymerase chain reaction (PCR) performed on extracted
DNA with specific primers (a gift from Dr. B. Berger). The detection limit of this technique is
104 CFU/ml, and is currently the more sensitive to detect the NCC2461 strain in mice faeces.
2.4.2 Analysis of the fecal microbiota by PCR coupled with denaturing
gradient gel electrophoresis (DGGE)
The principle of the DGGE analysis relies on the electrophoretic separation of PCR
fragments of equal length using a polyacrylamide gel. The gel contains a gradient of urea and
formamide which increases in the direction of the electrophoresis. Fragments of different
stability (due to their different sequence) will migrate until partial denaturation due to the
gradient and thus generate a profile of bands.
Before challenge, faeces of mice were freshly collected and stored at –80°C. Total
bacterial DNA was extracted directly from faeces (as in section 2.4.1) and used as template
for PCR amplification with specific primers. PCR amplification targets the 16 rRNA gene;
primers used for total microbiota analysis were HDA1 and HDA2192 and for Lactobacilli
microbiota LAC1 and LAC2193. PCR products were separated for 4.5 hours at 130 V on
gradient polyacrylamide gels. Gel gradients differ with the primers used; for total microbiota
analysis, 30 to 55% formamide and urea gradient gel were used, whereas for lactobacillus
mircobiota, 30-45% formamide and urea gradient were used. Following migration, gels were
stained for 30 min with SYBR Safe solution (Invitrogen, Basel, CH, cat. no. S33102) and
subsequently analysed with BioNumerics software package (version 4.01, Applied Maths).
DGGE profiles were compared by determining the Dice similarity coefficient at a sensitivity
of 2–3 %.
2.5 Statistical Analyses
All statistical analyses were performed using GraphPad Prism version 4. The Mann-
Whitney test was applied for allergic score and mast cell number, otherwise the unpaired
Student t test was applied. Limit of significance was set at p=0.05; * indicates 0.05 > p >
0.01, ** indicates 0.01 > p > 0.001 and *** indicates p < 0.001.
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Chapter 3 
Results
Part I   
Biological and structural properties of human
secretory component (SC)
3.1 Summary of the results
3.1.1 Neutralising properties of human SC toward rotaviruses
The innate immune properties of human SC toward the viral pathogen rotavirus were
evaluated. The working hypothesis was that human SC might interact with the virus through
its glycan residues and thus prevent subsequent infection. This hypothesis was supported by
the fact that i) rotaviruses make the first contact with epithelial cells in a galactose and sialic
acid-dependant fashion194,195, and ii) sialic acid and galactose residues are present on human
SC. To test this hypothesis, human SC was produced in Chinese hamster ovary cells and
purified to obtain fully glycosylated human SC. Three strains of rotaviruses were studied; the
simian SA11 strain, the bovine RF strain and the rhesus RRV strain, which were all produced
with a high degree of purity for biochemical analyses. Results obtained using ELISA, overlay
assay and electron microscopy methods clearly indicated that no interaction took place
between SC and the 3 strains of rotaviruses tested. Consistent with this, no protection against
infection of epithelial cells was observed in presence of human SC, even when high
concentrations of human SC were used. Altogether, these data indicated that human SC did
not interact with rotaviruses, and could not protect directly or indirectly epithelial cells from
infection. These data were nonetheless used, together with additional data form the
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laboratory, to generate the paper presented in annex 1. This paper demonstrates that human
SC interacts with Clostridium difficile toxin A, and with the adhesion molecule intimin of
enteropathogenic Escherichia coli. More importantly, these interactions mediate biological
protection of epithelial cells in vitro. Moreover, the interaction between both pathogenic
structures was shown to rely on the presence of glycans, and more specifically on galactose
and sialic acid.
Collectively, these data identify human SC as a microbial scavenger at mucosal surfaces.
The glycans present on the molecule confer innate-like properties to the molecule, and upon
association of SC to pIgA, might further enhance the neutralising potential of the complex.
In addition to this study, the neutralising properties the anti-viral protein 6 (VP6) IgA 7D9
antibody toward rotavirus infections was tested. This study was performed in collaboration
with I. Schwartz-Cornil’s laboratory at the Institut National de la Recherche Agronomique in
Paris. Proteins and viruses prepared during the study of the interaction between rotaviruses
and SC were instrumental to perform the series of experiments dealing with the neutralising
properties of IgA 7D9. Detailed description of this work is presented in the paper of annex 2.
Briefly, it was shown that IgA 7D9, an antibody directed at the inner core protein VP6 of
rotavirus, binds to triple-layer viral particles. When delivered systemically, this antibody
provides protection against rotavirus infection in mice101. This work identified for the first
time the mechanism responsible of this protection. Delivery of SIgA 7D9 intragastrically did
not protect mice of rotavirus infection, thus protection is not conferred by immune exclusion.
However, it was shown that replication of the virus in epithelial cells was abrogated in vitro
during the transport of pIgA 7D9 from the basolateral side to the apical side of cultured cells.
These findings identify a mechanism of protection relying on antibodies directed at inner core
protein of the virus and open new perspectives for the development of functional vaccines.
3.1.2 Structure of human SC and implications for biological functions
In parallel to the first project, human SC was produced and purified for structural
analyses. This work was performed in collaboration with Pr. S. Perkins and his collaborators
at the University College London. The techniques used to unravel the structural properties of
SC were specially adapted to highly glycosylated proteins and were performed in
physiological solutions with fully glycosylated human SC. These methods included X-ray and
neutron scattering, analytical ultracentrifugation and computer-based modelling. This work
led to the discovery of the three dimensional structure of free human SC depicted in figure 7.
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Unexpectedly, the protein displayed a “J-shaped” structure, where D4 and D5 were folded
back on D3 and D2. The seven glycosylation sites were distributed in two main regions and
more importantly, on the opposite site of the known IgA-binding sites. Thus, the critical sites
for IgA-binding were not covered by glycan residues and remained free to interact with IgA.
Moreover, the glycan residues were grouped together and can thus efficiently tether microbial
structures on SIgA. The long and flexible “tail” consisting of the linker between SC and the
transmembranar part of pIgR did not display any particular folding. This suggests that SC can
freely move around its membrane anchor and thus easily interact with surrounding pIgA.
Clusters of
glycans
CDR-like motifs
1, 2 and 3
Cys 502
Linker
Figure 7: The three-dimensional structure of human SC
Ribbon representation of the best-fit model of human SC with the five domains (DI
to DV) highlighted from blue (N-terminus) to red (C-terminus). Glycan residues are
shown in grey, and more specifically sialic acid residues and galactose in orange and
purple respectively. Glycans are clustered in two main regions, and thus leaves the 2
IgA-binding sites (Cys 502 in yellow and complementary determining region (CDR)-
like motifs in pink) accessible. The long “tail” represent the linker between SC and
the transmembranar portion of pIgR.
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Altogether, these data represent the first structural analysis of full length human SC and
pave the way to the discovery of the still unknown three-dimensional structure of SIgA. This
work is described in details in the paper presented in annex 3.
3.1.3 Concluding remarks
This first part allowed the identification of important novel information about defence
mechanisms at mucosal surfaces. SC was demonstrated to exert neutralising properties toward
pathogenic structures through specific glycan residues, and although not a universal
mechanism, this adds a novel property to this multi-functional protein. Structural analyses
revealed for the first time the three-dimensional structure of SC. The protective glycans
identified in the first study are optimally distributed on the protein to allow neutralisation
without affecting pIgA binding. Finally, the neutralising property of a defined IgA toward
rotavirus was identified to take place within epithelial cells. Collectively, these data provide
novel knowledge on several aspects of the intestinal mucosal defence.
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Part II
Modulation of allergic reactions with a probiotic
strain in a murine model of food allergy
3.2 The murine model of food-mediated allergy
3.2.1 Establishment of the model
In order to assess the potential protective or modulatory functions of microorganisms in
the development of food-mediated allergic reactions, a reliable model of food allergy was
needed. The first step of this work was thus to establish a robust and reproductive model of
food allergy in mouse. As mice do not spontaneously develop allergy and that no mutation of
genes identified so far provoke allergy, a sensitisation procedure is needed to generate
“allergic” or sensitised mice. Various sensitisation procedures have been described196-200 and
differ in the adjuvant, the allergen, the mouse genetic background and the way of
administration used. There are roughly two ways to sensitise mice: the first one consists of
one or two systemic sensitisations (generally intraperitoneal administration of the allergen
adjuvantised with alum198, or complete Freud adjuvant200) followed by repetitive intragastric
challenges with the allergen, which finally trigger an allergic intestinal inflammation
associated with diarrhea. The second approach to sensitise rodents consists of successive
intragastric administrations of the allergen together with the mucosal adjuvant cholera toxin
(CT). In the latter case, allergic reactions are observed after a single intragastric challenge
performed at the end of the sensitisation procedure. In order to avoid the systemic bias
associated with the first approach, we chose to work with cholera toxin-induced intestinal
sensitisation in the murine BALB/c background using the model allergen OVA. The
sensitisation procedure consisted of successive intragastric gavages (IG) of the allergen mixed
with CT every week.
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Mouse
Background
Allergen Nb of IG Reference
C3H/HeJ Peanut 2 197
C3H/HeOuJ β-lactoglobulin 3-4 199
C3H/HeJ Cow’s milk 5 196
C3H/HeJ Peanut 5 201
C3H/HeJ OVA 5 202
BALB/c Cow’s milk 6 141
C3H/HeJ Peanut 8 203
C3H/HeJ Peanut 10 204
As the number of IG required to induce a good sensitisation depends on the combination
of the genetic background and the allergen (as shown in Table 3), a first experiment was
conducted with 3 groups of mice sensitised with increasing numbers of IG with OVA and CT
(Figure 8A). One week after the end of the sensitisation, mice were challenged intragastrically
with 100 mg OVA to induce allergic reactions and allergic manifestations were evaluated.
Signs considered included i) the transient decrease of rectal temperature observed during an
anaphylactic choc. Due to degranulation of mast cells, vasodilatation occurs and consequently
pressure and temperature decrease; ii) allergic score, which was given along a pre-established
scale considering scratching, diarrhea and behaviour (see 2.2.6 and Table 2); iii) allergen-
specific IgE, which are essential partners of allergic reaction; iv) degranulation of mucosal
mast cells, which was monitored by quantification of mouse mast cell protease-1 (MMCP-
1)205 in serum after challenge. As shown in figure 8B-E, mice sensitised with 3 IG presented
only mild allergic manifestations compared to mice sensitised with 5 or 7 IG. Temperature
drop and allergic score were restricted to a small number of mice and were in average smaller
than in mice sensitised with 5 or 7 IG. The concentration of serum MMCP-1, was
systematically increased after challenge, but the concentration was greater in mice sensitised
with 5 or 7 IG. Finally, even though detectable in all sensitised mice, serum OVA-specific
IgE remained low up to the 7th IG. Altogether these data indicate that a greater sensitisation is
obtained with 5 or 7 IG, and that even though differences between 5 and 7 IG are not
significant, the 7 IG protocol tends to induce a more pronounced sensitisation in a larger
number of mice. Knowing that we aim to study down-regulation of allergic reaction with
microorganisms, we chosed to use the sensitisation procedure with 7 IG of OVA and CT. The
Table 3: Murine models of food-mediated allergy with CT-induced sensitisation
The various combinations of mouse background and allergen are presented with the
number of IG needed for efficient sensitisation and with the corresponding reference
in the right column.
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Figure 8: Establishment of the model
A, Three sensitisation protocols were compared for their ability to induce allergic
manifestations in mice following challenge with the allergen OVA. Mice were
treated either with 3 (light pink), 5 (pink) or 7 (red) intragastric gavages (IG) with 20
mg OVA and 10 µg CT. B, Temperature was recorded before and 30 min post-
challenge; differences are presented. C, Allergic scores. D, Concentration of
MMCP-1 was measured in serum one day before challenge (open circles) and 3-4
hours post-challenge (filled circles). E, Levels of serum OVA-specific IgE were
quantified at the end of the sensitisation procedure.
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use of this sustained sensitisation procedure will allow a larger number of mice to become
allergic and will constitute a more robust control group for comparison with probiotic-treated
groups. However, we are well aware that a too marked sensitisation might be more difficult to
down-regulate, but we preferred to have a strongly sensitised group to study possible
modulation of allergy. This decision were further supported in the view of the very large
intra-group variability occurring in this food-mediated allergy model.
3.2.2 Characterization of the model
Having established the sensitisation protocol, further characterization and additional
analyses were performed in particular with respect to two important control groups. The
immune response induced toward OVA in the sensitised mice must first be compared with the
normal immune response induced after administration of OVA only. Therefore, groups of
mice were fed with OVA following the same schedule, in order to induce conventional oral
tolerance. Additionally, as bystander effects of the mucosal adjuvant CT could not be ruled
out, groups of mice were treated with CT only (referred as negative control; see figure 9A).
All experimental groups were challenged intragastrically with 100 mg OVA, and subsequent
allergic reactions were analysed. Data are presented in figure 9. Temperature drop and
allergic score were induced specifically in the sensitised group in contrast to tolerised and
negative control mice, which did not present any changes after challenge. It must be noted
that the sensitised group presented a very large variability from one mice to another, a feature
that remained inherent to every experiment performed in this work. As shown before, the
concentration of MMCP-1 in sera of sensitised mice was significantly increased after
challenge demonstrating that degranulation of mucosal mast cells occurred in the presence of
OVA. Such degranulation was not observed in tolerised or negative control mice, where
MMCP-1 concentrations remained unchanged after challenge. Interestingly, MMCP-1
concentration before challenge differed between tolerised group and CT-treated groups,
suggesting a bystander inflammatory effect of CT within the intestinal mucosa. Although
known to be released at the level of the mucosa205, MMCP-1 was also quantified in intestinal
secretions 3-4 hours post-challenge. MMCP-1 could be detected in luminal secretions but was
only moderately increased in some sensitised mice. Even if MMCP-1 might be difficult to
measure in intestinal secretions due to dilution required for recovery, this suggests that this
protease is also released in the intestinal lumen and might thus have an effect there. However,
the differences between sensitised mice and control mice remained small and limited to a
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Figure 9: Characterization of the model
A, Groups of mice were treated either with 20 mg OVA + 10 µg CT to induce
sensitisation (red), or 20 mg OVA to induce tolerisation (green), or with 10 µg CT as
a negative control (white). Altogether, mice received 7 IG, once every week and
were then challenged intragastrically with 100 mg OVA. B, Temperature drop after
challenge. C, Allergic score. D, Serum MMCP-1 concentration before (open circles)
and 3-4 hours post challenge (filled circles). E, MMCP-1 concentration in intestinal
secretion post-challenge. Data presented are a pool of 2 representative experiments
for each group.
60
reduced number of mice; in subsequent experiments, degranulation of mucosal mast cells will
be monitored exclusively by the presence of MMCP-1 in serum. Histamine, another mediator
released by mast cells after degranulation has been used as a marker of allergy in some
models201. Here, histamine was undetectable in sera collected one hour post-challenge. Indeed
animal models with BALB/c mice have failed to detect any histamine releases so far141.
Histamine was therefore dropped as a read-out to measure allergic reactions.
Antibody response
Besides the allergic signs, the humoral response was quantified before, during and at the
end of the protocol in all experimental groups. OVA-specific IgE were already shown to
increase with the number of IG during sensitisation. Here we show that OVA-specific IgA,
IgG1 and IgG2a were also strongly induced upon sensitisation (figure 10A-D). Surprisingly,
OVA-specific antibodies were not detected in tolerised mice, even if dilution was 100 times
smaller. In some rare cases however, OVA-specific IgG1 could be slightly detected in
tolerised mice, but these were more exceptions than the rule. As expected, OVA-specific
antibodies were strictly absent in the negative control group. The levels of OVA-specific
IgG1 were extremely high in sensitised mice, (a 1 to 1’000’000 dilution failed to quench the
signal) yet, they did not prevent the apparition of signs after challenge. In addition to the
OVA-specific humoral response induced during the sensitisation, total IgE were also
quantified (figure 10E). Although significantly increased in the sensitised group at the end of
the experimental protocols, total IgE were however not be considered as a reliable marker of
food allergy, even if it has been used elsewhere198. Indeed, total IgE was shown to increase
unspecifically in some control experiments, as it might happen during parasitic or pathogenic
infections.
Besides antibodies present in serum, a large amount of antibodies (mainly SIgA) are
secreted within the intestine. As sensitisation and challenges were performed strictly at the
level of the intestinal mucosa, it was of great interest to measure OVA-specific SIgA in faeces
and thus to assess the role of SIgA in allergy. In our model, OVA-specific SIgAs were
strongly induced in sensitised mice, but remained absolutely undetectable in tolerised mice
(figure 11). This result contrasts with data obtained in a similar model of food allergy85, and
suggests that the genetic background of mice in combination with the allergen used results in
different immune responses. In the context of the generally accepted role of SIgA as a
neutralising agent responsible for immune exclusion, it is noteworthy to mention that even in
the presence of OVA-specific SIgA, allergic reaction occured. It is true however that levels of
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Figure 10: Humoral response induced by the sensitisation protocol
A, OVA-specific IgE concentration was measured before (d=-1), during (d=28) and
at the end (d=46) of the sensitisation protocol. B, C, D, Levels of OVA-specific IgA,
IgG1 and IgG2a, respectively, quantified at the same time points. Tolerised and
negative control groups are not presented as OVA-specific Igs were undetectable. E,
Concentration of total IgE in serum of sensitised (red), tolerised (green) and negative
control (white) mice; means and SD are presented.
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anti-OVA SIgA were probably not sufficient to neutralise the 100 mg OVA used for
challenge. Because CT is a mucosal adjuvant known to increase SIgA206,207, total SIgA
concentrations were quantified in all groups as a control experiment. A slight increase of total
SIgA was seen timewise in all experimental groups, probably reflecting the onset of immune
responses toward encountered antigens during life. No differences were observed between
tolerised and CT-treated groups, suggesting that CT had only minor bystander effects toward
the production of total SIgA and contributed mainly as an adjuvant to trigger OVA-specific
SIgA in this model.
Histology and mucosal mast cells
To further analyse the immune response taking place at the level of the intestinal mucosa,
the general aspect of the jejunum mucosa was examined after the challenge. Jejunum samples
were chosen because of their location in the upper part of the small intestine, which should
encounter the antigen first, when it is only partly degraded. In addition, differences between
jejunum and ileum sections have been shown to be limited198. No visible inflammation
(increased thickness of mucosa or recruitment of lymphocytes) was observed in the jejunum
of sensitised mice (data not shown), meaning that the overall integrity of the intestinal barrier
was preserved. Nonetheless, as shown earlier, MMCP-1 was strongly increased in sensitised
mice after challenge due to degranulation of mucosal mast cells. Therefore, mucosal mast
cells were analysed in sensitised, tolerised and negative control groups. Two mast cell-
specific staining procedure were used; a very large heterogeneity has been described among
Figure 11: Secretory antibodies induced during experimental protocosls
A, OVA-specific SIgA in faeces were quantified before (d=-1), during (d=28) and at
the end (d=46) of the sensitisation procedure. B, Concentration of total SIgA was
determined in faeces of sensitised (red), tolerised (green) and negative control (white)
mice.
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mast cells, which have been roughly divided in two subtypes according to their localisation:
the connective tissue mast cells (CTMC) and mucosal mast cells (MMC)208. The content of
proteoglycans and proteinases of the granules differs in these two populations even though a
strict distinction is not possible. Rodent CTMC granules contain mainly heparin and
esterases, whereas MMC granules contain chondroitin sulfate and various proteases, i.e.
tryptases and chymases (among which MMCP-1 is exclusively expressed in MMCs)209,210.
The different staining methods used are based on the content of the granule, and allow
therefore distinction between different subtypes of mast cells. In our hands, using paraffin
embedding, toluidine blue allowed the coloration of mast cell located at the periphery of the
cross sections, in close contact with blood vessels (figure 12A, right). Toluidine blue positive
mast cells were therefore considered as CTMCs, although in very close association with the
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Figure 12: Mast cells in jejunum cross-sections
A, Pictures of adjacent cross-sections stained with fuchsine (left) or toluidine (right)
revealing mast cells (arrowheads). Overlap of both pictures is presented in the
central image. B, Number of mucosal mast cells (MMC) stained with fuchsine per
cross-section was counted and represented as an average of 3-4 cross-sections per
mouse. C, Number of connective tissue mast cells (CTMC) stained with toluidine,
counted and represented as in B. Sensitised (red), tolerised (green) and negative
control (white) mice are presented.
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intestinal mucosa. Fuchsine staining on the other hand, allowed the visualisation of mast cell
at the periphery (as with toluidine blue) but also within the lamina propria (figue 12A, left);
these latter were thus considered as MMCs. Interestingly, only minor increase of MMCs was
observed in some sensitised mice as compared to tolerised or control negative group (figure
12B), and almost no differences (although statistically significant when compared with the
tolerised group) for CTMCs (figure 12C). This demonstrated that even if a consequent
degranulation was observed, there was no massive recruitment of mast cells within the
mucosa. This observation differs with data obtained in a different model198, in which
repetitive challenges induced an important recruitment of mast cells within the lamina propria
of the small intestine. This suggests that the model developed here does not lead to an
exacerbated inflammation at mucosal site, despite the long mucosal sensitisation required to
trigger physiologic manifestations of allergy.
Cytokine profile of immune cells
Up to now, the immune response induced toward OVA in sensitised and tolerised mice
was monitored at the antibody levels. In order to assess the cellular response taking place at
the mucosal level (in the MLN) and systemically (in the SPL), stimulation of immune cells
with the allergen was performed ex vivo and cytokine secretion was determined by ELISA in
culture supernatant. Briefly, MLN and SPL cells were collected 3-4 hours post challenge,
isolated and stimulated with OVA. Preliminary experiments allowed us to determine optimal
stimulation time as 5 days and optimal concentration of OVA at 250 µg/ml. Another
preliminary experiment was then performed to evaluate the potential role of LPS, which is
known to be present in considerable amount in the OVA preparation from Fluka, in skewing
the immune response toward a Th1-typed profile. MLN and SPL cells from sensitised mice
were thus either stimulated with OVA used for sensitisation (from Fluka, containing
approximately 15 pg LPS per µg OVA) or with highly purified OVA (from Worthington,
containing approximately 1.3 pg LPS per µg OVA; Caroline Boudousquié, personal
communication) and cytokine secretion was analysed in supernatants by ELISA. IL-5, IL-13
and IFN-γ concentrations were actually higher when stimulated with the OVA from Fluka
than with the highly purified OVA from Worthington, especially for MLN cells (Figure 13).
Nonetheless, the general profile of cytokine produced after stimulation with the two OVA
preparations was similar; the ratio between values obtained with OVA from Fluka and those
obtained with OVA from Worthington were almost identical for Th2 and Th1 cytokines. This
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suggests that LPS might stimulate the overall immune response but without affecting the
particular cytokine profile of immune cells. It should be noted however that the differences
observed between OVA from Fluka and OVA from Worthington might also result from the
OVA itself, which is in one case a crude stock known to aggregate, and in the other case a
highly purified OVA. This might also explain the differences of response, and indeed mice
were sensitised with OVA from Fluka. For this reason, ex vivo stimulation were then
performed with OVA from Fluka exclusively. An additional control experiment was
performed to ensure that no unspecific activation of cells with OVA was taking place. MLN
and SPL cells from naïve mice were thus stimulated using the same conditions (250 µg/ml
OVA form Fluka during 5 days). IL-5, IL-13 and IFN-γ were undetectable in culture
supernatant, similarly to cells that remained unstimulated. Altogether, these preliminary
experiments demonstrate that the assay is functional: the cytokine profile measured is the
result of specific activation and if LPS has some sort of boosting effect, it does not skew the
immune response specifically.
Having established optimal timing and conditions for cytokine assay, IL-5, IL-13, IL-10
and IFN-γ were quantified in culture supernatants of MLN and SPL cells from sensitised,
tolerised and negative control group (figure 14). IL-4 and TGF-β were also quantified in these
supernatants but were undetectable (Detection limits for IL-4: 5 U/ml and TGF-β: 1 ng/ml).
IL-5 and IL-13, two Th2 cytokines, were induced in sensitised mice but not in tolerised, nor
in the negative control as expected. Surprisingly, IL-10, a regulatory cytokine, which has been
Figure 13: Cytokine profile after stimulation with different source of OVA
MLN and SPL cells from sensitised mice were stimulated 5 days with 250 µg/ml
OVA either from Fluka (grey) or from Worthington (white). Concentrations of IL-5,
IL-13 and IFN-γ quantified in supernatant are represented as means and SD. Ratio
between values obtained with OVA Fluka and OVA Worthigton are indicated under.
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shown to play an important role in the induction of oral tolerance211, was also detected in
sensitised but not in tolerised mice. The presence of substantial amount of IFN-γ is somehow
also unexpected as allergic reactions have been shown to be related to Th2 cytokines, and that
INF-γ seems to be protective for allergy in similar model203,204. The presence of this INF-γ
could not be accounted to unspecfic activation of cells. Indeed, it had been shown that
different immune responses were generated according to genetic background and allergen141.
Moreover, IFN-γ has been mesured in different models of allergy, especially those with the
BALB/c background198,200.
The absence of any cytokine produced by cells of tolerised mice confirmed that oral
tolerance took place, and probably through the mechanism of anergy known to take place
with high doses of antigen212. There were probably no OVA-specific cells in these mice
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Figure 14: Cytokine profile of MLN and SPL cells
MLN and SPL cells of sensitised (red), tolerised (green) or negative control (white)
mice were collected post-challenge and stimulated with 250 µg/ml OVA. Cytokine
concentration was determined in the supernatant after 5 days of culture. A, IL-5. B,
IL-13. C, IL-10. And D, IFN-γ.
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anymore; the analysis was performed at the end of the experimental protocol and hence could
not identify immune reactions that took place when the immune system first encountered the
antigen. It is important to note as well that the concentrations of cytokines are similar between
MLN and SPL cells. Assuming that the sensitisation was restricted to the mucosa, it is clear
however that the sensitisation was distributed all over the organism, and that activation of
systemic cells occurred. This raises also the question of what part of the allergic reaction
takes place at the mucosal level, and what part of the reaction acts at the systemical level.
Considering all available read-outs related to the model, we tested whether any correlation
between read-outs could be established, with the aim to get inside into the mechanisms or
determinant factors associated with allergy. Every read-out, which was demonstrated to be
statistically different of the two control groups (i.e. temperature drop, allergic score, serum
MMCP-1, OVA-specific IgE, IgG1, IgG2a, IgA, SIgA, mast cell number, and cytokines)
were compared one by one, but none of them presented any correlation with the others. Some
correlations were sporadically observed, but never repeated from one experiment to the other,
probably being the fruit of hazard. It is somehow very surprising, as one might have expected
that high IgE was associated with high physiological manifestations, or high mast cell number
associated with high concentration of MMCP-1. The absence of any correlation between read-
outs suggests that some determinant aspects of food-mediated allergy remain do be explored.
Transfer of the model
To confirm the robustness of the model, and in order to know whether it can be used in
different environments, the established model was tested in two additional animal facilities: in
the Nestlé research centre (CRN) and in the specific pathogen free (SPF) section of the
CHUV. Major allergic manifestations are represented in figure 15, and confirmed that the
model was transferable in conventional animal facilities. Indeed, the sensitisation performed
in the CRN was as strong as, if not greater, than in the animal facility of the CHUV.
Interestingly, when sensitisation was performed in the SPF section of the CHUV, the
physiological signs (temperature drop and allergic score) of sensitised mice were almost
absent, although OVA-specific IgE were largely produced, and degranulation of mucosal
mast cells occurred. This raises interesting question regarding the underlying mechanisms of
physiologic signs, and it will be discussed later. These results further confirm the
reproducibility and strength of this model even though sensitisation in an SPF section reduces
the number of read-outs that can be used to measure allergy. Actually, animal models,
especially allergy models, are often difficult to transfer from one animal facility to another.
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These difficulties are probably related to differences in the mouse microbiota and unidentified
pathogens present in animal facilities.
To summarize, the model presented here was shown to be reproducible, to induce strong
manifestations of allergy, and to include different read-outs related to various aspects of the
disease. The strength of this model resides in the many read-outs used to measure allergy, and
will allow the study of potential modulators of allergy at different levels of the allergic
reactions.
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Figure 15: Allergic manifestations of mice sensitised in different animal facilities
A, Temperature variation after challenge of sensitised mice in 3 different animal
facilities. B, Allergic score. C, Serum MMCP-1 concentration before (open circles)
and after (plain circles) challenge. D, Level of OVA-specific IgE in sera at the end of
the sensitisation procedure. CHUV: Centre hospitalier universitaire vaudois; CRN:
Centre Recherche Nestlé; SPF: Specific pathogen free section of the CHUV’s animal
facility.
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3.3 Modulation of allergic reactions with a probiotic
bacterium
3.3.1 Persistence of the probiotic strain in the mouse gastrointestinal tract
and administration protocol
The Lactobacillus paracasei NCC2461 was used as probiotic strain to test its potential
role in the prevention and/or treatment of OVA-mediated allergic reactions in a mouse model.
In order to determine the optimal protocol of administration, the persistence of this
Lactobacillus strain in the gastrointestinal tract of mice housed in the animal facility of the
CHUV was evaluated. Mice were given 109 CFU NCC2461 strain intragastrically and its
presence was specifically tested in faeces collected 24h, 48h and 72h post-administration. L.
paracasei NCC2461 was detected in faeces of mice 24h post-administration, but only rarely
thereafter. Although the detection limit of the technique used was high, this result suggested
that the probiotic did not colonise the murine gastrointestinal gut, and was probably rapidly
washed out. For this reason, the administration protocol of the probiotic strain was established
as one intragastric administration of 109 CFU every 2 or 3 days, in order to ensure that L.
paracasei NCC2461 was present, at least in small quantities, in the gastrointestinal tract
throughout the protocol. Alternatively, administration of the probiotic could be performed
with feeding bottles, where the Lactobacillus strain is diluted in water and available ad
libitum to mice during the protocol. Even if feeding bottles circumvent the stress
experimented by mice in comparison to IG, they are also more susceptible to contamination
and sedimentation of the probiotic. This possibility was not chosen in order to ensure that all
mice received the same quantity of probiotic strains. Moreover, the variability of allergic
manifestation intensities within a group was already very high, thus, additional variations
were preferentially be avoided.
To summarise, L. paracasei NCC2461 strain was given to mice through IG every 2 or 3
days (Monday morning, Wednesday and Friday afternoon) throughout the experimental
protocol, with a dose of 109 CFU / dose (figure 16A). The presence of the probiotic was thus
guaranteed during the sensitisation protocol and maximised the likelihood to observe the
potential modulating effect of L. paracasei NCC2461 strain toward allergic reactions.
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3.3.2 Modulation of allergic reactions by L. paracasei NCC2461
The potential modulatory effect of L. paracasei NCC2461 was then tested in the murine
model of food-mediated allergy, following the administration protocol described above.
Probiotic-treated groups were systematically compared to a sensitised group (figure 16A).
This experiment was performed altogether four times, and resulted in divergent data. Results
of two representatives experiments (Exp A and Exp B) are presented in figures 16, 17 and 18.
Figure 16 presents allergic manifestations of sensitised and probiotic-treated mice after
challenge and demonstrates very clearly that the probiotic strain was able to prevent allergic
reactions in Exp A, but not in Exp B. Mice treated in Exp A did not display any decrease of
temperature (figure 16B) and showed only intermediate allergic score (figure 16C) post-
challenge. In contrast, mice treated in Exp B were equally affected as sensitised mice. The
percentage of mice suffering from diarrhea (a feature included in the allergic score scale) was
70 % in the sensitised group, totally absent in probiotic-treated group Exp A and 70 % in Exp
B, clearly indicating that in one case (Exp A) protection was effective. In addition to the
physiological signs, degranulation of mucosal mast cells was prevented in Exp A, but not in
Exp B, where concentrations of MMCP-1 were equal to those found in sensitised mice (figure
16D). It is interesting to note that the basal level of MMCP-1 before challenge was also
significantly lower in the probiotic-treated group (Exp A) suggesting that sensitisation was
prevented in these mice. This notion was further supported by the analysis of OVA-specific
IgE, which were significantly decreased throughout the protocol in the probiotic-treated group
of Exp A, and logically not in Exp B.
Further analysis of the humoral response showed that OVA-specific IgG1 and IgG2a in
both experiments were almost unaffected by the treatment (figure 17). At the end of the
protocols, levels of OVA-specific IgG1 were similar in the three groups of mice; similarly,
levels of OVA-specific IgG2a were only mildly influenced by the treatment. It is interesting
to note that the probiotic treatment in the two experiments seemed to act in an opposite
manner; in Exp A, OVA-specific IgG2a are slightly increased compared to the sensitised
group, a tendency inverted in Exp B. Whether this observation is linked to the mechanisms of
action of the probiotic strain remains very hypothetical, as significance was indeed very week.
Importantly, when protective modulation with L. paracasei NCC2461 was effective, mice
were fully protected from the occurrence of allergic reactions, but had, however, induced a
strong immune response against the allergen. This implies that the probiotic did not impair the
action of the adjuvant; OVA was still perceived by the immune system but did not lead to the
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Figure 16: Modulation of allergic reactions by L. paracasei NCC2461
A, Mice treated with L. paracasei NCC2461 received in total 23 administrations of
109 CFU during the sensitisation protocol (blue). For comparison, a group of mice
was sensitised as previously (red). The experiment was performed four times, and
two representative experiments are shown (Exp A and Exp B). B, Temperature
variation after challenge.  C, Allergic score. D, Serum MMCP-1 concentration
before (open circles) and after (plain circles) challenge. E, Level of OVA-specific
IgE in sera before (day=-1) during (day=21) and at the end (day=49) of the
sensitisation.
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production of the allergy-associated isotype IgE. The mechanisms leading to tolerisation on
one hand, and those induced by the probiotic treatment in the other hand must therefore
greatly differ.
Besides the allergic signs and the humoral response, the cytokine profiles of MLN and
SPL cells were determined for each experiment and are presented in figure 18. As cytokine
concentrations were slightly variable from one experiment to another, each probiotic-treated
group had to be compared with its own sensitised control group. Production of Th2 cytokines
(IL-5 and IL-13) by MLN and SPL cells of L. paracasei-treated mice of Exp A was strongly
reduced compared to the sensitised group. In contrast, MLN and SPL cells of mice treated in
Exp B produced as much of Th2 cytokines as cells from sensitised mice, except for IL-13 in
MLN, but this is most likely due to the large variability of the sensitised group rather than a
real effect of the probiotic. The situation was almost similar for IL-10, but interestingly,
probiotic-treated mice in Exp B displayed an increase of IL-10 production by MLN, and, in a
lesser extend, by SPL cells. Here again, it is difficult to evaluate if these differences are linked
to the mechanism of action of the probiotic and to the success of the treatment, or whether
they were consequences of unknown and/or unrelated events. Concentrations of IFN-γ were
more stable and seemed to be less affected by the probiotic treatment, except for MLN cells in
Exp A. This suggests that IFN-γ did not play a crucial role in the down-regulation of the
allergic reactions mediated by L. paracasei NCC2461.
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Figure 17: Humoral response induced in sensitised and probiotic-treated mice
A, OVA-specific IgG1 levels were measured before (d=-1), during (d=21) and at the
end (d=49) of the experimental protocols. B, OVA-specific IgG2a levels were
quantified similarly. Sensitised mice are shown in red and 2 representative
experiments of L. paracasei NCC2461-treated group in blue (Exp A and B).
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Altogether, these results demonstrate that down-regulation of allergic reactions through
the L. paracasei NCC2461 is feasible. However, a lack of reproductibility was observed,
although maximal care was taken to strictly repeat the experiment. The batch of L. paracasei
NCC2461 used for Exp A and B was the same; aliquots used for the treatment were derived
from the same original culture. Two additional experiments were conducted with a new batch
of the same probiotic and both gave similar lack of modulation as in Exp B, as reflected by
the absence of protection against any allergic manifestations. This points out that special
conditions are obviously required in order that the probiotic strain can act as a protector. Of
note, the only macroscopic difference between Exp A and Exp B, besides the mice
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Figure 18: Cytokines produced by MLN and SPL cells of sensitised and
probiotic-treated mice.
MLN and SPL cells were collected 3-4 hours post challenge and stimulated 5 days
with 250 µg/ml OVA. Supernatants were used to quantify cytokines. Data are
presented as box plots and whiskers that show the 5th, 25th, 50th, 75th, and 95th
percentiles. Sensitised mice are presented in red and L. paracasei NCC2461-treated
mice in blue. Two experiments are presented Exp A on the left and Exp B on the
right for each panel.  A, IL-5. B, IL-13, C, IL-10 D, IFN-γ.
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themselves, was the litter, which had been changed at the beginning of Exp B for technical
reasons. Although this sounds as a futile detail, one can however imagine that the general
environmental conditions around mice (dust, microparticles and humidity) might influence
the outcome of the experiment. Beside this difference, another important element, but that
remains unfortunately uncontrollable in conventional animal facilities, is the intestinal
microbiota of mice. As an attempt to understand what might have influenced the outcome of
the probiotic treatment, the intestinal microbiota of mice in Exp A and B was analysed. Data
are presented in the next section.
3.3.3 Variability of the intestinal microbiota
Commercially available laboratory mice are currently raised in SPF conditions and
possess a complex commensal microbiota derived from the Schaedler’s flora, a collection of
eight bacteria isolated from faeces of mice in the 1960s213. Successive generations in SPF
conditions protected mice against specific pathogens, but allowed however the accumulation
of much more complex microbiota214. The community of intestinal bacteria is further
modified upon arrival of mice at their final destination, especially in conventional area of the
animal facility, where the environment is less controlled. Intestinal microbiota is considered
nowadays to be stable, but flexible to environmental changes215, and might slightly differ
occasionally, following environmental variations. We thus hypothesised that the intrinsic
variability of our animal facility might have influenced the outcome of the probiotic treatment
in our experiments. We used PCR coupled to differential gradient gel electrophoresis (DGGE)
analysis to determine the variability among the intestinal microbiota of mice from one
experiment to another. In a second time, this method was also used to estimate whether a
defined DGGE profile was associated with the probiotic treatment and possibly to successful
modulation. Bacterial DNA present in faeces collected at the end of each experiment was
used to amplify 16rRNA sequences by PCR. Amplification products were then subjected to
DGGE to generate a profile of bands, which was subsequently analysed as a function of their
similarity. The analysis was assisted by a computer program that allowed the determination of
the Dice coefficient. Analysis of total microbiota was performed on three mice of each group
(Exp A and B; sensitised and probiotic-treated groups) and profiles were aligned along a tree
graph according to their similarities (figure 19). The results highlighted not only an
exceptional variability among experimental groups, but also a marked intragroup variability.
Mice housed in the same cage could present up to less than 75% homology (mouse n°2 and
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n°3 compared with n°1 of the probiotic-treated group in Exp A). This important information
demonstrated that a huge variability takes place in the animal facility of the CHUV, and this
might of course account for the differential results, especially in the case of a treatment with a
probiotic. This analysis could however not allow the identification of a defined profile
associated with the probiotic treatment or with successful modulation. Indeed, the variability
intrinsic to the animal facility was too pronounced to observe the effect of the probiotic
treatment. Moreover, the analysis presented here did not give information about the nature of
the microbiota, i.e. what species differ from one experiment to another, as it is only semi-
quantitative. A more detailed analysis of the microbiota present during the experiment would
probably give powerful insights to determine optimal conditions required for successful
treatment
3.3.4 Intestinal permeability in allergic reactions
Although not reproduced, the remarkable modulation mediated by the probiotic treatment
in Exp A raises exciting questions regarding the mechanisms involved in such a modulation.
As an attempt to understand how modulation by the probiotic took place, intestinal
permeability was studied in this model of food allergy. It is widely accepted that in case of
intestinal inflammation, as for example during a pathogenic infection216,217, an increase in
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Figure 19: DGGE profiles generated from faeces of sensitised and probiotic-
treated mice
DGGE profiles were aligned according to their similarities. Faeces of three (1, 2 and
3) mice from the four experimental group (Exp A and B; sensitised and probiotic-
treated mice) were analysed. Sensitised mice are shown in red, L. paracasei
NCC2461-treated mice in blue.
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intestinal permeability is observed. Autoimmune diseases and food allergy were also shown
to be associated to an increased intestinal paracellular permeability218, mainly due to the
action of mast cell proteases, which temporarily loosen tight junctions and thus increase the
paracellular permeability219. We thus hypothesised that the probiotic strain might directly or
indirectly decrease intestinal permeability, thus limiting the access of the allergen to the
mucosa and the systemic compartment, a critical step to trigger allergic reactions. This
hypothesis was further supported by recent findings that probiotics, including L. paracasei
NCC2461 does decrease intestinal permeability, at least for small molecules220,221. To address
this question, we first needed to determine whether increased intestinal permeability toward
the allergen was effectively associated with the allergic reactions in the murine model of food
allergy. Then, the effect of L. paracasei NCC2461 toward the intestinal permeability of the
allergen was evaluated.
To tackle this issue, a reliable method to measure intestinal permeability had to be
identified. Many different techniques have been described to quantify intestinal permeability,
which differ in the probes used. Basically, the size, the solubility, and the charge of the probes
will influence the rate of absorption, and thus define what permeability feature is measured218.
Here, we aimed to know how much OVA translocates from the luminal side to the systemic
compartment, and therefore OVA itself was quantified in sera of mice following intragastric
administration of OVA. A quantitative ELISA was thus developed to measure free or
antibody-complexed OVA present in the sera of mice. The principle of the ELISA is
schematically drawn in figure 20A. A first experiment was performed in order to determine
the optimal timing for blood recovery after OVA administration. Briefly, naïve mice (n=4)
received 50 mg OVA by intragastic gavages, and blood was collected before, and at different
time-points after administration. OVA was rapidly detectable in sera, and decreased gradually
after one hour (figure 20A) as previously observed in a similar model222. The highest
concentration was reached around one hour and thus sera were subsequently collected one
hour post-administration for quantification.
As the method allowed good detection of OVA in naïve, but also in sensitised mice,
intestinal permeability was then quantified in sensitised, tolerised and negative control mice at
the time of challenge. Figure 20B shows OVA concentrations found in sera of mice one hour
after challenge with 100 mg OVA, and clearly demonstrates that increased intestinal
permeability took place in sensitised mice. On average, at least 2 µg of immunoreactive OVA
(500 ng/ml x 4 ml blood) was present one hour post challenge in sensitised mice. We
77
hypothesised that this OVA might lead to the physiological allergic signs (temperature drop
and allergic score) observed during the allergic reaction. Indeed, intravenous challenge with
100 µg OVA resulted in strong allergic score leading systematically to death of sensitised
mice, in contrast to negative control mice which remained unaffected (data not shown).
Furthermore, concentrations of OVA found one hour post-challenge in mice sensitised in SPF
conditions were much lower than those found in mice sensitised in conventional area. As a
reminder, mice sensitised in SPF conditions had equal levels of OVA-specific IgE, and
MMCP-1 concentration post-challenge, but lacked physiological signs (temperature drop and
allergic score). This suggests that systemic OVA is responsible for the occurrence of
Serum OVA
0 1 2 3 4
0
10
20
30
40
50
5 6 7
hours
ng
/m
l
Serum OVA
PBS probiotic
0
100
200
300
400
500
ng
/m
l
Serum OVA
0
200
400
600
800
1000
1200
ng
/m
l
HRP
Rabbit anti-OVA
OVA
mouse anti-OVA
HRP-anti-mouse IgG
*** 
*** 
*** 
NS
Sens. Tol. Neg. Sens.
SPF
A
B C
Principle:      
Figure 20: Measurement of intestinal permeability
A, Schematic drawing of the principle of the ELISA used to detect OVA or
antibody-complexed OVA in mouse sera (left). Time course analysis of the
translocation of OVA from the lumen to the blood in naïve mice after administration
of 50 mg OVA (right). B, Serum concentration of OVA one hour post-challenge in
sensitised (red), tolerised (green) and negative control (white) mice. Mice sensitised
in SPF conditions are shown with a red square. C, Concentration of Serum OVA of
PBS-treated (white) or L. paracasei NCC2461-treated (black) mice one hour after
administration of 100 mg OVA.
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physiological signs, and that a threshold dose of OVA is required to trigger strong allergic
signs. Whether the increase of intestinal permeability is the cause and/or the consequence of
the allergic reaction will be discussed later, but it is clear that increased intestinal permeability
of the allergen is associated with anaphylaxis in this model of food-mediated allergy.
We then tested the hypothesis that the probiotic treatment might decrease intestinal
permeability toward large proteins like OVA, and thus protects mice from allergic reactions.
Groups of naïve mice were thus treated 3 times either with PBS or 109 CFU L. paracasei
NCC2461 every other day to test the effect of the probiotic in standart conditions. One day
after the last administration, mice (n=5-8) received 100 mg of OVA intragastrically and blood
was recovered one hour later to quantify intestinal permeability. Serum OVA concentrations
were found to be identical in both groups, suggesting that, in that case, probiotic treatment did
not affect intestinal permeability. It must however be noted that the protective effect of the
probiotic strain was not always observed and seems to require specific unidentified conditions
to be effective. It is thus unknown if such conditions were present when the intestinal
permeability was analysed, and therefore no definitive conclusions can be drawn.
Unfortunately, sera of probiotic-treated mice in Exp A and B were not collected, as the
method to quantify OVA in sera was not established at that time. The effect of the probiotic
treatment on intestinal permeability in sensitised conditions could thus not be analysed, and
might of course differ from the standard conditions.
To summarise, a sensitive method to measure intestinal permeability toward the protein
OVA was developed. This method allowed us to determine that increased intestinal
permeability of the allergen is associated with allergic reaction, and seems to be linked with
the severity of the physiological manifestations. Whether the probiotic treatment acts on
intestinal permeability itself remains an open issue and requires further analyses to draw
conclusions.
Altogether, these results show that treatment with L. paracasei NCC2461 can protect mice
from allergic reaction induced in a food-mediated allergy model. However, this modulation
requires specific and still unidentified conditions to be reproducible. The identification of
these conditions will certainly contribute to shed light on the mechanisms of action of this
probiotic strain.
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Chapter 4
Discussion and perspectives
4.1 The mouse as a model for studies of food allergy
This work allowed the study of food-mediated allergic reactions in mice, an animal that
does not develop allergic reactions under normal conditions. The choice of the BALB/c
background in combination with OVA was somehow challenging, as this combination was
historically used to study oral tolerance223. Indeed, the BALB/c strain was shown to induce a
more efficient oral tolerance to OVA than other strains such as BALB/B224 or BDFI225.
However, this mouse strain is known to induce preferentially a Th2 type of response
compared to other strains, as it is for Leishmania infections for example226. The ability to
induce a Th2 type of response was thought to be necessary in the development of allergic
disorders, thus the BALB/c strain was chosen. Moreover, allergic disorders, such as asthma227
or more recently food-mediated allergy198 are often studied in models combining BALB/c
mice and the prototype allergen OVA.
The model developed here used the mucosal adjuvant CT to bypass the induction of oral
tolerance, what led to the production of OVA-specific antibodies such as IgG and more
importantly in the case of allergy, IgE. Although the mechanisms of action of CT are still not
elucidated, it is thought to act at several levels228. CT was shown to increase intestinal
permeability toward antigens and might thus enhance the number of molecules getting into
contact with immunological cells229,230. CT also promotes antigen presentation by DC and up-
regulation of co-stimulatory molecules CD80 and CD86 as well as the chemokine receptor
CCR7231. Although often associated with Th2 responses, CT generally leads to a mixed
Th1/Th2 response108, which may rely on the genetic background of the mice.
The use of this mucosal adjuvant might appear artificial and far from the reality affecting
allergic humans. However, considering the above-mentioned modes of action of CT, one can
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easily imagine that similar mechanisms lead to the development of allergies in human,
although the cause is actually different. Therefore, even if the use of CT is somehow artificial,
the study of the development and subsequently the activation of allergic reactions in the
mouse is relevant. Indeed, our model included many features observed in humans; i) the
presence of antigen-specific IgE, ii) allergic signs including diarrhea and decrease of body
temperature triggered after antigen challenge, iii) degranulation of mast cells, and iv)
induction of Th2 cytokines upon allergen stimulation. The Th1 cytokine IFN-γ was also
strongly produced upon in vitro stimulation with the allergen. As the presence of IFN-γ could
not be accounted for unspecific activation of cells, these data confirmed that sensitisation of
BALB/c mice with CT induce a mixed Th1/Th2 response. It is interesting to note that even if
IFN-γ was largely produced, strong allergic reactions were however observed in sensitised
mice. This challenges the notion that Th1 cytokines can prevent141 or even cure204 allergic
reactions. Indeed, protective treatment of mice either with an engineered allergen mixed with
heat-killed Listeria monocytogenes203, or with food herbal allergic formula204 was associated
with Th1 cytokines. The demonstration that Th1 cytokines are essential for the protection is
however still missing, and, although obtained in a different model, our data suggest that other
mechanisms are required to induce complete protection.
A critical aspect of the model developed in this work was the important intra-group
variability. Mice treated with OVA and CT could develop allergic signs from strong to very
moderate intensities. More puzzling, was the fact that no correlation was observed between
the different allergic read-outs; high levels of IgE or important degranulation of mast cells
was not associated with the temperature drop or the allergic scores, nor with the levels of
other antibody isotypes. Analyses of these correlations were performed with data collected on
the day of challenge, thus limiting the bias due to differential timing. In addition, mice were
systematically roughly “synchronised” before the challenge, using 2-3h starvation to ensure
that OVA got directly in contact with the immune system, and was not “hidden” by other food
components. It might however be too demanding to find such correlations in a model where
many aspects are not controlled. Indeed, the analysis of the intestinal microbiota
demonstrated that although genetically identical and housed in the same conditions, mice
displayed a very heterogeneous microbiota. This heterogeneity might have influenced
differentially the multiple read-outs of allergy and might thus have masked the potential
correlation between read-outs. More importantly, differences among the intestinal microbiota
might directly explain the large variability among the sensitised group. In addition, the
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presence of the viral pathogen MHV in the animal facility must have greatly influenced the
status of the immune system. It is thought that the virus rapidly infects the mouse upon arrival
and that, after 3 weeks the mouse has cleared the infection. However, timing of infection and
clearance might have differed from one mouse to another and thus influenced the intensities
of allergic reaction observed in this model. However, MHV infection was not the only factor
influencing the sensitisation process, as mice sensitised and housed in SPF conditions also
displayed a large intra-group variability.
Nevertheless, this high variability did not prevent the analysis of allergic reactions
assuming that enough mice per group were used. Many read-outs consistently differed
significantly from the two control groups even in these variable conditions. This demonstrates
that the model is robust and might better reflect the reality than models performed in
excessively-controlled environment73,232.
4.2 Digression on oral tolerance and the role of SIgA
Comparison of sensitised mice with tolerised mice allowed the identification of
differential immunological mechanisms. Although in contact with the same amount of OVA
and following the same time-course of delivery, tolerised mice did not induce any antigen-
specific antibody responses throughout the protocol, except in some rare occasions, where
only low levels of IgG were detectable. Moreover, stimulation of SPL and MLN cells with the
antigen did not lead to the production of any cytokines; stimulated cells were comparable to
unstimulated ones with respect to all cytokines tested. This suggests that the underlying
mechanism of tolerisation taking place in this model was either anergy or deletion of most of
OVA-reactive immunological cells. Indeed, doses used here were very high, and therefore
deletion mechanisms should have preferentially taken place over suppression by regulatory T
cells. It can however not be ruled out that regulatory T cells were also contributing to
tolerisation in this protocol, but this question remains open as they were not inverstigated in
this work. Moreover, the analyses were always performed at the end of the protocol, when
tolerisation was completed. It might have been interesting to analyse the cellular response at
the beginning of the tolerisation process to get further insight on the mechanisms involved.
But this was beyond the scope of this work.
Due to the absence of any antigen-specific response, it could also be argued that ignorance
of the antigen was prevailing upon tolerisation. Ignorance describes the situation where the
82
antigen was never “seen” by the immune system, either because degradation occurred or
because it never got into contact with the immune system. This hypothesis is however
unlikely for the following reasons. In the case of sensitisation, the allergen was obviously
seen by the immune system, as a strong allergen-specific response was induced. This
demonstrates that even if degradation occurred within the lumen, a significant proportion of
undegraded OVA got into contact with the immune system. The presence of CT is unlikely to
affect the resistance of the allergen to proteases, and therefore the OVA used in the
tolerisation protocol should not have been more degraded. However, in order to prove that
mice were efficiently tolerised (and thus protected from subsequent sensitisation) a group of
tolerised mice should have been sensitised after the tolerisation protocol. Analysis of antibody
responses and evaluation of the intensity of the allergic reactions post-challenge would have
given the final proof of the efficacy of the tolerisation protocol. This experiment was not
conducted as a large body of evidences showed that oral administration of high or low doses
of antigen prior to immunisation with antigen and CT prevented the production of antigen-
specific IgE and more generally, antigen-specific antibodies at the systemic and mucosal
level233-236. Collectively these studies showed that repetitive oral administration of low doses
of antigen prevented the subsequent induction of allergen-specific IgE and SIgA, whereas a
single high dose of allergen prevented the production of any antibody isotypes upon
subsequent sensitisation with CT. This was shown for different antigens (OVA, BLG and
Kunitz soy-trypsin inhibitor; KSTI) in different murine genetic backgrounds (BALB/c and
C57bl/6). Altogether, these previous works suggest that mice tolerised by oral administration
of allergen effectively “sensed” the antigen and induced a suppressive or deletive immune
response toward allergen-reactive cells. More generally, this raises the following questions:
Does ignorance ever take place at all? Or, does the immune system perceive and subsequently
induces tolerance to every single antigen going through the intestine?  Or is there only a small
proportion of ingested antigens that ever gets into contact with immunological cells? These
questions remain unanswered for several reasons; first, studies are conducted with only a
limited number of proteins, which are generally known allergens, i.e. globular proteins, which
are more prone to resist to proteases. Second, the process of oral tolerance might not always
be “visible”. In the case of oral tolerance mediated by deletion mechanisms, antigen-reactive
cells will be rapidly deleted and thus, no longer observable.
An interesting point to develop is the role of antigen-specific SIgA toward food allergies.
Frossard and colleagues compared SIgA responses in faeces of C3H/HeOuJ mice sensitised
or tolerised to BLG. This study showed that tolerised mice had greater amounts of BLG-
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specific SIgA in faeces compared to sensitised mice. In contrast tolerised mice had lower
serum BLG-specific IgA than sensitised ones85. These results were somehow counterintuitive,
as CT is commonly known to strongly induce antigen-specific SIgA228. However, one
epidemiological study supports these findings; allergic infants were shown to have lower
levels of total SIgA compared to healthy ones, and sensitised but asymptomatic children had
higher levels of SIgA than symptomatic ones237. These data suggest a general protective role
of SIgA toward allergy. However, the antigen-specificity of these antibodies were not
determined, and it remains therefore difficult to draw conclusions on the relationship between
allergy and antigen-specific SIgA. In addition, although often suggested238, IgA deficiencies
are, to date, not correlated with increased susceptibility to food allergy239. Our data differ from
the work of Frossard and colleagues in that, tolerised mice displayed a complete absence of
allergen-specific SIgA (and other antibody isotypes), and in contrast, sensitised mice secreted
large amounts of allergen-specifc SIgA in the lumen. The tolerisation protocols used in these
two studies differed, what might explain the differences. Mice tolerised to BLG received low
doses of BLG in feeding bottle ad libitum, and mice tolerised to OVA received seven times a
high dose of OVA. According to the literature, immune suppression by regulatory T cells
producing IL-10 and TGF-ß would preferentially take place in the BLG-tolerised mice, and
thus favor SIgA production. As mentioned previously, mice tolerised to OVA would have
undergone deletion mechanisms and thus prevent any production of allergen-specific
antibodies. However, the explanation cannot lie solely on this theory. An experimental group
of mice were tolerised with low dose (0.8 mg/ml) of OVA in feeding bottles. This resulted
also in the complete absence of serum or mucosal allergen-specific antibodies throughout the
protocol (data not shown). Therefore, the differences observed more likely reflect
susceptibilities to a defined allergen related to different genetic background of mice.
We thus propose that oral tolerance can range between a gradual scale of immunological
responses, starting with a complete absence of any kind of antibodies to a more pronounced
immune response with production of protective antigen-specific IgG, IgA and SIgA. The
presence of allergen-specific SIgA in secretions does however not always signify a “healthy”
situation of oral tolerance, but can reflect mucosal inflammation, as it happens in the model
developed in this work. Even if SIgA might be protective, they cannot counteract completely
allergic processes. Moreover, it has been shown in models where allergen-specific SIgA are
produced in sensitised mice, that effective treatment either with IL-1285,240 or with vasoactive
intestinal polypeptide241 led to a decrease of allergen-specific SIgA. These studies argue in
favor of allergen-specific SIgA as a marker of inflammation. However, it cannot be ruled out
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that allergen-specific SIgA were active players in the success of the treatment. One can
speculate that SIgA might transiently be increased to allow the re-equilibration of the balance
allergy versus tolerance, which once biased to tolerance, no longer be produced. A careful
time-course analysis of antibody responses in these models with functional and reproducible
treatments might give insights to answer this question.
4.3 Increased intestinal permeability: the cause or the
consequence of allergic reactions?
Intestinal permeability has long been recognised to be associated with intestinal
autoimmune disease such as Crohn’s disease, celiac disease and food allergy218. However,
whether increased permeability precedes the inflammation or is only a consequence of this
inflammation remains controversial. The proof that increased intestinal permeability is at the
least a consequence of inflammation was given when mast cell proteases were shown to act
directly on paracellular permeability upon disruption of tight junctions219,242. In contrast,
evidences that increased intestinal permeability might be one of the causes of developing the
disease are more difficult to find. Studies on murine models of Crohn’s disease243 and even
epidemiological data244,245 showed that increased permeability is present prior to
inflammation. Food allergy was also associated with increased intestinal permeability, which
returned to normal values when the allergen is avoided246,247. It should be noted however that
the techniques used to measure intestinal permeability rely on small molecules and do not
necessarily reflect transport of larger molecules248,249. In the case of food allergy, this problem
is even more critical, as solely the whole allergen can trigger sensitisation and subsequently,
allergic reactions.
Coming back to the model of food-mediated allergy, we demonstrated that intestinal
permeability toward the allergen itself was strongly increased in sensitised mice compared to
tolerised or negative control mice. These data further confirmed that macromolecular
transport was increased upon intestinal inflammation triggered by allergen challenge, as it
was shown for unrelated proteins in other models of food allergy196,198. The data presented
here add novel information on the understanding of food-mediated allergic reactions as for the
first time, increased transport of the allergen from the lumen to the systemic compartment is
associated with systemic manifestations (drop of temperature and allergic score). A schematic
representation of the epithelium during the challenge is presented in figure 21. The absence of
85
86
signs of sensitised mice in SPF conditions suggests that the intestinal barrier was more tightly
controlled and thus limiting the amount of OVA that crossed the epithelium. Interestingly,
degranulation of mast cells in these mice were as important as in mice sensitised in the
conventional area. However, the proteases released upon degranulation did not, or only
mildly, affect paracellular transport of the allergen. Based on this observation, we can
hypothesise that differential intestinal permeability might precede the allergic reactions and
even the sensitisation. Mice housed in SPF conditions are protected from known pathogens,
and as a consequence might have an undisrupted intestinal epithelium, less prone to develop
allergy. This remains only speculation, as the definite proof of such hypothesis cannot be
explored in our experimental settings. Indeed, measurement of intestinal permeability before
the challenge cannot be done, as administration of OVA would constitute a challenge as such.
A very nice study from Perdue’s laboratory demonstrated that not only paracellular but
also transcellular transport of the allergen in the jejunum of rat was more important in
sensitised rat than in control ones250. Using Ussing chambers and electronmicroscopy, the
authors demonstrated that the allergen (HRP) was first transported transcellulary in endocytic
vesicles and reached the lamina propria where it bound to mast cells. In a second time only,
when mast cells degranulated, the allergen was transported paracellularly, leading to a more
important uptake of the allergen. Further studies demonstrated that the increased transcellular
transport of the allergen in sensitised rat was indeed IgE-mediated, involving CD23 expressed
at the apical side of epithelial cells251. Thus, IgE found in intestinal secretions can sample
allergens and bring them to the lamina propria via CD23. Such a mechanism is unlikely to
take place in the model of food-mediated allergy developed in this work, as no IgE were
detected in intestinal secretions of allergic mice (data not shown). However, other factors,
such as the endogenous microbiota or probiotics, might influence differentially the transport
of the allergen, and thus influence the intensity of the allergic reactions. The sensitisation
itself might depend on intestinal permeability. Do allergic people have an increased
permeability toward the allergen before they get allergic? To our knowledge, epidemiological
data do not exist yet to answer this question. However, pIgR-/- mice, which present an
intestinal “leakiness”, display a greater systemic response to food antigens115. Further studies
on the physiology of the intestine and its relation to food allergy will certainly bring novel
important discoveries.
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4.4 Probiotic treatment against food-mediated allergy
Administration of the probiotic strain L. paracasei NCC2461 during the sensitisation
protocol resulted in the prevention of allergic reactions in one out of the four experiments
conducted in this work. The lack of reproducibility and the reasons why the treatment was
effective or failed will be discussed later. First, attention will be drawn on the implantation of
the probiotics in the GI tract. Then beneficial effects of the probiotics will be analysed and
several hypotheses on the mechanisms of action of the probiotics will be postulated.
4.4.1 Colonisation of the murine GI tract by L. paracasei NCC2461
Lactobacilli are commonly known to preferentially colonise the small intestine. Upon
intragastric administration, L. paracasei NCC2461 was exposed to the acidity and the
numerous proteases of the stomach. A proportion of the administered bacteria resisted to this
harsh environment and reached the small intestine and might have colonised it permanently.
Analysis of the persistence of this probiotic strain in faeces of conventional mice revealed
however that the strain was rarely detectable 24 hours post-administration. This analysis did
not absolutely mean that the probiotic strain was washed out and did not colonise the murine
gut for the following reasons: the microbiota detected in faeces is closely related to the
microbiota detected in the ceacum or the colon23, but is only partially representative of the
microbiota residing in the small intestine. Assuming that some L. paracasei NCC2461 were
swept away with peristaltic movements, the latter needed to be alive in faeces to be
numbered, as the detection method requires a cultivation step. This means that if the probiotic
strain was dead within feaces, it was not detected even if it was present. Moreover, the
probiotic is “diluted” in the important population of lactobacilli residing in the murine GI
tract, rendering its detection difficult. However, it shall not be forgotten that L. paracasei
NCC 2461 was isolated from human faeces, and might be therefore better adapted to colonise
the human gut than the murine one. A detailed analysis of the implantation of the probiotic
within the GI tract of conventional mice is required to answer definitely this question.
Nevertheless, the dose (109 CFU) and the numerous administrations of the probiotic
ensured that it was present throughout the protocol and allowed the study of its modulatory
functions toward allergic reactions.
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4.4.2 Does the probiotic strain act in a preventive or curative manner?
When the probiotic treatment was effective, mice were protected from most of the allergic
manifestations induced after the allergen challenge; complete absence of temperature drop,
diarrhea, and degranulation of mast cells was observed. In addition, levels of OVA-specific
IgE were undetectable or very low, and, in contrast, OVA-specific IgG1 and IgG2a responses
were only mildly affected. Collectively, these data suggest that mice were protected from the
sensitisation and consequently from the occurrence of subsequent allergic reactions upon
challenge. The absence of IgE and, to a lesser extent, the lower concentrations of MMCP-1
before the challenge in probiotic-treated group, suggested that the treatment acted
preferentially in a prophylactic fashion, affecting the sensitisation phase. The effect of CT
was however not completely impaired, as a strong IgG1 and IgG2a response was induced.
Thus, the probiotic strain might have partially counteracted the effect of CT, which induced
an immune response, but without the production OVA-specific IgE.
The protective effect of probiotic could also have taken place during the effector phase
(i.e. the challenge), as the probiotic was given from the beginning of the sensitisation protocol
to the day preceding the challenge. Experiments with different timings of probiotic
administration will allow to differentiate between preventive effects and/or curative effects of
the probiotic, and will further help to understand the mechanisms involved in the protection.
The lack of reproducibility prevented us to perform such experiments. Several hypotheses on
how the probiotic strain acted to prevent the occurrence of allergic reactions, either during the
sensitisation phase or during the challenge are presented in the next sections. Hypotheses are
also schematically summarised in figure 22.
4.4.3 Influence of the probiotic bacterium on the intestinal microbiota
Upon arrival in the GI tract, the probiotic strain got into contact with the resident
commensal microbiota. It is not known whether L. paracasei NCC2461 colonised the GI tract
(see chapter 4.4.1), but it could, at least transiently, have interfered with other species (figure
22, 1). Competition for resources or cooperative relationship might have occurred between
the probiotic and other species, what might had impacted on the composition of the bacterial
community. The probiotic strain might have promoted the growth of “beneficial” species,
such as bifidobacteria or other lactobacilli, and affected negatively “harmful” bacteria like
Clostridia species known to be associated with allergy. Therefore, the impact of L. paracasei
NCC2461 administration on the total microbiota and on lactobacilli species was analysed in
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feaces using the PCR-coupled DGGE method. The results demonstrated that the probiotic
strain did not affect the general profile of the intestinal microbiota, nor the population of
lactobacilli specifically (data not shown). This suggests that the probiotic had only a minor
impact on the faecal bacterial composition. However, only dominant faecal species can be
semi-quantitatively analysed using this method, so that slight modifications are not visible. In
addition, the “particular conditions” required for the success of the probiotic treatment were
not necessarily present at that time, thus preventing us to draw definite conclusions.
Besides its influence on the bacterial composition, the probiotic might have affected the
metabolism of the commensal microbiota252. This is of major interest as metabolites, just like
the probiotic itself, might have influenced the host and its mucosal immune system. The
probiotic might have for example promoted the production of short-chain fatty acids (butyric
acid and other by-products of anaerobic fermentation), which posses anti-inflammatory
activities253,254. Therefore, metabolites of the probiotic or the whole intestinal community
might have influenced the host reactivity toward the allergen. Experiments using live or dead
bacteria or derived culture supernatants would give information on what are the critical
components required for protection255. In addition, novel in vitro three-stage continuous
culture with immobilized cells systems are currently available to mimic the intestinal
ecosystem256. The influence of the probiotic on the intestinal population and its metabolisms
could be studied in these simplified models. Analysis of culture supernatants or intestinal
secretions with HPLC, or even with proteomics, would give powerful insights on molecular
metabolites potentially implicated in the modulatory functions.
To summarise, the probiotic strain might act on the intestinal community either by
promoting positively or negatively the growth of specific strains, or by influencing their
metabolisms. Therefore, the probiotic might act directly or indirectly, as a prebiotic will do.
The hypotheses presented in the next sections will be discussed with the term probiotic,
referring to a direct action of L. paracasei NCC2461. However, most of the hypotheses
described below might be mediated by other intestinal bacteria or through their metabolites,
which would have been indirectly influenced by the probiotic.
4.4.4 Action of the probiotic bacterium on the allergen degradation
The probiotic might have directly affected the allergen integrity, thus decreasing its
allergenicity (figure 22, 2). Degradation of the allergen during the sensitisation or the effector
phase would have prevented allergic reactions to occur. Thus, we tested the effect of the
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probiotic on the integrity of the allergen. In vitro incubation of OVA with L. paracasei
NCC2461 for 24 hours did not result in increased degradation of OVA257. However, the
metabolism of the probiotic might be different in the GI tract, and probiotic proteases might
act cooperatively with acidic conditions and other intestinal proteases to hydrolyse the
allergen. Degradation might even lead sometimes to the production of peptides with
immunomodulatory functions. Indeed, degradation of BLG with L. paracasei NCC2461 and
additional proteases resulted in IL-10 promoting acidic peptides187. Thus degradation of the
allergen might have protected mice by reducing the allergenicity of the protein, and possibly
by inducing “tolerising” peptides.
4.4.5 Effect of the probiotic bacterium on the epithelial cell functions
Interaction between the probiotic strain and epithelial cells might have modified the
properties of the latter (figure 22, 3 and 23A). Cross-talk between epithelial cells and the
probiotic is known to be mediated, among others, by TLR or NOD receptors, expressed either
at the surface of the cell or intracellularly. It is not clear whether bacteria ever reach the
surface of the cells due to the important mucus layer258. Indeed viscosity gradient within the
mucus layer has been shown to determine the spatial organisation of the intestinal microbiota
according to the shape of the bacteria259. Long curly rods with filaments are preferentially
found in high-density mucus, near the epithelium, whereas cocci accumulate in the centre of
lumen, distant to epithelial cells. L. paracasei being a rod, it is likely that it interacted directly
with the epithelium, or at least indirectly through its cell wall components for example.
The probiotic strain might have affected differentially the transport of the allergen by
enterocytes. In the model of food-mediated allergy developed in this work, the transport of
immunoreactive OVA from the lumen to the blood of naïve mice was not affected by the
administration of the probiotic strain. As mentioned previously, definite conclusions cannot
be drawn from this experiment, as mice were not sensitised and the precise conditions
required for effective treatment were not all gathered. However, data obtained in an in vitro
model of sensitised epithelium demonstrated that L. paracasei NCC2461 increased
transcellular transport of OVA from the apical to the basolateral compartement, and in
parallel, decreased the paracellular transport, as monitored by an increase of trans-epithelial
resistance257. Based on this observation, we can speculate that transcellular transport favours
the presentation of the allergen to underlying immune cells. During the sensitisation phase,
this might have led preferentially to oral tolerance. On the other hand, the paracellular route
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does not allow a controlled entry of the allergen. Limiting this way of entry might thus have
prevented systemic dissemination and, thus prevented excessive inflammatory conditions.
Hence, the probiotic could have acted on the transport properties of enterocytes, which in turn
oriented the immune response toward a more tolerising way.
Besides their transport properties, epithelial cells were demonstrated to produce various
mediators like TSLP68, TGF-β260 and APRIL69 upon stimulation with bacteria. These
mediators allow, at the intestinal level, the differentiation of DC toward a tolerising
phenotype. It is interesting to note that excessive TSLP production is associated with the
asthma in respiratory epithelium261. At the intestinal level, excess of TSLP is not documented
to provoke inflammation, but in contrast, Crohn’s disease affected epithelium display an
absence of TSLP68. It seems therefore that the dose of newly described mediator is critical for
the subsequent immune response induced.
Thus, depending on the bacterial stimulus they received, differentiated DCs activate T
cells to mature to Treg or Th2 cells. Likewise, epithelial cells produce differentially
inflammatory or regulatory cytokines according to the bacterial stimulus. Gram- bacteria, like
E. coli, were shown to induce epithelial cells to produce more IL-8 than Gram+ bacteria such
as lactic acid bacteria does. Moreover, Gram- bacteria promote indirectly the maturation of
DCs, a feature that can be counteracted by the presence of lactic acid bacteria in a TLR-2
dependant fashion260. Therefore, we can speculated that in the model of OVA-mediated
allergy, the probiotic stimulated epithelial cells through, among others, TLR-2, leading to the
production of regulatory and tolerogenic factors, which in turn educated DCs to be more
tolerising. This is of major importance during the sensitisation phase, as this might constitute
one of the mechanisms that slightly shifted the allergy versus tolerance balance toward the
tolerance side, thus preventing the production of OVA-specific IgE.
4.5.6 Activation of the immune system by the probiotic bacterium
Immunomodulation of the immune system through the probiotic can also be mediated
direct interactions with the immune system either in the inductive sites (PP and ILF) or within
the LP (effector sites), (Figure 22, 4 and 23B). DCs were shown to carry bacteria from PP to
MLN, where protective IgA response is induced61. Moreover, DCs residing in the LP can
sample bacteria with their protruding dendrites, a process thought to promote intestinal
homeostasis59. Therefore, the probiotic strain might have been captured by DCs of PP or LP,
and a L. paracasei NCC2461-specific immune response might have been induced. In vivo, the
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Figure 23: Schematic and hypothetical mode of action of the probiotic strain
A, The probiotic (light blue) strain can interact with epithelial cells via TLR-2 for
example, and affect negatively paracellular transport and positively transcellular
transport of the allergen. Transcellular transport can lead to increased presentation of
OVA on MHC II molecules and promote oral tolerance either by anergy or by
promoting OVA-specific regulatory T cell (yellow). Moreover, probiotic stimulation
might promote the secretion of TSLP (orange), a tolerising mediator at the intestinal
level. B, Direct interaction between the probiotic and mucosal DCs can take place
either in inductive sites (left) or within the LP (right). Probiotic-specific T cells (blue)
will preferentially be differentiated in regulatory T cells producing IL-10 and TGF-β.
Alternatively, Th1 cells might also be induced and subsequently produce IFN-γ.
These cytokines might influence the bystander OVA-specific lymphocytes, thus
preventing the production of OVA-specific IgE.
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probiotic-specific response was not assessed, due to the difficulty to measure specific
responses toward the bacteria. However, in vitro stimulation of peripheral blood mononuclear
cells (PBMC) with L. paracasei NCC2461 resulted in intermediate production of Th1
cytokines and considerable amount of IL-10 compared to other lactobacilli and bifidobacteria.
The probiotic was also able to limit the production of Th2 cytokines of Th2-biaised PBMC
(A. Zürcher, personal communication). This suggests that the probiotic might act by
counteracting the allergic Th2 cytokines either by inducing Th1 or regulatory cytokines.
Noteworthy, these data were obtained with immune cells of the systemic compartement and
immune cells of the intestine are generally more difficult to activate, and preferentially induce
Treg cells or Th2 cells.
Recently, a study demonstrated in a murine model of asthma that a protective probiotic
treatment either with Lactobacillus rhamnosus GG or with Bifidobacterium lactis (Bb-12)
induced FoxP3+ Treg and TGF-β producing Treg262. Moreover, two other probiotic strains
(Lactobacillus rhamnosus Lr32 and Lactobacillus salivarius Ls33) were shown to protect
mice from colitis, a protection associated with the development of CD4+CD25+ regulatory
cells in an IL-10-independent pathway263. So, although the probiotic strains used in these
studies are different, we can speculate that such mechanisms could also have taken place in
our model. As a lactic acid bacterium, L. paracasei NCC2461 might have induced IL-10-
producing cells, or TGF-β secreting Treg, which, through a bystander effect, might have
modulated OVA-reactive T cells. Indeed, when the probiotic treatment was effective, MLN
and SPL cells produced lower level of IL-10 and Th2 cytokines upon in vitro stimulation. In
contrast, when the probiotic treatment failed to reduce allergic reactions, the production of
Th2 cytokines was unaffected, but IL-10 production was increased in MLN cells. We can thus
hypothesise that the probiotic had indeed affected the OVA-specific cellular response through
bystander effects of probiotic-specific T cell. However, these effects were not powerful
enough to counteract de development of the allergic reactions. These mechanisms might have
been operative in Exp A and just below an effective threshold in Exp B, leaving only residual
effects at the end of the protocol.
To summarise, the above-mentioned hypotheses are not mutually exclusive; it is even very
likely that the probiotic acted simultaneously at several levels to slightly modify the OVA-
specific immune response and thus allowing protection against allergic reactions. These
hypotheses also illustrate the importance of the complexity of the intestinal ecosystem, and it
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appears therefore that even small environmental changes might have affected the outcome of
the probiotic treatment. The next section will discuss possible explanations for the lack of
reproducibility observed in this work.
4.4.7 Hypotheses on factors influencing the success of the probiotic
treatment
This lack of reproducibility was initially surprising considering the maximal precautions
taken to repeat with accuracy the same experiment. We first hypothesised that the absence of
modulation was related to the capacity of the strain to colonise the GI tract of the mice.
Colonisation could have been successful in Exp A, but not in the three other experiments for
unknown reasons associated to environmental changes. However, faeces collected at the end
of Exp A and Exp B did not reveal the presence of L. paracasei NCC2461, suggesting that
this might not be the critical parameter for protection, while keeping in mind that the
detection limit of this technique is very high. More importantly than the absence of detection
of the probiotic strain, the variability of the intestinal microbiota assessed in the faeces was a
matter of big concern. Although all mice displayed the same genetic background, their
environment was extremely variable. Mice were housed in a room with thousands of
“neighbour” mice, which were subjected to a constant turnover. Thus, the bacterial load (and
other unidentified factors) of the room might have differred upon time, and as the exchange of
microbiota between cages is frequent, mice most likely harbour differential microbiota
according to the experiment. However, no defined microbiota could be associated to the
success or failure of the probiotic treatment. Indeed the variability was so important, even
between littermates, that other changes were not visible.
It is clear therefore that probiotic treatment might give differential results in such a
variable environment, and thus the lack of reproducibility between experiments was somehow
likely to happen. Considering the complexity of the intestinal ecosystem, and the very fine
tuning of an immune response induction, it is clear that even slight changes in the microbiota
or other components might have affected the outcome of the probiotic treatment.
This is of major importance regarding the ability of a probiotic treatment to act in human
populations. Indeed variability will be even greater in humans, due to genetics and lifestyles.
Therefore identification of crucial mechanisms for protection is required in order to maximise
the likelihood of success of probiotic-based treatments. Identification of these mechanisms
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needs to be performed in more controlled environment in order to, hopefully, ensure
reproducibility essential for research and future development.
4.5 Concluding remarks
The second part of this work allowed the establishment of a reliable model of food-
mediated allergy in mice. Using this model, the protective properties of a defined probiotic
strain was evaluated and demonstrated that modulation of the allergic reactions was feasible,
but however subjected to environmental changes affecting the success of the probiotic
treatment. Dissecting the mechanisms associated to the protective effect will certainly help to
develop a more efficient bacterial strain, and more importantly will shed light on the reasons
of the dramatic increase of allergic disorders in westernized countries.
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Glycans on Secretory Component Participate in Innate
Protection against Mucosal Pathogens*
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In mucosal secretions, secretory component (SC) is found either
free or bound to polymeric IgA within the secretory IgA complex.
SC displays numerous and various glycans, which are potential
ligands for bacterial compounds. We first established that human
SC (hSC) purified from colostrum (hSCcol) or produced in Chinese
hamster ovary cells (hSCrec) exhibits the same lectin reactivity.
Both forms bind to Clostridium difficile toxin A and functionally
protect polarizedCaco-2 cellmonolayers from the cytopathic effect
of the toxin. The interaction is mediated by glycans present on hSC
and involves galactose and sialic acid residues. hSCcol and hSCrec
were also shown to bind enteropathogenic Escherichia coli adhesin
intimin and to inhibit its infectivity on HEp-2 cells in a glycan-de-
pendentmanner aswell. SC remainedoperative in the context of the
whole secretory IgA molecule and can therefore enhance its Fab-
mediated neutralizing properties. On the contrary, hSC did not
interact with three different strains of rotavirus (RF, RRV, and
SA11). Accordingly, infection of targetMA104 cells with these rota-
virus strains was not reduced in the presence of either form of hSC
tested. Although not a universalmechanism, these findings identify
hSC as a microbial scavenger contributing to the antipathogenic
arsenal that protects the body epithelial surfaces.
Mucosal surfaces cover the respiratory, urogenital, and gastrointesti-
nal tracts and thus represent a large area, which is constantly exposed to
an abundant variety of antigens. It must therefore be efficiently pro-
tected against colonization and subsequent possible infection due to
pathogens (1, 2). This difficult task is achieved through a combination of
innate or constitutive immunity (e.g. mucus, lysozyme, defensins, and
lactoferrin) and by an induced specific immune response, whichmainly
relies at the antibody level on the secretion of secretory IgA (SIgA)3 (3).
SIgA, themajor immunoglobulin found in secretions, consists of two or
four monomeric IgA linked through a J chain in association with secre-
tory component (SC) (4). SC is derived from the polymeric immuno-
globulin receptor (pIgR) that ensures selective transport of polymeric
IgA (pIgA) across the epithelium to the luminal side, where the complex
is released through proteolytic cleavage (5). Once in secretions, SIgA
binds to antigen(s) and thus prevents their attachment to epithelial
surfaces, a process known as immune exclusion. SC plays a pivotal role
in this process by conferring to SIgA a remarkable stability to acid and
proteases (6) and by ensuring correct localization of the antibodywithin
the lumen (7). Besides SC comprised within the SIgA complex, a signif-
icant amount of SC is released as such in secretions (up to 25 M in
humanmilk) (8). SC is constituted of five immunoglobulin-like domains
decorated by carbohydrate residues, which constitute between 15 and
24% of the whole molecular mass and are dispatched among seven
N-glycosylation sites of the polypeptide (9). The composition of these
glycans includes bi- and triantennary or Lewis type structures consti-
tuting binding epitopes for bacterial adhesins (10). The highly glycosy-
lated nature of SC suggests that it might play an important role in the
protection of the mucosal surfaces through nonspecific interactions
with microbial antigens. The first evidence of such a role for SC was
given by the observation that human SC (hSC) purified from colostrum
binds to Clostridium difficile toxin A and limits its adherence on ham-
ster brush border membranes (11). Additionally, glycans associated to
SIgA have been shown to interact with Helicobacter pylori (12). How-
ever, little is known as to the underlying mechanisms and whether this
holds true for other gastrointestinal pathogens.Moreover, the relevance
of binding data with respect to protection was not examined.
Here, we provide biochemical characterization of the interaction
between highly purified hSC, either obtained from colostrum or pro-
duced in Chinese hamster ovary (CHO) cells, and (i)C. difficile toxin A,
(ii) enteropathogenic Escherichia coli (EPEC) adhesin intimin, and (iii)
rotavirus triple layer particles. Further, using established in vitro infec-
tion models for each pathogen tested, we evaluate the biological signif-
icance of the observed interactions in terms of protective activity, sub-
stantiating the role of SC in innate immunity.
MATERIALS ANDMETHODS
Cells and Culture Conditions—Human colonic adenocarcinoma
Caco-2 cells (HTB-37) were grown in Dulbecco’s modified Eagle’s
medium (4.5% glucose) (Sigma) supplemented with 10% fetal bovine
serum (Sigma), 10mMHEPES (pH7.0), 1%nonessential amino acids, 1%
sodium pyruvate, 2 mM glutamine, 0.1% transferrin, and 100 units/ml
penicillin and 100 g/ml streptomycin. For establishment of polarized
monolayers, Caco-2 cells cultivated to 80% confluence were seeded on
Snapwell filters (diameter, 12 mm; pore size, 0.4 m; Corning Costar
Corp., Cambridge,MA) at a density of 2 105 cells/cm2. The formation
of a polarized Caco-2 cell monolayer at week 3 was established by mor-
phology and monitoring of the transepithelial electrical resistance
(TER) using a Millicell-ERS apparatus (Millipore Corp., Bedford, MA)
(13). HEp-2 cells (CCL-23)were cultured inDulbecco’smodified Eagle’s
medium supplemented with 5% fetal bovine serum, 2 mM glutamine,
and 100 units/ml penicillin and 100 g/ml streptomycin. Embryonic
* This work was supported by Swiss Science Research Foundation Grants 3200-068038
and 3200-109545. The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked “advertise-
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2 To whom correspondence should be addressed: R&D Laboratory of the Division of
Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon,
BH 19-650, 1011 Lausanne, Switzerland. Tel.: 41-21-314-07-83; Fax: 41-21-314-07-71;
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3 The abbreviations used are: SIgA, secretory IgA; SC, secretory component; hSC, human
SC; hSCcol, hSCpurified fromcolostrum; hSCrec, recombinant hSC; pIgR, polymeric Ig
receptor; pIgA, polymeric immunoglobulin A; CHO, Chinese hamster ovary; EPEC,
enteropathogenic E. coli; TER, transepithelial electrical resistance; MEM, Earle’s mini-
mum essential medium; hSCdg, deglycosylated hSCrec; GST, glutathione S-transfer-
ase; PBS, phosphate-buffered saline; DTT, dithiothreitol; ELISA, enzyme-linked immu-
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rhesusmonkey kidneyMA104 cells (CRL-2378.1) were grown in Earle’s
minimal essential medium (MEM) (Invitrogen) supplemented with
10% fetal bovine serum, 20 mM HEPES (pH 7.0), 2 mM glutamine, 100
units/ml penicillin, and 100 g/ml streptomycin. All cell lines were
maintained at 37 °C in a 5% humidified CO2 incubator.
Proteins and Antibodies—Purified colostral hSC (hSCcol) was isolated
from human milk as described (14), and recombinant hSC (hSCrec) was
produced in a CHO cell clone (7). Complete deglycosylation of hSCrec
(hSCdg) was accomplished using N-Glycosidase F (EC 3.5.1.52; Roche
Applied Science) as described previously (7). Polymeric Ig receptor-con-
taining Caco-2whole cell extracts were prepared as described in Ref. 15.C.
difficile toxin Awas purchased fromCalbiochem. Hybridoma PCG4 (anti-
toxinA IgGmAb) (16), chimericmouse-humanpolymeric IgAPCG4 (IgA
PCG4) produced in CHO cells as described in Ref. 17, hybridoma 7D9
(anti-VP6 rotavirus IgA mAb) (18), and hybridoma 2A10 (anti-VP4 RRV
rotavirus IgA mAb) (19) were grown in a Celline-350 cartridge (Vitaris,
Baar, Switzerland) in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 2mMglutamine, 2mMsodiumpyruvate, 10mMHEPES (pH
7.0), 0.1 mM folic acid, and 100 units/ml penicillin and 100 g/ml strepto-
mycin. The IgG antibody was purified by affinity chromatography on pro-
tein G-Sepharose beads (Amersham Biosciences), whereas purified pIgA
was prepared as described (20).
Fusion protein was generated by fusing the coding sequence for
intimin from EPEC strain E2348/69 to glutathione S-transferase (GST).
Following isolation by alkali lysis, bacterial DNA was used for PCR
amplification. Primers were designed to hybridize to the bacteria path-
ogenicity island (GenBankTMnumberAF0022236) between nucleotides
26,610 and 26,635 (eaeA codons 588–596) and 27,845 and 27,873
(between eaeA and EscD). The PCR product was integrated into the
plasmid vector pDESTTM15 (Invitrogen) using the gateway cloning
technology (Invitrogen). Protein expression in the form of an N-termi-
nal GST fusion was carried out in E. coli BL21-SI using 300 mMNaCl to
induce gene expression. Recombinant protein was purified onGlutathi-
one-Sepharose 4B beads according to the manufacturer’s instructions
(Amersham Biosciences).
Radiolabeling of C. difficile Toxin A—Toxin A was labeled by alkyla-
tion-reduction based on the protocol of Wallace and Corthe´sy (21).
Briefly, 50 g of toxin A was dissolved in 200 l of 0.2 M sodium borate
buffer (pH 9.0) containing 10 g of NaBH4[3H] (specific activity 1,000
mCi/mmol; PerkinElmer Life Sciences). Five additions of aqueous form-
aldehyde (Fluka, Wohlen, Switzerland) were made over a period of 10
min. The reaction was stopped by the addition of an equal volume of
0.1 MHCl. Excess of reagent was removed by passage on a PD-10 desalt-
ing prepacked column (Amersham Biosciences) equilibrated and run in
phosphate-buffered saline (PBS).
Differential Deglycosylation of hSCrec—Treatment of hSCrec with car-
bohydrate-specific enzymes, including Clostridium perfringens neuramin-
idase (EC 3.2.1.18; Roche Applied Science), -galactosidase (EC 3.2.1.23;
Roche Applied Science), and -1-(2,3,4)-fucosidase (EC 3.2.1.51; Sigma)
was performed according to the manufacturer’s instructions with the
exception that the denaturation step was omitted, and exposure of hSCrec
to the different enzymes was for 4 h.
Lectin Blotting—200 ng of purified hSCcol, hSCrec, and hSCdg were
subjected to PAGE on 8% resolving gels under denaturing (0.1% SDS)
and reducing (0.1 M dithiothreitol (DTT)) conditions. Analysis of car-
bohydrate structures on hSCcol, hSCrec, and hSCdgwas done using the
DIG glycan differentiation kit fromRoche Applied Science, which com-
prises lectins Datura stramonium agglutinin, Galanthus nivalis agglu-
tinin, Maackia amurensis agglutinin, Sambucus nigra agglutinin, and
peanut agglutinin. Reactivity toward biotinylatedUlex europaeus agglu-
tinin-1 (Vector Laboratories, Burlingame, CA) was assayed according
to the manufacturer’s instructions. After transfer onto polyvinylidine
difluoride membranes (Millipore), glycan detection was performed
using the procedures and reagents provided in the kit.
Exposure of PolarizedMonolayers to ToxinAand SC—The sensitivity
of Caco-2 monolayers to C. difficile toxin A was compared with that of
T84 monolayers (17) by incubating Transwell filters with 3  1010 M
toxin A for 3 h andmeasuring TER (13). In order to assess SC-mediated
protection as a function of the amounts and presence of glycans, 3 
1010 M toxinAwas preincubatedwith a range (1 nM to 1M) of hSCcol,
hSCrec, or hSCdg for 30 min at room temperature in a final volume of
50 l. Following apical administration in a final volume of 0.8 ml, TER
were measured at 3 h using three independent replicate filters per
experiment. To evaluate binding inhibition, radiolabeled toxin A was
preincubated with various amounts of hSCcol, hSCrec, or hSCdg and
added to the apical cell compartment, and filters were recovered after
3 h and finally placed in vials for scintillation counting (model 2500TR;
Packard Instrument Co.). Controls were performed using protective
pIgA PCG4 specific for toxin A (17). The shielding effect of hSC prep-
arations was examined upon the addition of increasing concentrations
of the proteins toCaco-2 cellmonolayers for 1 h, threewasheswith PBS,
and subsequent incubation with 3 1010 M toxin A.
To evaluate the binding potential of hSC on polarized Caco-2 cells,
1 108 M hSCrec and hSCdg was incubated for 60min at 37 °C on the
cells in a final volume of 0.5 ml. Supernatants and sequential washes
were recovered, and cells were collected in lysis buffer (15 mM KCl, 2
mMMgCl2, 10 mMHEPES (pH 7.6), 0.1 mM EDTA, 0.2% Nonidet P-40,
and 5% protease inhibitors CompleteTM (Roche Applied Science)). The
concentration of hSC was then determined by enzyme-linked immu-
nosorbent assay (ELISA) as previously described (22), and the integrity
of the protein was verified by Western blot analysis.
SC Immunoblotting and Overlay Assay—Native or glycosidase-
treated hSC (200 ng) as well as pIgR (70 ng) in Caco-2 cell extracts were
subjected to PAGE on 8% resolving gels under denaturing (0.1% SDS)
and nonreducing conditions, these latter allowing the recovery of both
proteins with preserved pIgA binding properties after transfer onto
polyvinylidine difluoride membranes (15). Nonspecific binding sites
were saturated by incubation in blocking buffer (5% (w/v) nonfat dry
milk in PBS containing 0.05% Tween 20 (Bio-Rad); PBS-T), and the
membrane was probed for 1 h at room temperature with the following
reagents: toxin A at 500 ng/ml in PBS-T and GST-intimin at 200 ng/ml
in PBS-T. Membranes were washed four times for 5 min in PBS-T.
Toxin Awas detected using PCG4mAb (1:2,000 dilution in 0.5% nonfat
dry milk in PBS-T) (17) followed by goat anti-mouse IgG, horseradish
peroxidase-conjugated (1:5,000; Sigma). GST-intimin was detected using
mAb against GST (1:1,000 dilution in 0.5% nonfat dry milk in PBS-T;
Zymed Laboratories Inc., South San Francisco, CA), followed by goat anti-
mouse IgG, horseradish peroxidase-conjugated (1:500; Sigma). Mem-
braneswere treatedwith the chemiluminescence reagent fromAmersham
Biosciences and exposed to autoradiography films (Konica, Hohenbrunn,
Germany).
Microwell Binding Assay—Thewells of NuncMaxiSorp ELISA plates
were coated with 200 ng of hSCrec or hSCdg in 100l of 50mM sodium
bicarbonate (pH 9.6) for 1 h at room temperature. Wells were blocked
with 200l of PBS-T containing 5% (w/v) nonfat drymilk. Toxin A (500
ng/ml) or GST-intimin (200 ng/ml) in 100l of PBS were incubated for
2 h at room temperature. Following three washes with PBS-T, binding
was detected using specific antibodies as for the overlay assay above and
1,2-phenylenediamine as a chromogene. Reactions were stopped with
one volume of 2 M H2SO4, and the optical density was measured at 492
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nm using 620 nm as reference wavelength. For reduction of coated
proteins, DTT at the indicated final concentrations (Figs. 4 and 5) was
added for 15 min prior to the blocking step.
Bacterial Adhesion Assay—Confluent HEp-2 cells grown as mono-
layers in 6-well culture dishes were exposed overnight to 1  105 wild
type or the intimin deletionmutant EPEC (CVD206 (23); int EPEC) in
the presence of 6 M hSCrec or without hSCrec in controls. Following
four washes with PBS, HEp-2 cells were lysed in distilled water, and
associated bacteriawere plated onto LB-agar plates at serial dilutions for
colony counting.
Attachment/Effacement (A/E) Assay—HEp-2 cells (105 cells/ml) were
seeded into 4-well microscope slides (Chamber SlideTM, LabTek, Nalge
Nunc International) and grown for 16 h. EPEC strain E2348/69 was cul-
tivated overnight in brain-heart infusion medium and washed in PBS,
and 1  105 colony-forming units were added to 0.5 ml of Dulbecco’s
modified Eagle’s medium buffered with 10 mM HEPES (pH 7.0). EPEC
were preincubated for 30 min with hSCrec or hSCdg (1.2–12 M) at
37 °C, 5% CO2, 95% relative humidity prior to the addition to HEp-2
cells. HEp-2 cells were further incubated for 3 h, washed three times
with PBS, and fixed with 4% paraformaldehyde (Sigma) in PBS for 1 h at
4 °C. Fixed cells werewashedwith PBS and permeabilized for 5minwith
0.1% Triton X-100 (Bio-Rad) in PBS, and actin was stained with phal-
loidin coupled with tetramethyl rhodamine isothiocyanate (Sigma) to
quantify A/E lesions (24) bymicroscopic observation. Cells harboring at
least one colony with established A/E were counted as a positive A/E
event. Microscopic observations were done with a Zeiss Axiovert 100
equipped with a Zeiss 63 LD Achroplan objective (Zeiss, Jena, Ger-
many). Data are expressed as a percentage of untreated control for ease
of comparison.
Virus Propagation and Purification—The bovine RF strain, the sim-
ian SA11 strain, and the rhesus RRV strain were propagated in MA104
cells in the presence of trypsin as described previously (25). Virus titers
present in the lysed cell supernatant were determined by plaque assay
and expressed as plaque-forming units/ml. For purification, the viral
suspensions were frozen once at20 °C and then submitted to centrif-
ugation at 180,000 g for 1 h at 4 °C. The virus pelletswere resuspended
in 20mMPIPES buffer (pH 6.6), and the remaining lipids were extracted
with 1,1,2-trichloro-1,2,2-trifluoroethane (Freon 113). The viral solu-
tion was complemented with CsCl to achieve a homogeneous density of
1.369 g/ml and centrifuged at 140,000  g for 15 h at 4 °C. The band
located at 1.36 mg/ml corresponding to triple layer particles (TLP) was
recovered from the CsCl gradient and conserved at 4 °C until further
use. For biochemical analyses, purified rotavirus solutionswere desalted
immediately before use by gel filtration on Sephadex G-25 coarse beads
(Amersham Biosciences), and the protein content was measured using
the bicinchoninic acid protein assay (Uptima; Interchim, Montluc¸on,
France).
ELISA and Overlay Assay for SC-Virus Interaction—For ELISA,
96-well plates (Nunc Maxisorp) were coated overnight at 4 °C with 200
ng of purified TLP rotavirus strains (RF, SA11, and RRV) in a final
volume of 200 l of 0.1 M carbonate-bicarbonate buffer (pH 8.3). Wells
were blocked with 250 l of PBS-T containing 2% bovine serum albu-
min for 30 min at room temperature. Diverse dilutions of hSCrec or
hSCdg (60–600 nM) were incubated for 1 h at room temperature in 100
l of PBS-T. The VP6-specific IgA 7D9 was used as a positive control.
After extensive washing in PBS-T, bound ligands were detected with
antibodies to hSC (22) or mouse pIgA (20).
In the overlay assay, 50 ng of purified TLP rotavirus strains (RF, SA11,
and RRV) were blotted onto polyvinylidine difluoride membranes and
blocked overnight at 4 °C in PBS-T containing 2% bovine serum albu-
min. The membranes were then incubated for 4 h at room temperature
with various concentrations (0.1–1 M) of hSCrec or hSCdg or pIgA
7D9 (2 nM). After extensive washing in PBS-T, bound ligands were
detected as in ELISA, and the presence of adsorbed rotaviruses was con-
firmed using a sheep anti-rotavirus serum (a gift from Dr. I. Schwartz-
Cornil, Institut National de la Recherche Agronomique, France).
Virus Infectivity Assay—The virus infectivity assay was adapted
from the cytopathic effect assay developed by Marchetti et al. (26).
Briefly, MA104 cells were grown in 96-well tissue culture micro-
plates for 2 days, washed twice with PBS, and then incubated for 3 h
with Earle’s MEM supplemented with 20 mM HEPES (pH 7.0), 2 mM
glutamine, 100 units/ml penicillin and 100 g/ml streptomycin, 0.5
g/ml trypsin, and 60 nM hSCrec or 60 nM hSCdg (hSC-EMEM).
Cells were then infected with serial dilutions of the viral suspension
for 1 h at 37 °C in hSC-EMEM. After removal of the viral inoculum,
cells were incubated for 48 h in hSC-EMEM, and the cytopathic
effect induced by rotavirus was measured by neutral red dye uptake.
The measurement of infection was defined as the ratio of experimen-
tal optical density (OD) to noninfected OD.
RESULTS
In order to benefit from a continuous source of pure SC capable of
replacing hSCcol that can be obtained in limited amounts only, we
produced hSCrec in CHO cells. We have previously shown at the bio-
chemical level that hSCrec binds equally well to pIgA as hSCcol (6).
When used in in vitro and in vivomodels of infection, hSCrec proved a
valid tool to unravel several novel facets of the protein associated with
pIgA or as a free polypeptide (7, 27, 28). However, a comparison of the
respective glycosylation profiles was not performed. Since the aimof the
work reported herein is to evaluate the intrinsic protective properties of
SC and explore whether glycosylation plays a role in the process, we first
mapped the lectin reactivity of hSCcol and hSCrec. Using a battery of
lectins, we found that all major glycans that have previously been
reported to be present on native hSC (9) could be identically detected on
the two proteins (Fig. 1). Both hSCcol and hSCrecwere shown to display
galactose-(1–4)-N-acetylglucosamine (D. stramonium agglutinin-
positive), (1–3) terminally linked mannose (G. nivalis agglutinin-pos-
itive), terminally linked sialic acid in (2–3) linkage to galactose (M.
amurensis agglutinin-positive) or (2–6) linkage to galactose (S. nigra
agglutinin-positive), and (1–2)-linked fucose residues (U. europaeus
agglutinin-1-positive). As expected, no lectin binding was detected to
hSCdg, and no reactivity with peanut agglutinin-recognizing galac-
tose  (1–3)-N-acetylgalactosamine could be observed (data not
shown).
FIGURE1. Mappingof sugarmoietiespresent in
various preparations of hSC. Samples were sep-
arated by SDS-PAGE under reducing conditions,
blotted onto membranes, and incubated with
anti-hSC serum (lanes 1 and 2) or lectinsD. stramo-
nium agglutinin (DSA), G. nivalis agglutinin (GNA),
M. amurensis agglutinin (MAA), S. nigra agglutinin
(SNA), and U. europaeus agglutinin-1 (UEA-1).
Lanes 3, 6, 9, 12, and 15, hSCcol; lanes 4, 7, 10, 13,
and 16, hSCrec; lanes 5, 8, 11, 14, and 17, hSCdg.
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To investigate new properties of hSC and further compare both
sources of protein, in vitro models were used. As a mimic of the intes-
tinal epithelium, Caco-2 cells were grown on Transwell filters to form
monolayers whose TER indicates both integrity and polarization. Upon
incubation of cells with 0.3 nMC. difficile toxin A, a drastic and irrevers-
ible drop of TER values was observed within the first 3 h of challenge,
indicating disruption of the tight Caco-2 cell monolayer. This cyto-
pathic effect could be neutralized in a dose-dependent manner upon
preincubation of the toxin A with increasing concentrations of hSC,
resulting in maintenance of TER as observed with specific pIgA PCG4
(17) (Fig. 2A). Purified hSCcol and hSCrec conferred the same degree of
protection, indicating that the two sources of protein afford equivalent
biological activity. In contrast to hSCcol and hSCrec, hSCdg showed no
neutralizing capacity. Comparable data were obtained with T84 cell
monolayers (data not shown), strongly suggesting that protection is not
cell type-specific. Further, to assess whether hSC serves as a scavenger
precluding interaction of toxin Awith the cell surface, the adsorption of
radioactive toxin A was quantified as a function of hSC concentration
(Fig. 2B). The results demonstrate that both hSCcol and hSCrec inhib-
ited in a dose-dependent manner toxin A binding to the epithelial cell
monolayer. No such effect was observed using hSCdg under identical
conditions. Association of SC with specific or irrelevant pIgA main-
tained protection, indicating that docking sites for toxinA are preserved
in the context of the SIgA molecule (Fig. 2C).
To exclude that the protection observed was due to the possible abil-
ity of hSC to cover the Caco-2 cell monolayer and hence mask toxin A
receptor(s),monolayerswere pretreatedwith increasing concentrations
of hSCrec or hSCdg, washed, and then incubated with radiolabeled
toxin A. No change in terms of toxin A binding to epithelial cells was
observed (Fig. 3A), even at the highest concentration of hSCrec that
conferred protection upon preincubation with toxin A. To directly
assess the capacity of hSC to bind to epithelial cells, monolayers were
incubated with 10 nM hSCrec or hSCdg. No hSC was bound to the cell
surface or taken up by the cells. Accordingly, all hSC remained free in
culture medium, as measured by ELISA in serial dilutions of superna-
tant fluids (Fig. 3B). The absence of cell-associated hSC was confirmed
by confocal laser-scanning microscopy (data not shown). We excluded
the possibility that degradation had occurred, since the integrity of hSC
and hSCdg was maintained after incubation with the cell monolayer at
37 °C for up to 60 min (Fig. 3C). These results demonstrate that hSC
does not interact with polarized epithelial cells in this in vitromodel and
thus that the protection is not due to a surface shielding.
Data presented so far show that (i) the effects of toxin A on epithelial
cells are neutralized by SC, (ii) SC glycosylation status is a key factor, and
(iii) protection is not based on a shielding of the cell surface by SC.
Therefore, the capacity of SC to neutralize the toxin following direct
interactionwas investigated by different biochemical approaches. Using
an ELISA-based approach, the interaction between unreduced hSCrec
FIGURE 2. Blocking of toxin A-mediated cytotoxic effect is dependent on the pres-
ence of glycans on hSC. A, constant amounts of toxin A (0.3 nM) were mixed with hSC-
col, hSCrec, or hSCdg and incubated for 3 h in the apical compartment of polarized
Caco-2 cell monolayers in Transwell chambers. The shaded area represents the limit of
confidence of the TER values of individual control filters incubated in the absence of
toxin A. Toxin A-specific chimeric pIgA PCG4 served as an experimental positive control.
B, increasing concentrations of hSCcol, hSCrec, or hSCdg were mixed with radiolabeled
toxin A and incubated as in A. Transwell membranes were recovered, and associated
radioactivity was measured by scintillation counting. C, preserved TER using equimolar
amounts of free hSCrec (lane 1) or associated with specific (pIgA PCG4) or nonspecific
(pIgAC5)pIgA (lanes 2and3). Controls includehSCdgassociatedwith specific pIgAPCG4
and irrelevant pIgA C5 (lanes 4 and 5).
FIGURE 3. Assessment of the shielding effect of SC on polarized epithelial cells. A,
preincubation of Caco-2 cell monolayers with hSCrec and hSCdg preparations does not
prevent subsequent binding of toxin A to cells. B, hSCrec and hSCdg do not bind to
polarized Caco-2 cell monolayers. The amount of hSC was quantified by ELISA in super-
natants, washes, and cell lysates. BD, below the level of detection. C, Western blot anal-
ysis of the integrity of hSCrec and hSCdg after 1-h exposure on epithelial cells at 37 °C.
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and toxin A was demonstrated (Fig. 4A). Reduced (DTT-treated) or
heat-treated hSCrec was no longer able to interact with toxin A, indi-
cating that correct folding is also important to properly orient glycan
motifs. In support of our initial data (Fig. 2), hSCdg did not bind to toxin
A, confirming the importance of glycan residues for the toxin-neutral-
izing properties of hSC. Consistently, heat- or DTT-treated hSCrec lost
its capacity to protect polarized Caco-2 monolayers after incubation of
0.3 nM toxin A (Fig. 4B).
To characterize themonosaccharidemoieties implicated in the interac-
tion with toxin A, differentially deglycosylated hSCrecs were prepared
using galactosidase, fucosidase, and neuraminidase. The ability of these
various forms of hSCrec to bind to toxinAwas examined using the overlay
assay described under “Materials and Methods” (Fig. 4C). The assay
revealed thatgalactoseandsialic acid residuesaredeterminant for the inter-
action, since treatment of hSCrec with galactosidase and neuraminidase
prevented interaction with toxin A. In contrast, fucosidase treatment did
not affect the interaction between hSCrec and the toxin A, indicating that
fucose residues are not involved in the association. Control lanes showed
that toxin A bound to hSCrec and also to pIgR (Fig. 4C).
Since the neutralizing properties of SCwere demonstrated forC. difficile
toxin A, we investigated whether SC can also act as a microbial scavenger
on other bacterial components, such as adhesins and other virulence fac-
tors. Because EPEC adhesion molecule intimin possesses Ig-like domains
and a terminal C-type lectin-like domain (29, 30), we postulated that (i)
suchdomainsmight associatewith similardomains (31–33) and/orglycans
displayed by hSC and (ii) such an interaction would alter the intimin-de-
pendentEPECadhesion as reflectedby the formationofA/E lesions (34). In
preliminary in vitro binding experiments, we observed that in the presence
of hSCrec, the adhesion of wild type EPEC to target HEp-2 cells was
reduced to levels comparable with those foundwith the int EPECmutant
(Fig. 5A). To strengthen the biological significance of the binding experi-
ments, the A/E lesion assay reflecting intimin-dependent EPEC invasion
was performed (35). In this assay, hSCrec reduced the occurrence of A/E
lesions triggered upon challenge of HEp-2 cells with EPEC (Fig. 5B, arrow-
heads). Comparative observation of slides carrying control and infected
HEp-2 cells showed a drop in the percentage of damaged cells in the pres-
enceof increasingconcentrationsofhSCrec (Fig. 5C). hSCdgdidnot confer
equivalent protection against intimin-mediatedA/E lesion formation, thus
suggesting that the glycan residues are instrumental features for protection.
ReducedEPECbinding andA/E lesion formationwere not due to impaired
EPEC viability, since growth of the bacteria was not altered in the presence
of hSC (data not shown). We then analyzed biochemically whether this
protectionwas indeedmediatedbybindingof hSCrec to intimin, as initially
postulated. In ELISA, we found that hSCrec interacts with intimin-GST, a
capacityprogressively lost asa functionof theconcentrationofDTTknown
to disrupt Ig-like domain folding (Fig. 5D). As for toxin A, the glycan moi-
eties important for the interactionwere identified with differentially degly-
cosylated hSCrec subjected to an overlay assay with intimin-GST (Fig. 5E);
galactose and sialic acid residues were involved in the interaction, whereas
fucose was not. These data suggest that SC can serve as a microbial scav-
enger helping to protect the surface of epithelial cells from bacterial attack
in a carbohydrate-dependent fashion.
To further challenge the scavenger properties of SC, the viral gastroin-
testinal pathogen rotaviruswas examined. Three different strains of rotavi-
ruswere analyzed, namely thebovineRF strain, the simianSA11 strain, and
the rhesus RRV strain. Four different approaches were followed to test the
possible inhibitory properties of hSC on rotavirus infectivity. ELISA and
overlay assaywere performed as described under “Materials andMethods”
using highly purified TLP rotaviruses to guarantee specific interactions
between partners (Fig. 6, A and B). Both experiments demonstrate that
none of the rotaviruses tested interact with hSCrec or hSCdg. To ensure
that disruption of the three-dimensional conformation of the virus during
coating and blotting did not affect binding artifactually, two additional
assays were performed in solution. Electron microscopy analyses using a
mixtureofpurifiedTLPandhSCrecpresentnoevidenceof interactionwith
the outermost layer of the virus (data not shown). Additionally, no protec-
tionwas observedwhen 60nM (104-foldmolar excesswith respect to virus)
hSCrec or hSCdg was added before, during, and after infection of MA104
cells with serial dilutions of the three rotavirus strains (Fig. 6C). Thus, our
results show that hSC is unable to protectMA104 cells by either (i) shield-
ing their cell surface, (ii) neutralizing the virus in solution before its attach-
ment, or (iii) inhibiting infectivity following virus attachment.
DISCUSSION
The protection of mucosal surfaces is achieved through a combina-
tion of innate and adaptive immunity. To draw a distinct border
FIGURE 4. Structural features of SC involved in toxin A recognition. A, hSCrec or
hSCdg coated in wells ofmicrotiter plates was treatedwith increasing concentrations of
DTT prior to the addition of toxin A. SC-toxin A interaction was detected with anti-toxin
A IgG (PCG4 mAb). Heat-treated hSCrec or hSCdg was coated in ELISA plates, and bind-
ing of toxin A was tested as above. B, 0.3 nM toxin A was mixed with hSCrec or hSCdg,
untreated or heat- or DTT-treated, and added to in the apical compartment of polarized
Caco-2 cell monolayers in Transwell chambers. The shaded area represents the limit of
confidence of the TER values of individual control filters incubated in the absence of
toxin A. Toxin A-specific chimeric pIgA PCG4 served as an experimental positive control.
C, hSCrec, partially deglycosylated hSCrec, or pIgR preparations were separated by SDS-
PAGE under nonreducing conditions, blotted onto membranes, and incubated with C.
difficile toxinA, followedbydetectionwithanti-toxinA IgG (PCG4mAb).NGF,N-glycosidase
F;Gal,-galactosidase; Fuc,-1-(2,3,4)-fucosidase;Neu, C. perfringens neuraminidase.
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between the two is becomingmore andmore illusive, since themultiple
partners involved increasingly show overlapping properties (36). SC, a
protein with defined roles in the transport, protection, and anchoring of
IgA and IgM at mucosal surfaces (37), is shown here to have strong
bacterial scavenger properties as a free polypeptide. Previous data have
shown that SC from human colostrum can limit the binding of toxin A
to hamster brush border membranes and bind to the toxin in an overlay
assay (11). Human milk-derived lactoferrin and SC reduce heamagglu-
FIGURE 5. The neutralizing property of hSC
toward EPEC is mediated by direct interaction
with the adhesion molecule intimin. A, binding
experiments performed with HEp-2 cells incu-
bated with wild type (wt) EPEC and the intimin
deletion mutant (Int EPEC). After overnight
infection with 1  105 EPEC in the presence or
absence of 6M hSCrec, cell-bound bacteria were
plated for numbering. B, imaging by fluorescence
microscopy of HEp-2 cells obtained after infection
with 1 105 EPECmixedwith hSCrec or hSCdg for
3 h. The arrowheads indicate A/E lesions typical of
infection. C, quantification in 50 different fields of
the effect of hSCrec and hSCdg on A/E lesion
occurrence. Data are expressed as a percentage of
the value obtainedwithout hSC (100%).D, hSCrec
or hSCdg coated in wells of microtiter plates was
treated with increasing concentrations of DTT
prior to the addition of intimin-GST. SC-intimin-
GST interaction was detected with anti-GST anti-
serum. Heat-treated hSCrec or hSCdg was coated
in ELISA plates, and binding of intimin was tested
as before. E, hSCrec and pIgR preparations were
separated by SDS-PAGE under nonreducing con-
ditions, blotted onto membranes, and incubated
with E. coli intimin-GST, followed by detection
with anti-GST. NGF, N-glycosidase F; Gal, -galac-
tosidase; Fuc, -1-(2,3,4)-fucosidase; Neu, C. per-
fringens neuraminidase.
FIGURE 6. SC does not interact with rotavirus or protect MA104 cells from infection. A and B, purified TLPs from RF, SA11, and RRV rotaviruses were coated in wells of microtiter
plates (A) or blotted as dots ontomembranes (B) and incubated with hSCrec, hSCdg, and the specific anti-rotavirus pIgA 7D9 as positive control. Boundmolecules were detected as
described under “Materials and Methods.” C, MA104 cells were exposed to various amounts (plaque-forming units (p.f.u.)) of RF, SA11, or RRV rotaviruses in the presence of 60 nM
hSCrec, hSCdg, or PBS. InfectionofMA104 is expressedas the ratiobetweenexperimentalODandnoninfectedOD;data arepresented for threenonsaturatingviral loads. As apositive
control, specific neutralization by anti-RRV pIgA 2A10 is depicted on the right.
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tination of human erythrocytes by enterotoxigenic E. coli (38). This
study suffered from the limitation that human SC and lactoferrin iso-
lated from colostral milk might have cross-contaminated each other
and that no cytopathic effect was studied in appropriate target epithelial
cells. Further, the biological effect of the interactionwas not evaluated at
the biochemical level and in cellular models of infection. The current
work addresses the “innate-like” properties of SC toward three different
gastrointestinal pathogens and underscores the essential role of glycan
residues in conferring intrinsic protective function to the protein.
We show herein that both hSCrec and hSCcol appear equivalent in
terms of glycosylation profile and biological effect, as concluded from
lectin binding andprotection of polarized epithelial cells from the action
ofC. difficile toxinA.Dallas and Rolfe (11) showed that preincubation of
hamster brush border with colostral hSC did not subsequently inhibit
the binding of the toxin A. This is in agreement with our findings that
protection of in vitro polarized Caco-2 cells is notmediated by shielding
of cells from toxin A binding but rather results from trapping of toxin A
by hSC. Hence, the neutralizing action of hSC toward toxin A exerts
itself through the direct contact between the two proteins that subse-
quently prevents toxin A from recognizing its receptor on epithelial
cells. In the physiological context, however, we cannot exclude the pos-
sibility that the secretion of free SC and SC bound to its pIgA cargo
might endow the epithelium with a sort of SC “shield.”
Molecular mapping of the association established that it is mediated
through glycans and more specifically through terminal galactose and
sialic acid residues. Disruption of the three-dimensional conformation
of hSC upon reduction of disulfide bridges abolished the interaction
with toxin A, indicating that the carbohydrate residues need to be
arranged correctly in space in order to create specific docking sites for
toxin A. Therefore, glycans confer to free hSC strong microbial scav-
enger properties, which add to the specific action of IgA in the context
of SIgA. Glycans are exposed when SC is associated with pIgA, thus
explaining the finding that SIgAwith no antigenic specificity for toxin A
protects epithelial monolayers from the action of toxin A.
In addition to blocking the action of toxin A, we found that SC exhib-
its scavenger properties in the context of EPEC intimin. The initial
interaction between EPEC and target HEp-2 cells involves, among other
adhesins, intimin. Eventually, interaction of intimin with the bacterially
produced translocated intimin receptor causes the characteristic inti-
mate EPEC adhesion that results in A/E lesion formation (39). Clearly,
upon interaction with intimin through its galactosyl and sialic acid res-
idues, hSC interferes with A/E lesion formation. Using 1.2–12 M hSC,
we fall in a range of concentrations similar to physiological conditions
(8) and can exclude the possibility that a too low amount of hSC was
added to neutralize EPEC. As expected, even with this high ratio, HEp-2
cells are not completely protected, since intimin-Tir interaction is not
the only requirement for invasion (40). Further, since intimin possesses
other receptors on host cells (34), one can argue that binding of SC
to intimin might not interfere with interaction mediated by other
adhesins. It is worth noting that in vivo, the concerted action of diverse
factors, including lactoferrin, might advantageously complement the
innate function of SC in secretions (41, 42).
Both toxin A and intimin also bind to the precursor, membrane form
of SC, pIgR. The biological significance of this remains unclear. Direct
interaction of Streptococcus pneumoniae choline-binding protein A
with the extracellular domain of pIgR facilitates the invasion of the
human nasopharyngeal cell line Detroit 562 (43). However, the phe-
nomenon is observed only for human cell lines exposed to the unencap-
sulated, nonpathogenic S. pneumoniae strain R6x (44). This species and
strain limitation rather favors the classical view that the excess of free SC
and SIgA in secretions will prevail over apical pIgR and blocks the
attachment of the bacterium to the surface of epithelial cells (45). This is
confirmed by our observation that Madin-Darby canine kidney cells
stably transfected by pIgR (46) do not get infected when exposed to a
mixture of toxin A and SC (data not shown). Our data also agree with
previous observations that free SC and/or SIgA inhibit attachment to
the gut epithelium of pathogens, including Helicobacter pylori (47),
E. coli (48, 49), and the ricin toxin (50).
No interaction between SC and three strains of rotavirus and no
protection from rotavirus adhesion and infection of target MA104 cells
could be detected. These data are intriguing and somehow counterin-
tuitive, considering the abundant literature about the inhibitory
effect of glycans on rotavirus infection (51). Among the three strains
of rotaviruses we tested, two are neuraminidase-dependent (SA11 and
RRV), yet none of them bound to SC known to have many accessible
sialic acid residues at its surface (10). Similarly, galactose is implicated in
the entry process of rotavirus (52), yet its distribution on hSC was with-
out effect on infectivity. Although present on hSC, the identity and
spatial arrangement of glycans appear not to be optimal enough to per-
mit interaction with rotavirus; this is consistent with the observation
that specific rotavirus-glycan interaction is indeed highly constrained
(53). Other milk proteins, including lactoferrin and lactadherin, appear
to protect epithelial cells from rotavirus infection irrespective of the
presence of carbohydrate residues (54–56). We conclude that neither
glycan structures present on SC nor the protein backbone can serve as a
decoy to abrogate binding to rotavirus particles. This adds to the spec-
ificity of data collected with toxin A, intimin, and numerous other gly-
can structures as reviewed in Ref. 57.
In summary, this study demonstrates that the abundant and various
glycans carried by SC contribute to the protein antimicrobial scavenger
properties, although this does not represent an universal mode of
action. In the context of commensal homeostasis, SC can add to the
function of low affinity IgA, protecting the host from the penetration of
the endogenous microbiota (58). As far as the whole SIgA molecule is
concerned, this confers further antigen binding sites in addition to the
four Fab sites, making the antibody an active entity bridging adaptive
and innate immunity.
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to Protection via Intracellular Neutralization but Not
via Immune Exclusion†
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Immunoglobulin A (IgA) monoclonal antibodies (MAbs) directed at the conserved inner core protein VP6 of
rotavirus, such as the IgA7D9 MAb, provide protective immunity in adult and suckling mice when delivered
systemically. While these antibodies do not have traditional in vitro neutralizing activity, they could mediate
their antiviral activity either by interfering with the viral replication cycle along the IgA secretory pathway or
by acting at mucosal surfaces as secretory IgA and excluding virus from target enterocytes. We sought to
determine the critical step at which antirotaviral activity was initiated by the IgA7D9 MAb. The IgA7D9 MAb
appeared to directly interact with purified triple-layer viral particles, as shown by immunoprecipitation and
immunoblotting. However, protection was not conferred by passively feeding mice with the secretory IgA7D9
MAb. This indicates that the secretory IgA7D9 MAb does not confer protection by supplying immune exclusion
activity in vivo. We next evaluated the capacity of polymeric IgA7D9 MAb to neutralize rotavirus intracellularly
during transcytosis. We found that when polymeric IgA7D9 MAb was applied to the basolateral pole of
polarized Caco-2 intestinal cells, it significantly reduced viral replication and prevented the loss of barrier
function induced by apical exposure of the cell monolayer to rotavirus, supporting the conclusion that the
antibody carries out its antiviral activity intracellularly. These findings identify a mechanism whereby the
well-conserved immunodominant VP6 protein can function as a target for heterotypic antibodies and protective
immunity.
Rotavirus (RV) is the main cause of severe diarrhea in
young infants worldwide and is responsible for 611,000 deaths
per year (36). Two vaccines based on attenuated live viruses
have recently completed successful phase III clinical trials and
showed efficacy in preventing severe RV diarrhea caused by
multiple serotypes (45, 50). However, the relevant immune
effectors required for achieving protection against diverse cir-
culating strains are still a matter of considerable debate. While
CD8 T cells facilitate the timely clearance of rotavirus infec-
tion, B cells with the appropriate pattern of mucosal homing
receptors and antibody production have been demonstrated as
crucial for protection from reinfection (17, 24).
Neutralizing antibodies against RV that block viral replica-
tion in cell culture are felt to play a major role in defense. A
variety of passive antibody transfer studies in animals (28), as
well as immunization studies using selected rotavirus reassor-
tants in humans (7), have demonstrated a clear role for VP4
and VP7 in protective immunity. Neutralizing antibodies are
directed against the outer shell VP4 and VP7 proteins, whose
variable antigenic specificities define multiple serotypes, as-
signed as P and G serotypes, respectively (41). Worldwide, the
G1-to-G4 serotypes associated with P4 and P8 and the more
recently described G9/P6 or P8 serotypes are globally impor-
tant rotavirus G/P combinations in humans (47). This diversity
suggests that VP4- and VP7-encoding segments from many
strains might have to be included in vaccines to provide broad
immunity to reinfection with multiple serotypes. However, a
body of evidence from animal studies indicates that either
humoral or cell-mediated immunity directed at the intermedi-
ate capsid VP6 protein can also mediate protection, at least in
some animal models (3, 5, 15, 32, 48). Of note, one of the two
recently introduced human rotavirus vaccine only contains a
single VP4 and VP7 serotype specificity but is clearly able to
induce heterotypic protective immunity (45). Interestingly
VP6, which represents 51% of the virion by mass, is antigeni-
cally conserved among most circulating group A RV strains
and could, therefore, provide heterotypic protection (40).
In mucosae, polymeric immunoglobulin A (pIgA), compris-
ing four heavy and light chains and the associated J chain,
binds to the polymeric Ig receptor (pIgR) at the basolateral
pole of epithelial cells. Following vectorial transport to the
apical surface, it is released in the lumen attached to a pro-
teolytic product of the pIgR called secretory component (SC),
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Mole´culaires UR892 INRA, Domaine de Vilvert, 78352 Jouy-en-Josas
Cedex, France. Phone: 33-134652641. Fax: 33-134652621. E-mail:
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giving rise to secretory IgA (sIgA) (8). It is generally accepted
that sIgA prevents microbial infections by forming immune
complexes responsible for “immune exclusion” (i.e., the pre-
vention of pathogen interaction with the target mucosal cell).
The possible mechanisms involved in immune exclusion in-
clude competition for adhesion sites on target cells, blockade
of motility of bacterial pathogens, and trapping in the mucus
layer for which sIgA-immune complexes display strong affinity
(43). In a previous study, we showed that the polymeric Ig
secretory pathway plays a key role in the protection induced by
intranasal immunization with virus-like particles (VLP) made
exclusively of VP2 and VP6 proteins (VLP2/6) (48). Two plau-
sible mechanisms could explain these findings: (i) the anti-VP6
pIgA could interfere with the viral life cycle during its intra-
cellular transcytosis along the pIgR vesicular pathway, or (ii)
the anti-VP6 sIgA could react with triple-shelled particles in
the gut lumen through holes in the capsid or via areas of partial
decapsidation (49) and thus exclude the antibody-particle com-
plexes in the intestinal mucus layer and prevent infection.
Several anti-VP6 IgA monoclonal antibodies (MAbs), in-
cluding the IgA7D9 MAb, when used in hybridomas in back-
pack experiments, were found protective in mice and could
clear chronic infection in SCID mice (3). However, the same
IgA MAb lacking SC was not protective when fed orally and
was not neutralizing in classical in vitro assays using nonpolar-
ized cells (3, 15). At the molecular level, anti-VP6 IgA7D9
MAb blocked viral transcription in vitro by introducing a con-
formational change in the VP6 trimer (15). Furthermore,
IgA7D9 MAb competed with VP7 in binding to VP6, thus
potentially perturbing VP7 assembly onto VP6 (20). Although
suggesting intracellular neutralization, these in vivo and in
vitro experiments provided only indirect information as to the
possible mechanism of IgA7D9 MAb-mediated protection in
the physiological context.
In order to directly determine at which biological step anti-
VP6 IgA MAb interferes with rotavirus production, we tested
the antiviral function of purified pIgA7D9 MAb and SIgA7D9
MAb in two complementary experimental settings: (i)
SIgA7D9 MAb, assembled by association of purified SC and
pIgA7D9 MAb, was delivered orally to mice, and its capacity to
inhibit virus replication in the intestine was examined; (ii) the
intracellular neutralizing potential of pIgA7D9 MAb was eval-
uated during transport from the basolateral compartment of a
polarized epithelial cell monolayer mimicking the intestinal
barrier.
MATERIALS AND METHODS
Preparation of pIgA7D9 and SIgA7D9. Ascites fluid (30 ml) was obtained from
BALB/c mice inoculated intraperitoneally (i.p.) with 2  106 IgA7D9 hybridoma
cells (3). Hybridoma IgA2A10 (anti-VP4 rhesus monkey rotavirus [RRV] MAb)
(19) and hybridoma IgAC5 (anti-Shigella flexneri lipopolysaccharide [LPS] MAb)
(39) were grown in Celline-350 cartridges (Vitaris, Baar, Switzerland) in RPMI
1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM glu-
tamine, 2 mM sodium pyruvate, 10 mM HEPES (pH 7.0), 0.1 mM folic acid, 100
U/ml penicillin, and 100 g/ml streptomycin. Preparations were loaded onto two
successive Sephacryl S-300 columns (1 m by 2.6 cm; Amersham Biosciences),
equilibrated and run in phosphate-buffered saline (PBS), coupled to an Akta-
Prime automated fraction collector (13). Samples of column fractions were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under nonreducing conditions, and those containing pIgA, as confirmed
by immunoblotting using anti-alpha chain and anti-J chain antisera (42), were
pooled. Purified SC was obtained from stably transfected CHO cells (38).
Reconstitution of sIgA was performed by combining, in 5 ml of PBS, 4 mg of
purified pIgA with 1.2 mg of purified SC (13). The excess SC was separated by
fast protein liquid chromatography using a Superdex 200 column (1 m by 1.6 cm;
Amersham Biosciences). The association between SC and pIgA was confirmed
by subjecting the protein to SDS-PAGE under nonreducing conditions that
allowed the detection of covalent and noncovalent sIgA complexes following
immunoblotting with rabbit anti-SC antiserum (26).
Viruses. For the in vivo study, a crude stock of wild-type murine RV which
causes epizootic diarrhea of infant mice (Cambridge ECw, P[16], G3) was pre-
pared as intestinal homogenates from 4-day-old BALB/c neonates. The titer of
ECw in 6-week-old adult mice was determined as previously described (14) and
was found to correspond to 1  108 shedding doses 50 (SD50) per ml. For the in
vitro study, RRV stock was generated in MA104 cells after a 24-h preincubation
of the cells in a serum-free culture medium. Viruses were treated with 0.5 g of
trypsin per ml for 30 min, and MA104 cell monolayers were infected at a
multiplicity of infection (MOI) of 1. After 1 h of adsorption at ambient temper-
ature with gentle shaking, the inoculum was removed, and infected cells were
incubated in fresh medium containing 0.5 g of trypsin per ml. After complete
cytopathic effect was obtained (usually within 5 days), the cultures were submit-
ted to three freeze-thaw cycles, and cell debris was cleared by centrifugation at
2,200  g. Virus titer in the supernatant was determined by plaque assay on
MA104 cells as previously described (6).
Immunoprecipitation of RV by different molecular forms of IgA7D9 MAb.
Purified rotavirus triple-layer particles (TLP) (50 g) (25) were incubated for 2 h
at ambient temperature with 50 and 500 g of pIgA7D9 MAb or 62.5 and 625 g
of SIgA7D9 MAb, respectively, in a final volume of 800 l of PBS. Goat
anti-mouse IgA (Sigma, St. Louis, MO) diluted 1:500 was added, and the mixture
was left with gentle shaking for 1 h prior to addition of 50 l of protein
G-Sepharose (settled beads) equilibrated in PBS. After 1 h at ambient temper-
ature, the beads were washed three times with TENT (50 mM Tris-HCl [pH 7.5],
5 mM EDTA, 150 mM NaCl, 0.05% Triton X-100). Bound proteins were eluted
by boiling in SDS-PAGE loading buffer (50 mM Tris-HCl [pH 6.8], 100 mM
dithiothreitol, 10% glycerol, 2% SDS, 0.1% bromophenol blue) and loaded onto
a 12% polyacrylamide gel in 0.1% SDS. Following transfer onto a polyvinylidene
fluoride membrane, nonspecific binding sites were blocked by incubation in 5%
nonfat dry milk in PBS–0.05% Tween 20 (Bio-Rad, Hercules, CA), and the
membrane was probed for 2 h using the 5.73 MAb to VP4/VP8* (33) diluted
1:500 in 0.5% nonfat dry milk in PBS–0.05% Tween 20. Bound MAb was
detected using horseradish peroxidase-conjugated goat anti-mouse IgG (1:3,000;
Sigma) followed by treatment with chemiluminescence reagents (Amersham
Biosciences) and exposure to autoradiography films.
In vivo immune exclusion assay. BALB/c mice (6 weeks old; Charles River
Laboratories) were shown to be free of RV-specific antibodies prior to vaccina-
tion by an enzyme-linked immunosorbent assay (ELISA) on serum samples.
They were housed in an A3 animal facility (Unite´ d’Expe´rimentation Animale
Rongeurs, Jouy-en-Josas, France) under the 78-20 license delivered by the “Di-
rection des Services Ve´te´rinaires de Versailles” (France). Each mouse was in-
dividually marked. The assay was performed early in the morning in order to take
advantage of the relatively higher stomach pH at that time of the day.
In order to examine the in vivo protective efficacy of purified pIgA7D9 MAb
via the secretory pathway, a group of three mice was inoculated i.p. twice (1 mg,
then 400 g) with pIgA7D9 MAb in PBS 16 and 2.5 h before viral challenge,
respectively. Groups of six mice were used for testing the luminal neutralization
of RV. Two hours before challenge and right after oral administration of 1.3%
buffering bicarbonate, preparations of SIgA7D9 MAb (500 g), pIgA7D9 MAb
(400 g), SC alone (200 g), or PBS were given orally by esophageal gavage in
a final volume of 400 l. Five minutes before challenge, the gavages were
repeated with doses representing one third of the initial dose. The mice were
infected with 1  102 SD50 of ECw murine virus after administration of 100 l
1.3% buffering bicarbonate (48). Feces were then collected for each mouse in
order to monitor SIgA7D9 MAb transit. From challenge to day 7 (time point at
which no virus could be detected in the control PBS group), stools were har-
vested on absorbent paper from individual mice placed in independent cages on
a daily basis. The feces were kept at 20°C until processed for analysis of the
quantity of RV. The experiment was done three times.
Detection of SIgA7D9 MAb in feces. Two fecal specimens were suspended in
500 l of a mixture of 10 mM Tris (pH 7.4), 140 mM NaCl, 10 mM CaCl2, 25 mM
EDTA, 0.05% Tween 20, and 1% protease inhibitor cocktail (Complete Mini;
Roche, Basel, Switzerland). After a 45-min incubation on ice, the fecal suspen-
sions were frozen at80°C, thawed, and spun down at 13,000 g, and the crude
supernatants were tested for the presence of anti-VP6 activity by ELISA (48).
Serial dilutions of reconstituted complexes of SIgA7D9 MAb were used to
establish a standard curve. The sensitivity of the assay was 1 ng/ml. Feces were
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considered positive when the optical density (OD) value reached 0.2 or above.
The results were expressed as nanograms of SIgA7D9 MAb (inferred from the
standard curve) per ml of stool specimen.
Detection of RV antigens in feces. Detection of group A RV antigens in mouse
feces was performed using a commercial ELISA (IDEIA RV; Dako, Ely, Cam-
bridgeshire, United Kingdom) according to the manufacturer’s recommenda-
tions. Stools from noninfected mice were included as control samples and gave
a mean OD450 value of 0.02. The total fecal virus shedding for each mouse was
calculated by integrating the area under the shedding curve defined by the OD450
of each feces sample (y axis) over the 7-day period of feces collection (x axis),
using Microcal Origin 5.0 software (37). Protection was determined by reduction
of viral shedding relative to that of the PBS-treated group.
Cells and culture conditions. Human colonic adenocarcinoma Caco-2 cells
were grown in Dulbecco’s modified Eagle’s medium (4.5% glucose; Sigma)
supplemented with 10% FBS (Sigma), 10 mM HEPES (pH 7.0), 1% nonessential
amino acids, 1% sodium pyruvate, 2 mM glutamine, 0.1% transferrin, 100 U/ml
penicillin, and 100 g/ml streptomycin. For establishment of polarized monolay-
ers, Caco-2 cells cultivated to 80% confluency were seeded on Snapwell filters
(diameter, 12 mm; pore size, 0.4 m; Corning Costar Corporation, Cambridge,
MA) at a density of 2  105 cells/cm2. The formation of a polarized Caco-2 cell
monolayer at week 3 was established by morphology and monitoring of the
transepithelial electrical resistance (TER) using a Millicell-ERS apparatus
(Millipore, Bedford, MA) (10). The TER values ranged between 350 and 400  
cm2. Embryonic rhesus monkey kidney MA104 cells were grown in Earle’s
minimal essential medium (Invitrogen, Carlsbad, CA) supplemented with 10%
FBS, 20 mM HEPES (pH 7.0), 2 mM glutamine, 100 U/ml penicillin, and 100
g/ml streptomycin. All cell lines were maintained at 37°C in a 5% humidified
CO2 incubator.
Virus infection of, and intracellular neutralization in, polarized Caco-2 cells.
An RRV virus inoculum was activated for 30 min by treatment with 0.5 g of
trypsin per ml. Caco-2 cells grown on Transwell filters were cultured without FBS
in the apical compartment for 24 h and were then infected apically with the
trypsin-treated inoculum at an MOI of 2 or 10 for 1 h at ambient temperature.
The inoculum was then removed, and FBS-free fresh medium containing 0.5 g
of trypsin per ml was added. Infected cells were incubated at 37°C for the
indicated experimental time and processed postinfection to measure stability of
TER (20 h). Equimolar amounts of pIgA (5 g/ml) or monomeric IgA (mIgA;
2.5 g/ml) antibody were added 4 h prior to infection in the basolateral com-
partment. Virus release in the apical cell culture medium from infected filter-
grown Caco-2 cells in the presence of basolateral antibodies was determined at
20 h postinfection by plaque assay on MA104 cells as previously described (6).
The experiment was done twice under each condition in triplicate.
Cell viability measurements. Polarized monolayers of Caco-2 cells were
washed once with PBS to remove desquamated cells (usually less than 10 to 15%
at 24 h postinfection), Snapwell filters were detached from the insert, and cells
attached to the membrane were exposed to a solution of 0.25% trypsin-1 mM
EDTA (Sigma) for 5 min. Cells were recovered by centrifugation, resuspended
in FBS-free medium containing 0.1% trypan blue, and counted using a hema-
cytometer. Percent viability was assessed using the formula [(total cells stained
cells)/total cells]  100.
RESULTS
Purified pIgA7D9 and SIgA7D9 interact with TLP. We first
prepared biochemically defined pIgA7D9 and SIgA7D9 MAbs
for subsequent in vivo oral administration. Ascitic fluid prep-
arations of pIgA7D9 MAb were separated by size exclusion
chromatography, the pIgA fraction was isolated, a portion was
associated in vitro with SC, and the resulting SIgA7D9 MAb
complex was purified by another size exclusion chromatogra-
phy as described previously (13). The quality of the prepara-
tions was assessed by electrophoresis under nonreducing con-
ditions followed by immunodetection analysis. Most SIgA7D9
and pIgA7D9 MAb was found in the polymeric form (Fig. 1A)
containing covalently bound J chain (Fig. 1B). SIgA7D9 MAb
was made of covalently assembled complexes, with some SC
not covalently bound (Fig. 1C), as previously reported (26).
Preliminary experiments demonstrated that cesium chloride
density gradient-purified TLP were recognized by the
pIgA7D9 MAb in ELISA (data not shown). However, a small
proportion of double-layered particles are generally present in
a purified-TLP preparation, and thus a positive signal in
ELISA does not necessarily indicate that the anti-VP6 7D9
MAb actually reacts with TLP. Therefore, immunoprecipita-
tion studies of RV with pIgA7D9 MAb or SIgA7D9 MAb were
conducted. Detection of a 28-kDa band corresponding to VP4-
derived VP8* was used to establish that TLP were bound by
both pIgA7D9 MAb and SIgA7D9 MAb (Fig. 2). Together,
these data suggest that immune complexes can form between
IgA7D9 and RV TLP, with TLP being mostly complete yet
containing some partially uncoated viruses, as observed by
electron microscopy (data not shown). Hence, it was reason-
able to determine if such anti-VP6 antibodies were capable of
offering passive protection in mice after oral feeding.
Inhibition of viral replication by pIgA7D9 does not involve
immune exclusion in vivo. Two different protocols of passive
administration were used to assess in vivo whether protection
mediated by purified pIgA7D9 can be achieved. We first in-
jected i.p. purified pIgA7D9 MAb into three mice 16 h (1 mg)
and 2.5 h (400 g) before viral challenge (Fig. 3A, i.p.). This
treatment led to a 51.0%  0.7% reduction of viral shedding
(Fig. 3B) as compared to the level in mice given PBS (P 
0.005) in accordance with previously published data (15). Im-
portantly, anti-VP6 activity was detected in the stools of the
inoculated mice at the time of challenge and corresponded to
12, 9, and 6 ng/ml SIgA7D9 MAb (Fig. 3C). This raises the
possibility that the protection observed is mediated by
SIgA7D9 through immune exclusion in the intestinal lumen.
FIG. 1. Western blot analysis of the pIgA7D9 MAb, SIgA7D9
MAb, and SC preparations. Polymeric IgA7D9 MAb, reconstituted
SIgA7D9 MAb, and SC were purified by size-exclusion chromatogra-
phy and analyzed by Western blotting under nonreducing conditions.
(A) pIgA7D9 and SIgA7D9 MAbs were revealed with horseradish
peroxidase-coupled anti-murine IgA serum. (B) Both polymeric forms
contained the J chain, reflecting proper assembly. (C) Expected cova-
lent and noncovalent association of SC and pIgA7D9 MAb was con-
firmed upon immunodetection with anti-SC antiserum. Molecular
mass markers (kDa) are indicated alongside the sample lanes.
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However, in a prior work, passive oral administration of pIgA
did not block viral replication in mice (3). We postulated that
in the previous oral feeding studies, the normal IgA molecular
form present in secretions, i.e., sIgA, was not used, and hence
stability of the orally administered antibody molecule might
not have been ideal. For optimal assessment of oral delivery,
mice (six per group) were fed (2 h and 5 min before challenge)
with SIgA7D9 MAb (500 g and 170 g), pIgA7D9 MAb (400
g and 130 g), SC (200 g and 70 g), or PBS (Fig. 3A, oral).
No significant reduction in viral shedding was observed in any
of the SIgA7D9 MAb-fed mice nor in the pIgA7D9 MAb- and
SC-fed groups (Fig. 3B). Protection was not seen despite the
fact that three out of six mice had, at the time of challenge,
amounts of SIgA7D9 MAb in the stools comparable to those
found in the i.p.-injected group (30, 10, and 9 ng/ml feces; Fig.
3C). Overall, these data show that protection mediated by the
anti-VP6 IgA7D9 MAb does not rely on immune exclusion in
the intestinal lumen, thus prompting us to investigate intracel-
lular neutralization mechanisms.
Intracellular neutralization of RV by IgA7D9 MAb in po-
larized Caco-2 intestinal epithelial monolayers. As direct lu-
minal virus neutralization was not detected in vivo using either
pIgA7D9 or SIgA7D9 MAbs, we sought to examine the pos-
sibility of intracellular neutralization of the virus during trans-
cytosis of the antibody. To address this issue, we took advan-
tage of the observation made by Jourdan et al. (23) that
following apical infection of Caco-2 cell polarized monolayers,
RRV is released almost exclusively from the apical surface
(99.9%) without any cell lysis. We thus postulated that addition
of test pIgA MAb to the basolateral compartment might con-
tribute to virus neutralization during transcytosis. We then
determined the optimal MOI that ensures infection of polar-
FIG. 2. Interaction between RV TLP and pIgA7D9 or SIgA7D9
MAbs. Immunoprecipitation (IP) of RV TLP was performed with two
quantities (50 g and 500 g) of pIgA7D9 MAb and equimolar
amounts (62.5 g and 625 g) of SIgA7D9 MAb. Following protein
separation by SDS-PAGE, detection of VP8* by specific 5.73 MAb
indicates that TLP are recognized by the two molecular forms of the
anti-VP6 MAb, namely pIgA7D9 MAb (lanes 1 and 2) and SIgA7D9
MAb (lanes 3 and 4). No signal was observed in the absence of IgA7D9
MAb (lane 5) or with 500 g of irrelevant pIgAC5 MAb (lane 6).
FIG. 3. Oral feeding with SIgA7D9 does not reduce viral shedding. (A) Time frame summarizing the kinetics of i.p. and oral passive
administration of the various molecular forms of pIgA7D9 and SIgA7D9. (B) Mean percentages of reduction of virus shedding ( standard error)
compared to the PBS group are reported from BALB/c mice inoculated i.p. with pIgA7D9 MAb or dosed orally with SIgA7D9, pIgA7D9 MAb,
and SC. A statistically significant difference was only achieved for viral shedding in the group receiving pIgA7D9 MAb i.p. (Student’s t test, P 
0.005). Similar results were obtained in two other independent experiments. (C) Level of IgA7D9 MAb in mouse feces measured 2 h after passive
administration of pIgA7D9 MAb i.p. or SIgA7D9 MAb orally. BD, below the level of detection.
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ized Caco-2 cells and subsequent apical release within a time
frame appropriate for assessing possible protection by transcy-
tosed MAb. Figure 4A indicates that an MOI of 10 led to a
significant drop in TER at 20 h postinfection, confirming that
viral replication taking place within the epithelial cells affects
the integrity of the monolayer. Apical incubation of polarized
Caco-2 cells with medium lacking FBS did not artifactually
perturb the TER of the monolayer, which remained stable
during the time course of analysis (data not shown). We then
defined the kinetics of transcytosis for pIgA MAb (7D9, C5,
and 2A10). We demonstrated that transport of IgA began
within 4 h and was sustained at 20 h (Fig. 4B). This indicates
that pIgA antibodies on their way to the apical surface are
likely to be present within Caco-2 cells after 4 h. We found that
transport of pIgA MAb was highly specific, resulting in the
release of up to 100 ng per filter of sIgA MAb in the apical
compartment (Fig. 4B); as expected, no mIgA7D9 MAb un-
able to be bound by pIgR was recovered in the apical chamber
(Fig. 4B) and the amount of remaining IgA in the basal cham-
ber at 20 h indicates that the antibodies were not in limiting
quantities (Fig. 4C).
We then examined the effect of MAb on the maintenance of
Caco-2 cell polarization in the presence of apically adminis-
tered RRV. In comparison with cells incubated with the virus
alone, cells transporting pIgA7D9 MAb exhibited preserved
TER similarly to noninfected Caco-2 cells (Table 1). Mono-
meric IgA7D9 MAb not capable of transcytosis and nonspe-
cific pIgAC5 did not protect Caco-2 cells from infection, lead-
ing to a drop in TER (Table 1). The anti-VP4 pIgA2A10 MAb,
which is capable of neutralizing apical rotavirus (44), showed
only little if any effect on preservation of TER stability (Table
1). Appropriate cell viability was preserved at the end of the
assay (Table 1).
The impact of MAb transport during infection was further
assessed by measuring the level of the viral progeny secreted
into the apical chamber. In the absence of MAb, a rotavirus
titer above 107 PFU/ml was found in the apical well, which
decreased to 103 to 104 PFU/ml in the presence of pIgA7D9
MAb (Table 1). Values in the same range as for virus alone
were observed using either mIgA7D9 or IgAC5 (Table 1).
Incubation with anti-VP4 IgA2A10 yielded a 50- to 100-fold
decrease in apical viral titer (approximately 105 PFU/ml),
which is likely explained by rapid transcytosis and subsequent
extracellular neutralization of a portion of the virus in the
apical chamber, as previously reported (44). This intracellular
neutralization phenomenon could be reproduced using polar-
ized intestinal HT29 cells (data not shown). The sum of these
data indicates that pIgA7D9 MAb acts intracellularly during
transcytosis across epithelial cells.
FIG. 4. Intracellular neutralization of RRV by pIgA7D9 MAb. (A) Stability of the Caco-2 monolayer TER exposed to different virus MOI as
a function of time. (B) Transcytosis of the various IgAs used in this study and molecular forms thereof across Caco-2 cell monolayers was measured
by ELISA as the appearance of SIgA in the apical chamber 4 and 20 h after addition of the purified IgA MAbs in the basolateral compartment
(B). (C) The amount of IgA present in the basolateral chamber (5 g/ml) is not limiting in the assay, as measured at 20 h.
TABLE 1. Release of RRV from polarized Caco-2 epithelial cellsa
Exptl setup for
apical compartment
Antibody addition
(basolateral compartment)b % TER
c % Cell viability
on filtersd Virus titer (PFU/ml)
RRV (MOI  10) No antibody 26 3 88 1.5  107–2.75  107
pIgA7D9 (5 g/ml) 98  5 93 5.75  103–12.5 103
mIgA7D9 (2.5 g/ml)e 26  2 95 1.1  107–3.5  107
pIgAC5 (5 g/ml) 27  4 90 1.75  107–4.5 107
pIgA2A10 (5g/ml) 38  4 88 2.5  105–6  105
No virus No antibody 100 94
a Monolayers of 24-day-old Caco-2 cells grown on Transwell filters were infected with RRV at an MOI of 10 PFU/cell. At 20 h postinfection, media were collected
from apical chambers and analyzed for virus content by plaque assay.
b MAbs were added 4 h prior to infection.
c TER values are expressed as the percentage of TER measured in the absence of viral infection fixed at 100%.
d Cell viability is expressed as the percentage of total live cells on membrane filters.
e IgA7D9 used in the form of a monomer was added at 2.5 g/ml to yield an equimolar amount to polymeric IgA antibodies in the basolateral chamber.
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DISCUSSION
Our study demonstrates that the IgA7D9 MAb directed to
the VP6 inner core protein can neutralize rotavirus intracellu-
larly, most likely by an encounter with viral particles within the
host cell. The luminal secretory form of the same IgA did not
show any inhibition of viral replication in vivo after oral feed-
ing, arguing for the primary effect of the antibody taking place
inside cells. From a more general point of view, our findings
further support the notion that transcytosing pIgA antibodies,
together with the documented role of CD4 T cells (4, 31, 32),
contribute to the VP6-dependent heterotypic protection ob-
served in vivo.
In the course of this work, we confirmed prior observations
that pIgA7D9 MAb given i.p. interferes with viral replication
(15). In the present study, purified pIgA and not crude ascites
fluid was tested, further strengthening the conclusion that in-
hibition of viral replication was due to bona fide effects of
IgA7D9 MAb and not to other nonspecific activities poten-
tially present in ascites fluid or secreted from 7D9 hybridoma
cells. In addition, the observed reduction of viral shedding
supports the notion that the molecular form of the pIgA7D9
MAb used to prepare SIgA7D9 MAb is biologically active.
Administration of only two intraperitoneal doses (1.4 mg in
total) of antibody is the most likely explanation for the finding
that viral replication was not more completely abrogated. In
fact, Feng et al. (15) documented that full protection was
observed after daily injections of 3 mg IgA7D9 MAb over a
9-day period and that only limited protection was seen with a
lower dose.
One of our working hypotheses to explain the protective
efficacy of the IgA7D9 MAb was that it might interact with
infectious particles via spaces in the viral outer shell or other
forms of exposed VP6 and thereby could anchor the viral
immune complex in the mucus and prevent infection. How-
ever, our experiments demonstrated that we could not achieve
protection by passive oral administration of SIgA7D9 MAb
alone, as would be expected if our working hypothesis was
correct. It remains possible that polyclonal sIgA with a broader
spectrum of action or directed against other viral antigens,
including VP4 and VP7, might work by this mechanism. Actu-
ally, oral administration of milk from RV-immunized dams
protected suckling mice against challenge (34); protective ac-
tivity was detected in both the anti-rotavirus IgA and IgG
fractions, but IgA was more potent in vivo than IgG (34). The
use of a milk concentrate prepared from rotavirus-hyperimmu-
nized cows resulted in a significant reduction in the duration of
viral excretion in infants hospitalized for acute rotavirus gas-
troenteritis (1, 12, 21). However, milk from dams immunized
with VLP2/6 did not prevent diarrhea in suckling offspring (9),
while milk from VLP2/6/7-vaccinated mothers was protective,
indicating that sIgA directed at VP7, but not at VP6, could be
implicated in mediating immune exclusion.
One can argue that the amount of SIgA7D9 MAb (670 g)
given orally might not have been sufficient to confer protection
by passive administration. However, the concentration of fecal
SIgA7D9 recovered after oral delivery of SIgA7D9 in our
experiments was in the same order of magnitude as the amount
of specific fecal sIgA observed following nasal vaccination with
VP6 (31). It represents 35 times more antibody than the
amount used to passively protect against a Shigella infection via
the nasal route in mice (38). Furthermore, 100 times less anti-
VP4 or -VP7 IgG, an isotype not optimal for protection at
mucosal surfaces, was sufficient to protect newborn mice from
RV challenge after oral administration (35). While passive
administration of sIgA is not strictly comparable to the phys-
iological transport of pIgA across the mucosae, it results in the
location of sIgA in mucus lining epithelial cells (38) and does
lead to comparable levels of VP6-reacting sIgA in feces. Taken
together, our data support the notion that IgA7D9 MAb acts
against rotavirus predominantly inside cells in vivo.
In most cases where intracellular neutralization by IgA has
been described, for human immunodeficiency virus (HIV) (2,
22), Sendai virus (18), and influenza virus (29), the active IgA
molecule was directed at a viral protein known to be the target
of extracellularly acting neutralizing antibodies. However, in
the case of RV, such neutralizing antibodies directed to VP4
(44) did not exhibit intracellular neutralization activity. Con-
versely, we show here that the anti-VP6 IgA7D9, which is
unable to inhibit viral replication in a classic neutralization
assay, can indeed mediate intracellular neutralization. The
mechanism involved is most probably associated with the
pIgR-mediated transcystosis pathway. Polymeric Ig receptor-
mediated transcytosis of polymeric IgA occurs via a vesicular
pathway divided into three steps: step 1, internalization from
the basolateral plasma membrane into basolateral early endo-
somes; step 2, translocation from the basolateral early endo-
somes to the apical recycling endosomes (ARE); and step 3,
delivery from the ARE to the apical plasma membrane (27).
Step 3 is rate-limiting, resulting in accumulation of pIgA-pIgR
in the ARE. We propose that VP6, although first synthesized
in the cytosol, encounters IgA either before or after new viral
protein synthesis, leading to impediment of replication. This
hypothesis will be addressed in future studies. Rotavirus par-
ticles enter the cell through a still-debated mechanism, but
experiments showing that infection is a dynamin-dependent
phenomenon (46) strongly support the hypothesis that RV is
initially internalized via endocytosis. Thus, IgA7D9 MAb as-
sociated with pIgR could complex VP6 during transepithelial
transport in the ARE, the compartment where IgA-mediated
intracellular neutralization of HIV has been shown to occur (2)
and where LPS signaling in epithelial cells can also be blocked
(16). As previously hypothesized, IgA7D9 MAb could impede
viral transcription by causing subtle architectural rearrange-
ments within the VP6 capsid layer, reducing the enzymatic
activity of the viral RNA polymerase in the core (15). The fact
that this antitranscriptional property was limited to IgA7D9
MAb (15) may explain why all anti-VP6 antibodies are not
capable of intracellular neutralization (44). Actually, the struc-
ture of the VP6 epitope recognized by the anti-VP6 IgA is
probably crucial for intracellular neutralization to occur (44).
This might also explain why J chain-dependent protection was
observed when mice were immunized with VLP2/6 (48) and
not with recombinant chimeric VP6 (31). Alternatively, recent
studies have clearly identified a secretory transport pathway of
RV from the endoplasmic reticulum, through the endoplasmic
reticulum-Golgi intermediate compartment that eventually
leads to rotavirus secretion from the apical surface of the cell;
transcytosis of IgA7D9 might interact with VP6 during this
phase of assembly and release (11).
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Heterotypic protection observed after rotavirus infection
can involve several mechanisms. Using a specific anti-VP6 IgA
(IgA7D9), we show that intracellular neutralization can be one
of these mechanisms. Since humoral immunity has been im-
plicated in protection induced after live virus immunization
(17, 30), it is likely that heterotypic protection with anti-VP6
IgA MAb occurs primarily after natural infection or live virus
vaccination. However, when protection was generated by re-
combinant VP6 (5, 32) or by VLP2/6 (M. Conner, unpublished
results), CD4 T cells were found to play a pivotal role. Finally,
heterotypic neutralizing antibodies to VP7 and VP4 (28) may
also contribute to broad protection. Thus, heterotypic immu-
nity probably involves several distinct immunological pathways,
and this work illustrates that one anti-VP6 IgA MAb acts via
an intracellular neutralization mechanism.
ACKNOWLEDGMENTS
We thank Ningguo Feng for providing ascites fluid, Franco Ruggeri
for the kind gift of 2A10 hybridoma cells, Matthieu Pillot and the
animal facility staff for invaluable help with mouse work and Maria
Christina Jaimes for helpful advice regarding the in vitro system. Crit-
ical readings of the manuscript by Daniel Speiser and Monica McNeal
are gratefully acknowledged.
I.S.-C. and B.C. thank the PAI-Germaine de Stae¨l-SATW exchange
program (SAMW-03-001). B.C. is supported by grant no. 3200-109545
from the Swiss Science Research Foundation, and I.S.-C. is supported
by INRA institutional funds. Work on this study was also supported by
a grant from the Veterans Administration (H.G.).
REFERENCES
1. Bogstedt, A. K., K. Johansen, H. Hatta, M. Kim, T. Casswall, L. Svensson,
and L. Hammarstrom. 1996. Passive immunity against diarrhoea. Acta
Paediatr. 85:125–128.
2. Bomsel, M., M. Heyman, H. Hocini, S. Lagaye, L. Belec, C. Dupont, and C.
Desgranges. 1998. Intracellular neutralization of HIV transcytosis across
tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immu-
nity 9:277–287.
3. Burns, J. W., M. Siadat-Pajouh, A. A. Krishnaney, and H. B. Greenberg.
1996. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies
that lack neutralizing activity. Science 272:104–107.
4. Choi, A. H.-C., M. Basu, M. M. McNeal, J. D. Clements, and R. L. Ward.
1999. Antibody-independent protection against rotavirus infection of mice
stimulated by intranasal immunization with chimeric VP4 or VP6 protein.
J. Virol. 73:7574–7581.
5. Choi, A. H. C., M. Basu, M. M. McNeal, J. Flint, J. L. VanCott, J. D.
Clements, and R. L. Ward. 2000. Functional mapping of protective domains
and epitopes in the rotavirus VP6 protein. J. Virol. 74:11574–11580.
6. Ciarlet, M., and M. K. Estes. 1999. Human and most animal rotavirus strains
do not require the presence of sialic acid on the cell surface for efficient
infectivity. J. Gen. Virol. 80:943–948.
7. Clark, H. F., P. A. Offit, R. W. Ellis, D. Krah, A. R. Shaw, J. J. Eiden, M.
Pichichero, and J. J. Treanor. 1996. WC3 reassortant vaccines in children.
Arch. Virol. Suppl. 12:187–198.
8. Corthe´sy, B., and F. Spertini. 1999. Secretory immunoglobulin A: from
mucosal protection to vaccine development. Biol. Chem. 380:1251–1262.
9. Coste, A., J.-C. Sirard, K. Johansen, J. Cohen, and J. P. Kraehenbuhl. 2000.
Nasal immunization of mice with virus-like particles protects offspring
against rotavirus diarrhea. J. Virol. 74:8966–8971.
10. Cottet, S., I. Corthe´sy-Theulaz, F. Spertini, and B. Corthe´sy. 2002. Mi-
croaerophilic conditions permit to mimic in vitro events occurring during in
vivo Helicobacter pylori infection and to identify Rho/Ras-associated pro-
teins in cellular signaling. J. Biol. Chem. 277:33978–33986.
11. Cuadras, M. A., B. B. Bordier, J. L. Zambrano, J. E. Ludert, and H. B.
Greenberg. 2006. Dissecting rotavirus particle-raft interaction with small
interfering RNAs: insights into rotavirus transit through the secretory path-
way. J. Virol. 80:3935–3946.
12. Davidson, G. P., P. B. Whyte, E. Daniels, K. Franklin, H. Nunan, P. I.
McCloud, A. G. Moore, and D. J. Moore. 1989. Passive immunisation of
children with bovine colostrum containing antibodies to human rotavirus.
Lancet ii:709–712.
13. Favre, L. I., F. Spertini, and B. Corthe´sy. 2003. Simplified procedure to
recover recombinant antigenized secretory IgA to be used as a vaccine
vector. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 786:143–151.
14. Feng, N., J. W. Burns, L. Bracy, and H. B. Greenberg. 1994. Comparison of
mucosal and systemic humoral immune responses and subsequent protection
in mice orally inoculated with a homologous or a heterologous rotavirus.
J. Virol. 68:7766–7773. (Erratum, 69:3246, 1995.)
15. Feng, N., J. A. Lawton, J. Gilbert, N. Kuklin, P. Vo, B. V. Prasad, and H. B.
Greenberg. 2002. Inhibition of rotavirus replication by a non-neutralizing,
rotavirus VP6-specific IgA mAb. J. Clin. Investig. 109:1203–1213.
16. Fernandez, M. I., T. Pedron, R. Tournebize, J. C. Olivo-Marin, P. J.
Sansonetti, and A. Phalipon. 2003. Anti-inflammatory role for intracellular
dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithe-
lial cells. Immunity 18:739–749.
17. Franco, M. A., and H. B. Greenberg. 1995. Role of B cells and cytotoxic T
lymphocytes in clearance of and immunity to rotavirus infection in mice.
J. Virol. 69:7800–7806.
18. Fujioka, H., S. N. Emancipator, M. Aikawa, D. S. Huang, F. Blatnik, T.
Karban, K. DeFife, and M. B. Mazanec. 1998. Immunocytochemical colo-
calization of specific immunoglobulin A with Sendai virus protein in infected
polarized epithelium. J. Exp. Med. 188:1223–1229.
19. Giammarioli, A. M., E. R. Mackow, L. Fiore, H. B. Greenberg, and F. M.
Ruggeri. 1996. Production and characterization of murine IgA monoclonal
antibodies to the surface antigens of rhesus rotavirus. Virology 225:97–110.
20. Gilber, J. M., N. Feng, J. T. Patton, and H. B. Greenberg. 2001. Rotavirus
assembly—interaction of surface protein VP7 with middle layer protein VP6.
Arch. Virol. 146:1155–1171.
21. Hilpert, H., H. Brussow, C. Mietens, J. Sidoti, L. Lerner, and H. Werchau.
1987. Use of bovine milk concentrate containing antibody to rotavirus to
treat rotavirus gastroenteritis in infants. J. Infect. Dis. 156:158–166.
22. Huang, Y. T., A. Wright, X. Gao, L. Kulick, H. Yan, and M. E. Lamm. 2005.
Intraepithelial cell neutralization of HIV-1 replication by IgA. J. Immunol.
174:4828–4835.
23. Jourdan, N., M. Maurice, D. Delautier, A. M. Quero, A. L. Servin, and G.
Trugnan. 1997. Rotavirus is released from the apical surface of cultured
human intestinal cells through nonconventional vesicular transport that by-
passes the Golgi apparatus. J. Virol. 71:8268–8278.
24. Kuklin, N. A., L. Rott, N. Feng, M. E. Conner, N. Wagner, W. Muller, and
H. B. Greenberg. 2001. Protective intestinal anti-rotavirus B cell immunity is
dependent on alpha 4 beta 7 integrin expression but does not require IgA
antibody production. J. Immunol. 166:1894–1902.
25. Ludert, J. E., M. C. Ruiz, C. Hidalgo, and F. Liprandi. 2002. Antibodies to
rotavirus outer capsid glycoprotein VP7 neutralize infectivity by inhibiting
virion decapsidation. J. Virol. 76:6643–6651.
26. Lullau, E., S. Heyse, H. Vogel, I. Marison, U. von Stockar, J. P. Kraehen-
buhl, and B. Corthe´sy. 1996. Antigen binding properties of purified immu-
noglobulin A and reconstituted secretory immunoglobulin A antibodies.
J. Biol. Chem. 271:16300–16309.
27. Luton, F., M. H. Cardone, M. Zhang, and K. E. Mostov. 1998. Role of
tyrosine phosphorylation in ligand-induced regulation of transcytosis of the
polymeric Ig receptor. Mol. Biol. Cell 9:1787–1802.
28. Matsui, S. M., P. A. Offit, P. T. Vo, E. R. Mackow, D. A. Benfield, R. D. Shaw,
L. Padilla-Noriega, and H. B. Greenberg. 1989. Passive protection against
rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neu-
tralization domain of VP7 and the VP8 fragment of VP4. J. Clin. Microbiol.
27:780–782.
29. Mazanec, M. B., C. L. Coudret, and D. R. Fletcher. 1995. Intracellular
neutralization of influenza virus by immunoglobulin A anti-hemagglutinin
monoclonal antibodies. J. Virol. 69:1339–1343.
30. McNeal, M. M., K. S. Barone, M. N. Rae, and R. L. Ward. 1995. Effector
functions of antibody and CD8 cells in resolution of rotavirus infection and
protection against reinfection in mice. Virology 214:387–397.
31. McNeal, M. M., S. C. Stone, M. Basu, J. A. Bean, J. D. Clements, B. A.
Hendrickson, A. H. Choi, and R. L. Ward. 2006. Protection against rotavirus
shedding after intranasal immunization of mice with a chimeric VP6 protein
does not require intestinal IgA. Virology 346:338–347.
32. McNeal, M. M., J. L. VanCott, A. H. C. Choi, M. Basu, J. A. Flint, S. C.
Stone, J. D. Clements, and R. L. Ward. 2002. CD4 T cells are the only
lymphocytes needed to protect mice against rotavirus shedding after intra-
nasal immunization with a chimeric VP6 protein and the adjuvant
LT(R192G). J. Virol. 76:560–568.
33. Nejmeddine, M., G. Trugnan, C. Sapin, E. Kohli, L. Svensson, S. Lopez, and
J. Cohen. 2000. Rotavirus spike protein VP4 is present at the plasma mem-
brane and is associated with microtubules in infected cells. J. Virol. 74:3313–
3320.
34. Offit, P. A., and H. F. Clark. 1985. Protection against rotavirus-induced
gastroenteritis in a murine model by passively acquired gastrointestinal but
not circulating antibodies. J. Virol. 54:58–64.
35. Offit, P. A., R. D. Shaw, and H. B. Greenberg. 1986. Passive protection
against rotavirus-induced diarrhea by monoclonal antibodies to surface pro-
teins vp3 and vp7. J. Virol. 58:700–703.
36. Parashar, U. D., C. J. Gibson, J. S. Bresse, and R. I. Glass. 2006. Rotavirus
and severe childhood diarrhea. Emerg. Infect. Dis. 12:304–306.
37. Parez, N., C. Fourgeux, A. Mohamed, C. Dubuquoy, M. Pillot, A. Dehee, A.
Charpilienne, D. Poncet, I. Schwartz-Cornil, and A. Garbarg-Chenon. 2006.
10698 CORTHE´SY ET AL. J. VIROL.
Rectal immunization with rotavirus virus-like particles induces systemic and
mucosal humoral immune responses and protects mice against rotavirus
infection. J. Virol. 80:1752–1761.
38. Phalipon, A., A. Cardona, J. P. Kraehenbuhl, L. Edelman, P. J. Sansonetti,
and B. Corthe´sy. 2002. Secretory component: a new role in secretory IgA-
mediated immune exclusion in vivo. Immunity 17:107–115.
39. Phalipon, A., M. Kaufmann, P. Michetti, J. M. Cavaillon, M. Huerre, P.
Sansonetti, and J. P. Kraehenbuhl. 1995. Monoclonal immunoglobulin A
antibody directed against serotype-specific epitope of Shigella flexneri lipo-
polysaccharide protects against murine experimental shigellosis. J. Exp.
Med. 182:769–778.
40. Prasad, B. V., and W. Chiu. 1994. Structure of rotavirus. Curr. Top. Micro-
biol. Immunol. 185:9–29.
41. Ramig, R. F. 1997. Genetics of the rotaviruses. Annu. Rev. Microbiol. 51:
225–255.
42. Rindisbacher, L., S. Cottet, R. Wittek, J. P. Kraehenbuhl, and B. Corthe´sy.
1995. Production of human secretory component with dimeric IgA binding
capacity using viral expression systems. J. Biol. Chem. 270:14220–14228.
43. Rojas, R., and G. Apodaca. 2002. Immunoglobulin transport across polarized
epithelial cells. Nat. Rev. Mol. Cell Biol. 3:944–955.
44. Ruggeri, F. M., K. Johansen, G. Basile, J. P. Kraehenbuhl, and L. Svensson.
1998. Antirotavirus immunoglobulin A neutralizes virus in vitro after trans-
cytosis through epithelial cells and protects infant mice from diarrhea. J. Vi-
rol. 72:2708–2714.
45. Ruiz-Palacios, G. M., I. Perez-Schael, F. R. Velazquez, H. Abate, T. Breuer,
S. C. Clemens, B. Cheuvart, F. Espinoza, P. Gillard, B. L. Innis, Y. Cer-
vantes, A. C. Linhares, P. Lopez, M. Macias-Parra, E. Ortega-Barria, V.
Richardson, D. M. Rivera-Medina, L. Rivera, B. Salinas, N. Pavia-Ruz, J.
Salmeron, R. Ruttimann, J. C. Tinoco, P. Rubio, E. Nunez, M. L. Guerrero,
J. P. Yarzabal, S. Damaso, N. Tornieporth, X. Saez-Llorens, R. F. Vergara,
T. Vesikari, A. Bouckenooghe, R. Clemens, B. De Vos, and M. O’Ryan. 2006.
Safety and efficacy of an attenuated vaccine against severe rotavirus gastro-
enteritis. N. Engl. J. Med. 354:11–22.
46. Sa´nchez-San Martin, C., T. Lo´pez, C. F. Arias, and S. Lo´pez. 2004. Char-
acterization of rotavirus cell entry. J. Virol. 78:2310–2318.
47. Santos, N., and Y. Hoshino. 2005. Global distribution of rotavirus serotypes/
genotypes and its implication for the development and implementation of an
effective rotavirus vaccine. Rev. Med. Virol. 15:29–56.
48. Schwartz-Cornil, I., Y. Benureau, H. Greenberg, B. A. Hendrickson, and J.
Cohen. 2002. Heterologous protection induced by the inner capsid proteins
of rotavirus requires transcytosis of mucosal immunoglobulins. J. Virol.
76:8110–8117.
49. Tosser, G., T. Delaunay, E. Kohli, J. Grosclaude, P. Pothier, and J. Cohen.
1994. Topology of bovine rotavirus (RF strain) VP6 epitopes by real-time
biospecific interaction analysis. Virology 204:8–16.
50. Vesikari, T., D. O. Matson, P. Dennehy, P. Van Damme, M. Santosham, Z.
Rodriguez, M. J. Dallas, J. F. Heyse, M. G. Goveia, S. B. Black, H. R.
Shinefield, C. D. Christie, S. Ylitalo, R. F. Itzler, M. L. Coia, M. T. Onorato,
B. A. Adeyi, G. S. Marshall, L. Gothefors, D. Campens, A. Karvonen, J. P.
Watt, K. L. O’Brien, M. J. DiNubile, H. F. Clark, J. W. Boslego, P. A. Offit,
and P. M. Heaton. 2006. Safety and efficacy of a pentavalent human-bovine
(WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354:23–33.
VOL. 80, 2006 ANTI-VP6 MAb NEUTRALIZES ROTAVIRUS INTRACELLULARLY 10699
115
Annex 3
116
Solution Structure of Human Secretory Component and
Implications for Biological Function*□S
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Secretory component (SC) in association with polymeric IgA
(pIgA) forms secretory IgA, the major antibody active at muco-
sal surfaces. SC also exists in the free form, with innate-like neu-
tralizing properties against pathogens. Free SC consists of five
glycosylated variable (V)-type Ig domains (D1–D5), whose
structure was determined by x-ray and neutron scattering,
ultracentrifugation, and modeling. With a radius of gyration of
3.53–3.63 nm, a length of 12.5 nm, and a sedimentation coeffi-
cient of 4.0 S, SC possesses an unexpected compact structure.
Constrained scattering modeling based on up to 13,000 trial
models shows that SC adopts a J-shaped structure in which D4
and D5 are folded back against D2 and D3. The seven glycosyla-
tion sites are located on one side of SC, leaving known IgA-
binding motifs free to interact with pIgA. This work represents
the first analysis of the three-dimensional structure of full-
length free SCandpaves theway to a better understandingof the
association between SC and its potential ligands, i.e. pIgA and
pathogenic-associated motifs.
Themucosal epithelia lining the gastrointestinal, respiratory,
and urogenital tracts represent the largest surface (400 m2 for
the human body) in contact with the external environment (1).
Consequently, they are permanently exposed to foreign anti-
gens andmust therefore be efficiently protected to prevent pos-
sible damage by pathogenic agents (2). In response to this
threat, a major immune defense system is mediated by secre-
tory immunoglobulin A (SIgA)5 within the lumen (3), where
SIgA exerts its function of antigen neutralization. IgA is pro-
duced locally as polymeric IgA (pIgA), which consists of two or
four IgA molecules linked covalently by a J chain (4). Subse-
quent transport of pIgA (and to a lesser extent pentameric IgM)
across the epithelium is ensured by the polymeric Ig receptor
(pIgR), which is expressed on the basolateral surface of epithe-
lial cells. Following cleavage at luminal surfaces, SIgA is
released as a complex of pIgA and the cleaved extracellular
portion of the pIgR which is termed secretory component (SC).
Because secretory IgM can be present in external secretions
with an accessory role as a neutralizing antibody, this suggests
that SC has a generic antibody-binding ability, being able to
bind to both pIgA and pentameric IgM (5). This selectivity may
be required to allow only larger, polymerized antibodies pro-
tected by heavily glycosylated SCs to enter the harsh environ-
ment of external secretions.
SC consists of five immunoglobulin-like domains (D1–D5)
and up to seven glycan chains. SC bound to pIgA protects the
antibody against proteolytic digestion (6) and governs anchor-
ing of SIgA at mucosal surfaces (7). Free SC is also found in
secretions and is now recognized as an active antibacterial par-
ticipant to protect mucosal surfaces againstHelicobacter pylori
(8), enteropathogenic Escherichia coli and Clostridium difficile
toxinA (9), and Streptococcus pneumoniae choline binding pro-
tein A (10, 11). Recombinant human SC produced from trans-
fected Chinese hamster ovary (CHO) cells behaves identically,
and its neutralizing properties rely on the presence of oligosac-
charides on SC (12).
Despite the importance of SC and its glycosylation, only par-
tial information is available on its structure. SC comprises the
first 585 residues in pIgR (Fig. 1A) (13). Homology modeling of
rabbit SC domains 1 and 2 (D1 and D2) indicates that both
exhibit the typical features of Ig variable (V)-type superfamily
members with seven -strands A–G and an extra two desig-
nated C and C (14, 15). A similar topology was determined in
themodeling of domains 2 and 3 (D2 andD3) ofmouse SC (16).
These were confirmed by the crystal structure of D1 of human
SC, which revealed a V-type fold (17). So far, the three-dimen-
sional domain arrangement of full-length SC has not been con-
sidered, even though this is essential to appreciate molecular
mechanisms that are involved in mucosal immunity. Its high
glycosylation and the presence of long interdomain linkers sug-
gest that SC may be too flexible to be crystallized intact. In a
situation such as this, x-ray and neutron scattering and analyt-
ical ultracentrifugation in combination with constrained mod-
eling techniques will reveal the domain arrangement of SC (18).
Here, we determine a solution structure for recombinant
human SC produced in CHO cells. We show that SC forms a
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compact domain arrangement, and this structure rationalizes
many of the biological roles of both free and bound SC for the
first time.
MATERIALS ANDMETHODS
Recombinant Secretory Component and Its Fragments—
CHO cells producing human SC (7) were cultured in suspen-
sion inCHO-S-SFMIImedium (Invitrogen) usingCELLine 350
bioreactors (Integra-Biosciences). Supernatants (8 ml) were
collected twice a week, and immediately chromatographed
onto a 1.6-cm  1-meter long Superdex-200 column in PBS.
Fractions containing human SC as confirmed by immunoblot-
ting were pooled and filtered through 0.22-m cartridges. Fil-
tered aliquots were stored at 4 °C in PBS (116 mM NaCl, 10.4
mM Na2HPO4, 3.2 mM NaH2PO4, pH 7.2) prior to use for scat-
tering and ultracentrifugation. Cleaved SC fragments were
obtained from purified SC samples that were stored for at least
6 months at 4 °C. Separation was performed by chromatogra-
phy onto a 1.6-cm  1-m Superdex-200 column (Amersham
Biosciences) in PBS. Pools of fractions containing fragments
D1–D3 and D4–D5 were concentrated using Amicon Ultra
(30-kDa molecular mass cut-off) and Centricon YM-10 (10-
kDa molecular mass cut-off) filters (Millipore), respectively.
Further purification of fragments D1–D3 and D4–D5 was
achieved by repeating chromatography onto the Superdex-200
column. To identify the SC cleavage site, N-terminal sequenc-
ing of purified D4–D5 from a polyvinylidene difluoride blot
was performed by Edman degradation at Alta Biosciences (Uni-
versity of Birmingham, UK).
For the x-ray scattering and ultracentrifugation experiments,
samples were recovered in PBS. For neutron scattering, the
buffer was Dulbecco’s PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM
Na2HPO4, 1.5 mM KH2PO4, pH 7.5), made up in 100% 2H2O.
The neutron samples were dialyzed at 6 °C into this 100% 2H2O
buffer for 36 h with four buffer changes. The two buffer densi-
ties in H2O solvent were predicted to be 1.00485 g/ml and
1.00543 g/ml, respectively, from these compositions using
SEDNTERP. The SC, D1–D3, andD4–D5 concentrations were
determined using absorption coefficients of 12.3, 7.1, and 18.7
(1%, 280 nm, and 1-cm path length) that were calculated from
its composition by assuming the presence of seven biantennary
complex-type oligosaccharides Man3GlcNAc4Gal2NeuNAc2
(see Fig. 1) (19). The partial specific volume v for SC, D1–D3,
and D4–D5 was calculated to be 0.717, 0.717, and 0.718 ml/g,
respectively, from their compositions (19). The calculated
molecular masses for SC, D1–D3, and D4–D5 were 79.6, 45.5,
and 34.1 kDa, respectively, their unhydrated volumeswere 99.7,
56.9, and 42.7 nm3, respectively, and their hydrated volumes
were 132.2, 75.5, and 56.7 nm3, respectively (assuming 0.3 g of
H2O/g of glycoprotein).
X-ray and Neutron Scattering and Ultracentrifugation Data—
X-ray scattering data were obtained in two sessions on the
Beamline ID02 at the European Synchrotron Radiation Facility
(Grenoble, France), operating at 6.03 GeV (20). To reduce the
incident flux, the experimentswere performed in 16-bunch and
4-bunch mode with storage ring currents ranging between 92
and 53 mA (SC) and 4-bunch mode with currents ranging
between 41 and 23 mA (D1–D3 and D4–D5). The sample-to-
detector distance of 3.0 m, yielded a Q range from 0.07 to 2.1
nm1 (whereQ 4 sin /; 2 scattering angle; wave-
length). Samples were measured at concentrations between
0.62 and to 2.0 mg/ml (SC), 0.39 to 1.6 mg/ml (D1–D3), and
0.40 to 0.73 mg/ml (D4–D5). Data were acquired using five or
ten time frames of 0.5, 1, 2, or 4 s to establish the absence of
radiation damage. Neutron scattering data for SC were col-
lected in one session in a Q range between 0.02 and 1.93 nm1
on Instrument LOQat the ISIS facility at the RutherfordApple-
ton laboratory, Didcot, UK (21). The proton beam current was
172–173 A, and acquisition times were 1–2 h for concentra-
tions between 0.62 and 2.0 mg/ml, measured at 15 °C. Other
details, including calibrations and data reduction, the Guinier
analyses to determine the radius of gyration RG and the radius
of gyration of the cross-sectional structure RXS, and the calcu-
lation of the distance distribution function P(r) using GNOM
for whichQ ranged between 0.08 and 2.06 nm1, are described
previously (22, 23).
Analytical ultracentrifugation was performed at 20 °C on a
Beckman XL-I instrument, equipped with an AnTi50 rotor.
Sedimentation equilibrium data sets for SC between 0.20 and
2.50 mg/ml were acquired over 45 h with column heights of 2
mm at rotor speeds of 8,000, 11,000, 14,000, 18,000, and 23,000
rpm, until equilibrium had been reached at each speed as
shown by the perfect overlay of runs measured at 5-h intervals.
Sedimentation velocity data for SC, D1–D3, and D4–D5 were
acquired over 16 h at rotor speeds of 20,000, 25,000, 30,000, and
35,000 rpm (and 42,000 rpm for D1–D3 and D4–D5) with col-
umn heights of 12 mm. SC was studied at five concentrations
from0.30 to 2.50mg/ml. D1–D3 andD4–D5were each studied
at two concentrations of 0.39–1.6mg/ml and 0.40–0.73mg/ml
respectively. DCDT g(s*) time-derivative analyses and SED-
FIT Lamm equation fits based on the non-interacting species
model were performed as previously described (23).
Constrained Modeling of SC—SC corresponds to residues
19–603 of the polymeric immunoglobulin receptor (SwissProt
code P01833). The start and end of D2–D5 is defined as resi-
dues 1–104 in Fig. 1. The homology modeling of D2–D5
employed MODELLER v7 (24) and was based on a topological
sequence alignment with the D1 crystal structure identified
using BLASTP (PDB code 1xed) (17). The models were struc-
turally validated using PROCHECK. Seven biantennary oligo-
saccharide chains Man3GlcNAc4Gal2NeuNAc2 were incorpo-
rated in extended conformations in theD1–D5models (25, 23).
The first SC residue Lys was added to the D1 crystal structure
usingMODELLER v7. Tomodel the other interdomain linkers,
residues 109–116, 219–221, 324–335, 440–446, and 543–585
(Fig. 1B) were created in extended -strand conformations
using INSIGHT II 98.0 with BIOPOLYMER, DISCOVER,
HOMOLOGY, and DELPHI modules (Accelrys, San Diego,
CA), and 5000 randomized conformations for each were gen-
erated using DISCOVER3 (22). Linker length constraints of
95–100% were applied to generate sufficient conformational
variability when needed. Full SCmodels were created by super-
impositions of the domains and the linkers.
Each SC, D1–D3, and D4–D5 model was converted into
Debye spheres to calculate the x-ray and neutron scattering
curves (22, 23). A cube side length of 0.542 nm in combination
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with a cutoff of 4 atoms consistently produced sphere models
within 95% of the total unhydrated volume of 99.7, 56.9, and
43.8 nm3, respectively, calculated from their compositions.
Hence the optimal totals of unhydrated spheres were 626, 268,
and 353 respectively, whichwere then hydrated. The number of
spheres N in the unhydrated and hydrated models after grid
transformation was used to assess steric overlap between the
D1, D2, D3, D4, and D5 domains.
The models were assessed by calculation of the RG and RXS
values in the same Q ranges used for the experimental Guinier
fits. Models that passed these RG and RXS filters were ranked
using the R-factor goodness-of-fit agreement. A flat back-
ground correction of 2.7% of I(0) was applied to the final neu-
tron scattering curve fits in Fig. 8 to allow for a uniform inco-
herent scattering of residual protons in the sample. Other
details, including those of calibration studies used to validate
this approach, are given elsewhere (22, 26). The sedimentation
coefficients s20,w0 were calculated directly from the hydrated SC,
D1–D3, and D4–D5 sphere models using the GENDIA and
HYDRO programs (22, 23). Control calculations of s20,w0 were
performed using HYDROPRO shell modeling directly from the
molecular models for SC, D1–D3, and D4–D5 (27). The ten
best SC -carbon co-ordinate models were deposited in the
Protein Data Bank with the accession code 2OCW.
RESULTS
Characterization of SC and Its Fragments—In SC, sequence
similarities between D1 and the other four SC domains (D2–
D5) show that all belong to the immunoglobulin (Ig) variable
(V)-type classification (Fig. 1A). For clarification, the domains
and interdomain linkers are depicted in Fig. 1B. As glycosylation
andproperdisulfidebonding are essential features of SC,wechose
to produce the protein in CHOcells, which yields SC that is indis-
tinguishable when compared with colostrum SC (12, 28). Purified
recombinant human SC resulted in a major band at an apparent
molecular mass of 75 kDa when analyzed by silver staining and
immunodetection (Fig. 1C, lanes 1, 3, 5, and 7). This molecular
mass agrees well with the sequence-derived value of 79.6 kDa.
Upon storage for several months at 4 °C, two additional bands
at 45 and 30 kDa appear (Fig. 1C, lanes 2, 4, 6, and 8). InWestern
blots, detection with polyclonal antisera specific for D1 and D5
established that the bands at 45 and 30 kDa represent cleavage of
full-length SC into D1–D3 and D4–D5 fragments. This was con-
firmed byN-terminal sequencing of fragmentD4–D5 that identi-
fied the sequence SPTVVKGVAG corresponding to the begin-
ning of domain 4 and indicating cleavage between Arg336 and
Ser337. The PeptideCutter web tool (available from the ExPASy
server) suggested that the enzymatic cleavagemay be caused by
one of trypsin, thrombin, or other related proteases. This unex-
pected observation provided us with three different polypep-
tides that were used to generate the results presented below.
X-ray and Neutron Scattering—X-ray scattering identified
the domain arrangements in SC, D1–D3, and D4–D5 at con-
centrations between 0.40 and 2.7 mg/ml (see “Materials and
Methods”). Because no radiation damage was detectable, the
ten time frames of each acquisition were averaged for analyses.
SDS-PAGE analyses before and after runs showed that,
although SC and D4–D5 generally remained intact, further
cleavages occurred in D1–D3 to give single domain fragments
as well as the three-domain fragment. All the SC and D4–D5
results below correspond to samples shown to be intact by SDS-
PAGE before and after the experiment.
At low Q values, Guinier analyses of ln I(Q) against Q2
resulted in linear plots for SC and its two fragments, yielding
the radius of gyration (RG) (Fig. 2, A, E, and F). At larger Q
FIGURE 1.TheD1–D5domains of humanSCand characterizationof recombinant polypeptides.A, the sequence alignment of D2–D5withD1. Conserved
residues are highlighted in gray. The linker peptides are boxed. Putative glycosylation sites are underlined. The Arg336-Ser337 cleavage site and Cys502 that is
covalently linked within SIgA are highlighted in black. The Define Secondary Structure Prediction-assigned secondary structure and the labeling of the
-strands are shown below the alignment. B, schematic representation of the V-type D1–D5 domains. Residue numberings indicate the cleavage site that
yields D1–D3 andD4–D5 and the seven glycosylation sites. The lengths of linker peptides are shown in brackets. C, SDS-PAGE andWestern blot analyses of SC
(lanes 1, 3, 5, and 7) and cleaved SC (lanes 2, 4, 6, and 8). Silver stain (lanes 1 and 2) andWestern blot performedwith anti-SC (lanes 3 and 4), anti-D1 (lanes 5 and
6), and anti-D5 (lanes 7 and 8) identify full-length SC at 75 kDa, D1–D3 as a major band at 45 kDa, and D4–D5 at 30 kDa.
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values, analyses of ln I(Q)Q against Q2 yielded the RG of the
cross-section (RXS). For SC, a mean x-ray RG of 3.53 ( 0.03)
nm and mean RXS of 1.76 ( 0.08) nm were recorded from
seven runs (Table 1). Another SC sample gave a similar mean
x-ray RG of 3.64 ( 0.17) nm and RXS of 1.63 ( 0.12) nm from
six runs. A partially cleaved samplewith33%SC, 33%D1–D3,
and 33%D4–D5 showed a small increase in themeanRG to 3.77
( 0.17) nm and a small decrease in the mean RXS to 1.60 (
0.61) nm. From five runs, the partially cleaved sample ofD1–D3
showed an apparent RG of 3.44 ( 0.27) nm and an apparent
RXS of 1.07 ( 0.07) nm (supplemental Fig. S1). From five runs,
D4–D5 was found to have a mean RG of 3.16 ( 0.04) nm and a
mean RXS of 1.11 ( 0.08) nm (supplemental Fig. S1). The
Guinier analyses were confirmed by the I(0)/c values, which are
proportional to molecular masses, where c is the concentration
(18). The observed I(0)/c values were in the ratio of 1:0.30:0.53,
respectively, relative to Lupolen. The sequence-derived molecu-
larmass ratioswere 1:0.57:0.43 in that order. I(0)/c forD1–D3was
lower than expected, which is attributed to its cleavage, whereas
that for D4–D5 was in fair agreement with the sequence.
Interestingly SC appearedmore compact than either D1–D3
orD4–D5. Shape informationwas determined from the anisot-
ropy ratio, RG/RO (where RO is the RG value of a sphere of equal
volume to that of the hydrated glycoprotein). The ratios were
1.44–1.49, 1.69, and 1.70 for SC, D1–D3, and D4–D5 in that
order (Table 1). Because RG/RO for globular proteins is close to
1.28 (29), all three proteins are elongated. Assuming that the
proteins possess cylindrical shapes, the lengths of SC, D1–D3,
and D4–D5 were calculated from its RG and RXS values to be
10.6–11.3, 11.3, and 10.2 nm, respectively. From the I(0) and
[I(Q)Q]Q30 values, the lengths were calculated to be 11.9, 9.1,
and 10.8 nm, respectively (Table 1). Despite the cleavage in the
D1–D3 sample, the similarity of these three lengths is explained
by postulating that SC is folded back upon itself. If the end-to-
end length of the SC domains is
taken to be 3.7 nm from theD1 crys-
tal structure (17), SC, D1–D3, and
D4–D5 are predicted to be 18.5,
11.1, and 7.4 nm long if they are fully
extended but with no linkers. The
disparity between the observed SC
length of 10.6–11.9 nm and the 18.5
nm prediction shows that SC must
be folded back. That D4–D5 (Table
1) is observed to be longer than the
predicted value may result from the
42 C-terminal residues in SC (Fig.
1A). The observed lengths for
D1–D3 are in fair agreement with
the predicted length of 11.1 nm.
Neutron scattering data for SC
confirm the x-ray RG values (Table
1). These were obtained as a control
of radiation damage by x-rays,
because these effects are absent in
neutron scattering. The neutron
data are complementary in that the
hydration shell surrounding SC is
not detectable (26). The high nega-
tive protein-solvent scattering con-
trast acts as a control of any scatter-
ing inhomogeneity effects caused by
the high proportion of carbohydrate
FIGURE 2. Guinier RG and RXS analyses for SC. Data points included in the Guinier fits are indicated by filled
circles between the arrowed QRG andQRXS ranges. Where required for clarity, the Guinier plots were displaced
on their vertical axes. TheQ ranges for SC are 0.18–0.39 nm1 (RG) and 0.42–0.86 nm
1 (RXS). A and C, x-ray fits
for SC (1.3 mg/ml); B and D, neutron fits for SC (2.0 mg/ml (upper) and 1.3 mg/ml (lower)). For the Guinier
analyses for D1–D3 and D4–D5, see supplemental Fig. S1.
TABLE 1
Experimental x-ray and neutron scattering and ultracentrifugation analyses for SC, D1–D3, and D4–D5
Protein
Guinier analyses P(r) analyses AUC analyses
RG RXS RG/R0 L from RGand RXS
L from I(0)
and 	I(Q)Q
Q30 RG M L s20,w
0 (SEDFIT) s20,w0 (DCDT) f/fo
nm nm S
SC (x-ray) 3.53 0.03 1.76 0.08 1.44 10.6 11.9 3.66 0.19 3.8 0.2 13.0 4.2 4.0 (int) 1.55
SC (x-ray) 3.64 0.17 1.63 0.12 1.49 11.3 NAa 3.71 0.12 NA NA 3.9 (abs)
SC (neutron) 3.63 0.28 1.30 0.10 NA 11.7 13.1 3.73 0.17 3.2 12.0
D1–D3 (x-ray) 3.44 0.27b 1.07 0.07b 1.69 11.3 9.1 3.52 0.27 2.9 12.0 3.1 NA 1.42
D4–D5 (x-ray) 3.16 0.04 1.11 0.08 1.70 10.2 10.8 3.15 0.18 2.7 10.0 2.4 2.4 (int) 2.3 (abs) 1.48
aNA, data not available.
bApparent (see text).
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in SC. Themean of threeRG andRXS values for SCwere 3.63 (
0.28) nm and 1.30 ( 0.10) nm, respectively (Fig. 2). The
decrease in the neutron RXS compared with the x-ray RXS value
is attributed to the absence of hydration effects on the cross-
section of SC (25). The length of SC from the neutronRG andRXS
was 11.7 nm and from I(0) and [I(Q)Q]Q30 was 13.1 nm, which is
consistent with the x-ray determined lengths. The neutron data
givesmolecularmasses from the expression I(0)/c 9 105 (22).
The observed I(0)/c of 0.087 ( 0.009) resulted in 78 ( 8) kDa,
which is close to the sequence-derived value of 79.6 kDa.
The transformation of I(Q) into the distance distribution
function, P(r) confirmed that SC has a folded back conforma-
tion in solution. The P(r) curves for SC (x-rays and neutrons)
and for D1–D3 and D4–D5 (x-rays) were reproducible with
single maxima (Fig. 3). The RG from these were 3.66 ( 0.19)
nmand3.71 (0.12)nm(twoSCx-ray samples), 3.73 (0.17)nm
(SC neutrons), 3.52 ( 0.27) nm (D1–D3), and 3.15 ( 0.18) nm
(D4–D5), all of whichwere consistent with theGuinier analyses
(Table 1). The maximum, M, corresponds to the most fre-
quently occurring interatomic distance. These were 3.8 ( 0.2)
nm and 3.2 nm, respectively, for the x-ray and neutron data for
SC and were slightly smaller at 2.9 nm and 2.7 nm for D1–D3
and D4–D5, respectively. The length, L, is determined when
P(r) becomes zero at large r values and is not dependent on
shape assumptions. For SC, Lwas determined to be 13 ( 1) nm
(x-rays) and 12 ( 1) nm (neutrons). For D1–D3 andD4–D5, L
was determined to be 12 ( 1) nm and 10 ( 1) nm, respec-
tively. Although the D1–D3 analysis may be affected by
cleaved products, this analysis will reveal the maximum
length of the intact protein as any cleavage products will be
shorter in length. These lengths were consistent with the
Guinier-derived analyses (Table 1).
Analytical Ultracentrifugation—The oligomerization of SC
at concentrations between 0.2 and 2.5 mg/ml was determined
by sedimentation equilibrium to show that this is monomeric.
Assuming a single species was present, good curve fits with
small random residuals were obtained (Fig. 4). SDS-PAGE anal-
yses before and after runs confirmed that any SC cleavage was
not detectable. A small decrease in the molecular mass of SC
was observed with increasing rotor speed, which is attributable
to sample polydispersity (30). This is most likely to result from
heterogeneous occupation at the seven N-linked glycosylation
sites, and/or any cleavage products (Fig. 1). Thus the presence
of seven bi-antennary oligosaccharides would give a molecular
mass of 79,600 Da, whereas seven tetra-antennary ones would
give 88,800 Da. In addition, the molecular masses slightly
increased on dilution (lower panels, Fig. 4). This was attributed
to decreased interactions between SC molecules at lower con-
centrations, because any oligomerization would result in a
decrease in molecular masses on dilution. Regressions resulted
in molecular masses of 79,500 ( 2,900) Da (interference) and
81,600 ( 5,500) Da (absorbance) at zero concentration. These
agree well with the sequence-derived molecular mass. The
equilibrium data therefore showed that all seven putative gly-
cosylation sites are filled.
The sedimentation coefficient, s20,w0 ,monitors themacromo-
lecular elongation, independently from RG. Sedimentation
velocitywas used to examine SC,D1–D3, andD4–D5, aswell as
SC that was cleaved into an equimolar mixture of the three
forms, by incubating this at room temperature. The advantage
of SEDFIT c(s) distribution plots is that these identify the s20,w0
values of any species present in each sample (Table 1), hence
these values are independent of degradation effects. All the
boundary fits showed good agreements (Fig. 5, A–D). The c(s)
FIGURE 3.Distance distribution functions P(r) for SC, D1–D3, andD4–D5.
M represents the most frequent distance, and L represents the maximum
dimension (Table 1).A and B, the x-ray and neutron P(r) curves for SC. C andD,
the x-ray P(r) curves for D1–D3 and D4–D5.
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plots showed that SC sedimented as a single species at 4.2 S,
whereas major species were seen at 3.1 S for D1–D3 and 2.4 S
for D4–D5 (Fig. 5, E–G). This interpretation was confirmed by
the three major peaks seen in the cleaved SC sample (Fig. 5H).
The c(s) plot for D4–D5 showed aminor peak at 0.7 S (Fig. 5G).
In contrast, the D1–D3 c(s) analysis showed peaks at 0.7 S and
2.2 S to indicate more extensive cleavage, in agreement with
the x-ray scattering and SDS-PAGE analyses above. The
c(M) analyses represent the c(s) peaks as molecular mass
values. The three major peaks in Fig. 5H correspond to
24,500 ( 5,600), 44,700 ( 6,200), and 79,000 ( 7,200) Da.
These agree well with the sequence-derived values of 34,100,
45,500, and 79,600 Da.
The SEDFIT analyses for SC and D4–D5 were confirmed by
the good fits obtained in time-derivative g(s*) analyses using
DCDT (Fig. 6 and supplemental Fig. S2). The s20,w0 values
were determined to be 4.0 S and 3.9 S for SC (interference and
absorbance optics, respectively) and 2.4 S and 2.3 S for D4–D5
(interference and absorbance optics, respectively (Table 1)).
D1–D3 could not be analyzed by DCDT.
The s20,w0 values lead to frictional ratios f/fo that confirm the
folded back structure of SC, where fo is the frictional coefficient
of the sphere of volume equal to that of the hydrated protein.
Many globular proteins show f/fo of 1.2 to 1.3. For SC, D1–D3,
andD4–D5, the f/fo ratioswere determined to be 1.55, 1.42, and
1.48. These show that all three glycoproteins possess similar
degrees of elongation. They are consistentwith theRG/R0 ratios
of 1.44–1.49, 1.69, and 1.70 in that order.
Constrained Modeling—The constrained modeling of the
solution data utilized the D1 crystal structure, which has a
-sheet sandwich formed from the DEBA and AGFCCC
-strands (17). These -strands are defined in Fig. 1A. D1
showed sequence identities from 24% to 36% with D2–D5,
where over 30% is considered significant (31). Cys22–Cys92
forms the internal disulfide bridge between -strands B and F
and was conserved in D1–D5. Sequence gaps and insertions
were minimal, except that -strand C is deleted in D5. The
alignment using BLASTP thus defined theD1–D5domains and
their six flanking peptides. Homology models for the D2–D5
domains were constructed and validated, and oligosaccharides
FIGURE4.Sedimentationequilibrium fits for SC. The curve fits at 14,000 rpmcorrespond to interferenceoptics (A) and absorbanceoptics (B) at awavelength
of 280 nm. InA, concentrations are 2.5, 1.2, and 0.48mg/ml. In B, concentrations are 0.64, 0.48, and 0.21mg/ml. The residuals are shown above the exponential
fits, whereas the concentration dependence of the observed molecular masses is shown below.
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were attached (“Materials and Methods”). The four linkers
were defined to run from the end of -strand G to -strand A
between domain pairs (25). Linkers (boxed in Fig. 1A) were
created from conformational libraries, from which random
selections were used to generate full SC models in all orienta-
tions. Secondary structure analyses of the 42-residue C-termi-
nal peptide predicted little secondary structure (32). BLASTP
sequence searches of over 39,000 structures in the Protein Data
Bank did not reveal any significant structural similarity for this
C-terminal peptide (33). Its amino acid composition showed a
high proportion of 12 negatively charged Asp/Glu residues and
nine positively charged Arg/Lys residues, together with 14
small Gly/Ala/Ser residues, all of which promote random struc-
tures (27). Accordingly theC-termi-
nal peptide was modeled as another
unconstrained structure.
In the D4–D5 modeling, for
which the x-ray scattering curvewas
free of cleavage, the only conforma-
tional variables were the D4–D5
linker and the C-terminal peptide.
Unconstrained linkers resulted in
too many models that were over-
lapped betweenD4 andD5.Accord-
ingly, the D4–D5 linker was con-
strained to be between 95 and 100%
of itsmaximum length to permit full
domain reorientations. The C-ter-
minal peptide was set to be at mini-
mum lengths of 5, 7, 9.8, and 11.8
nm to enforce the generation of a
wide range of conformations. The
resulting 6000 models spanned a
wide range of conformational sepa-
rations of the N terminus and C ter-
minus from0.6 to 20.6 nm (Table 2).
Filtering to retain aminimumof 346
hydrated spheres (i.e. those with no
significantly overlap) and a RG
between 3.00 and 3.20 nmgave 1011
satisfactory models (Table 2). Sort-
ing based on the R-factor goodness-
of-fit parameter identified the best
nine models. The best D4–D5
model has an RG of 3.15 nm and an
RXS of 1.14 nm, giving the closest
agreement with the experimental
values (Table 2), and gave an excel-
lent curve fit. Its sedimentation
coefficient of 2.04 S is close to the
experimental values of 2.3–2.4 S. All
nine best-fitmodels showed that the
D4 and D5 domains were V-shaped
with an extended C-terminal pep-
tide. The constrained modeling
parameters and curve fits are pre-
sented in panels D–F of supplemen-
tal Figs. S3 and S4.
A poor-fit D4–D5model is exemplified by that with the larg-
est RG of 3.71 nm, an RXS of 1.45 nm, and a sedimentation
coefficient of 1.94 S. This has a linear D4–D5 arrangement and
showed a large discrepancy with the experimental I(Q) curve
(supplemental Fig. S4F). Another model was created from the
best-fit model in which the oligosaccharides were folded back
against the protein surface of D4–D5 (green in supplemental
Fig. S4, D–F; see “CHO in” in Table 2). Although the RG and
sedimentation coefficient from thismodel were similar, theRXS
was significantly reduced from 1.14 to 0.86 nm.
GoodD1–D3 curve fits were obtained by postulating that the
observed x-ray scattering corresponded to a mixture of D1–D3
and single-domain fragments (cf.: the SDS-PAGE and c(s) anal-
FIGURE5.Sedimentationvelocity fits for SC,D1–D3, andD4–D5bySEDFIT.Theboundary fits are shown to
the left and the c(s) plots are shown to the right. A and E, SC at 1.24mg/ml and 30,000 rpm, showing every 5th
boundary of the first 100; B and F, D1–D3 at 1.6 mg/ml and 42,000 rpm, showing every 16th boundary of 500;
CandG, D4–D5at 0.40mg/ml and42,000 rpm, showingevery5thboundaryof the first 55; andDandH, cleaved
SC at 0.31 mg/ml and 42,000 rpm, showing every 5th boundary of the first 110.
FIGURE 6. Sedimentation velocity fits for SC byDCDT. In the g(s*) plots, the s,20,w values are arrowed. SC at
2.5 mg/ml (A) and 1.2 mg/ml (B), using 35,000 rpm. The residuals are shown above each g(s*) analysis. For the
sedimentation velocity fit for D4–D5 by DCDT, see supplemental Fig. S2.
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yses above). The D1–D3 modeling was achieved in five
searches. The use of three unconstrained linkers yielded few
good fits. Hence the linkers were constrained to be 95–100%
extended, and this gavemodels that spanned a sufficiently wide
range of RG, but with RXS that were too high. The final search
was based on the randomization of only the D1–D2 linker. The
D2–D3 linker proved too short to permit movement without
steric overlap, and the C-terminal D3–D4 linker was held fixed
in an extended conformation. Even with this, whereas 65 mod-
els showed compatible RG values, none showed a low enough
RXS of 1.07 nm. All ten best-fit models exhibited linear domain
arrangements. Alterations of the oligosaccharide conforma-
tions were also unable to account for the reduced RXS value.
The final good D1–D3 curve fits were obtained only by com-
puting composite scattering curves from the best-fit D1–D3
model with the lowestR-factor of 13.2% and a single domainD1
model. The sum of 74%D1–D3 and 26%D1 gave the best curve
fit with an R-factor of 6.0%. The linear D1–D3 model gave a
sedimentation coefficient of 3.02 S that agrees well with the
observed value of 3.1 S. Other poor-fit D1–D3 models con-
firmed this interpretation. For example, combining a U-shaped
D1–D3model with theD1model did not reduce theR-factor or
RXS, even though it gave a good RG. The D1–D3 constrained
modeling parameters and curve fits are shown in panels A–C in
the supplemental Figs. S3 and S4.
Intact SC (for which the x-ray scattering curve was shown to
be free of cleavage products) was modeled using either five
unconstrained linkers or the best-fit D1–D3 and D4–D5 mod-
els. The unconstrained search is summarized by the filled cyan
circles in Fig. 7 (A–F). Convex distributions of RXS as a function
of RG were observed. Their maxima agreed well with the
observed RG of 3.53 nm (x-rays) and 3.63 nm (neutrons) in Fig.
7 (A and D), and their minima corresponded to the lowest
R-factors in Fig. 7 (B and E). However, many models showed
FIGURE 7. Constrainedmodeling of SC. The parameters for 10,000 models for
SC are shown (A–F). The top panels compare the RXS and RG values. The middle
panels compare the R-factorswith the RG. The bottompanels compare theN-ter-
minal and C-terminal -carbon separation with the RG. The dashed lines corre-
spond to the experimental RG and RXS. The 5,000 SCmodels represented by blue
circles show theunrestrained linker conformations. The final SC analyses are rep-
resented by 5,000 unfilled circles. In each analysis, the best-fit model is shown in
red, related best-fit models in yellow, models with compact oligosaccharides in
green, and selected poor fit models in blue. For the results of the constrained
modeling for D1–D3 andD4–D5 see supplemental Fig. S3.
TABLE 2
Summary of the x-ray and neutronmodeling fits for the SC, D1–D3, and D4–D5 solution structures
Glycoprotein Filter Models Spheres RG RXS R-factor N/C-terminal distance s20,w0
nm % nm S
SC (x-ray) None 5000 678–869 3.43–4.71 1.05–2.00 3.3–19.4 2.2–22.3 NAa
RG 268 680–865 3.46–3.75 1.40–2.00 3.4–7.4 3.1–18.3 NA
RG, RXS, N 10 824–865 3.53–3.74 1.71–1.88 3.9–7.4 4.7–14.4 3.95–4.24
Best-fit 1 850 3.53 1.80 4.4 7.2 4.06
CHO in 1 853 3.52 2.00 5.8 7.2 4.09
Linear 1 1125 4.72 1.42 18.0 21.5 3.38
Experimental NA 830 3.53 0.03 1.76 0.08 NA NA 3.9–4.0
SC (neutron) None 5000 498–625 3.17–4.37 1.01–1.77 3.8–11.2 2.2–22.3 NA
RG 268 3.22–3.52 1.24–1.77 3.9–7.1 3.1–18.3 NA
RG, RXS, N 10 592–630 3.30–3.51 1.58–1.74 5.9–7.1 4.7–14.4 NA
Best-fit 1 619 3.30 1.70 6.8 7.2 NA
CHO in 1 616 3.30 1.77 7.4 7.2 NA
Linear model 1 850 4.38 1.33 10.7 21.5 NA
Experimental NA 626 3.63 0.28 1.30 0.10 NA NA NA
D1–D3 (x-ray) None 1000 421–525 2.47–3.68 1.19–1.77 13.2–16.8 4.6–15.1 NA
RG 65 474–518 3.40–3.49 1.24–1.44 13.2–16.5 10.0–14.8 NA
RG, RXS 10 475–509 3.40–3.49 1.24–1.30 13.2–15.7 10.2–13.3 2.64–3.02
Best linear 1 484 3.40 1.27 13.2 11.7 3.02
CHO in 1 484 3.26 1.24 11.6 11.7 3.00
Bent model 1 507 3.11 1.66 15.8 6.6 3.04
Best hybrid 1 NA 2.98 1.06 6.0 NA NA
D1 domain 1 179 1.90 0.73 19.9 2.9 1.64
Experimental NA 474 3.44 0.27 1.07 0.07 NA NA 3.1
D4–D5 (x-ray) None 6000 278–410 2.02–3.71 0.90–1.76 7.3–18.0 0.6–20.6 NA
RG, N 1011 346–410 3.00–3.20 0.98–1.68 7.7–17.2 5.3–19.1 NA
RG, N, R-factor 9 346–368 3.06–3.19 1.10–1.22 7.7–8.1 10.5–17.7 2.00–2.26
Best-fit 1 367 3.15 1.14 8.1 11.6 2.04
CHO in 1 367 3.13 0.86 8.6 11.6 2.22
Linear model 1 384 3.71 1.45 16.4 18.5 1.94
Experimental NA 356 3.16 0.04 1.11 0.08 NA NA 2.3–2.4
aNA, data not available.
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steric overlap; accordingly, this search was not pursued further.
The second search varied only the D3–D4 linker between the
best-fit D1–D3 and D4–D5 models. The unfilled circles in Fig.
7 (A–F) showed that these followed the same trends as the cyan
circles, but resulted in fewer sterically overlapping models with
too low RG values. Filtering showed that 268 SC models agreed
with the experimental x-ray RG of 3.53 nm, of which 70 agree
with the experimental RXS of 1.76 nm (Table 2). The removal of
partially overlapping SC models gave the 10 best-fit SC models
(yellow in Fig. 7, A–C). All 10 best-fit SC models showed a
folded-back arrangement in which D1–D3 is in proximity to
D4–D5 in an overall J-shaped conformation. This arrangement
was also found in the best-fit models from the unconstrained
search, although their R-factors were slightly higher. The sedi-
mentation coefficient of 4.06 S is close to the experimental val-
ues of 3.9–4.0 S. The neutron modeling in Fig. 7 (D–F) also
resulted in the same J-shaped best-fit models and a good curve
fit in Fig. 8D. A linear domain arrangement showed signifi-
cantly worsened fits (blue in Figs. 7 (A–F), 8C, and 8F). When
the extended oligosaccharide orientations in the best-fit model
were replaced by more compact
ones, slightly worsened curve fits
were usually seen (green in Figs. 7
(A–F), 8B, and 8E). These results are
summarized in the models of Fig. 9,
in the formof the ten best-fitmodels
(A), a stereo view of the best-fit
model with oligosaccharide chains
(B), an electrostatic map of the frag-
ments D1–D3 and D4–D5 (C), and
a view showing the availability of
pIgA binding motifs (D).
DISCUSSION
Molecular modeling and crystal
structures of SC domains from rab-
bit, mouse, and human have already
contributed insight into the topol-
ogy of SC and pIgA complexes (14,
15, 17). However, the analyses of
only protein fragments, the use of
strictly predictive computer-based
modeling, and the absence of infor-
mation on carbohydrate residues all
represent limitations when com-
pared with the determination of the
three-dimensional structure of full-
length SC. Given the demonstrated
importance of free SC in innate
immunity and its role in endowing
SIgA with optimal biological activ-
ity, our study of intact SC provides
several novel insights on the struc-
ture-function relationship in the
whole protein.
In view of the importance of gly-
cosylation, and inter-domain flexi-
bility to the SC structure, all the
analyses were conducted in near-physiological solution con-
ditions using complementary methods based on x-ray and
neutron scattering and analytical ultracentrifugation. When
analyzed with constrained modeling, the three-dimensional
structure of free SC was found to be a compact, folded-back
structure. The ten best-fit models of Fig. 9A are very similar
to each other. As all adopted a J-shaped structure, this
emphasized the robustness of the procedure. A stereo view
of the best-fit model is presented in Fig. 9B. The J-shaped
structure is confirmed by the lengths of Fig. 3, the sedimen-
tation coefficients (Figs. 5 and 6) and the constrained mod-
eling (Fig. 8). The point at which SC is folded back to form a
compact J-shaped structure was located to the junction between
the D3 and D4 domains in both modeling searches of all five SC
domains. In support of this model, the length and sedimentation
coefficient data obtained with the D1–D3 and D4–D5 fragments
both fit perfectlywith theSCstructure (Figs. 3 and5) and reinforce
the accuracy of the SCmodel.
This compact, folded-back structure of SC was unex-
pected in the light of the extended domain arrangements of
FIGURE8.Best-fit andpoor-fitmodels for SC.The color codingof themodels and the I(Q) andP(r) curves from
these is explained in Fig. 7. The experimental curves are in black. A ribbon trace of themodel used in each fit is
shown,with theoligosaccharides inblue. Theupper panels show thebest fitmodels, themiddle panels show the
models with compacted oligosaccharide conformations, and the bottom panels show representative poor
curve fits as examples of disallowed models. For the best-fit and poor-fit models for D1–D3 and D4–D5 see
supplemental Fig. S4.
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the structurally related seven Ig-like domains in carcinoem-
bryonic antigen and four FnIII domains in anosmin-1 (25,
34). In fact, the linker between D3 and D4 comprises 10
amino acids and is unusually long (Fig. 1). This length pro-
vides the requisite flexibility needed to form the J-shaped
conformation. It is noteworthy that the cleavage site
between Arg336 and Ser337 is exposed on the surface in all ten
best-fit structures (Fig. 9A), thus accounting for its suscep-
tibility to protease(s) and justifying the appearance of the
two D1–D3 and D4–D5 polypeptides. The Poisson-Boltz-
mann electrostatic maps of the carbohydrate-free surfaces in
D1–D3 and D4–D5 (Fig. 9C) suggest that there are spatially
well defined areas of negative and positive charges, respec-
tively, on these that can attract each other to form the bent
structure of SC. The short linker between D2–D3 may
reduce flexibility between D2 and D3, hence facilitating the
binding of D4 and D5 to these.
Themodeling showed that theC-terminal polypeptide linker
connecting SC with the transmembrane domain of the pIgR
exhibits no particular folding (Figs. 1 and 9). Hence D1–D5 of
SC can freely move with respect to this C-terminal linker, thus
enhancing their likelihood to encounter and interact with their
cargo represented by polymeric Ig present in the lamina pro-
pria. In a more physiological context, this length facilitates
access to proteases in order that SC or SIgA can be released at
mucosal surfaces. The unfolded nature of the linker also sug-
gests that the structure of SC identified in this work will be
similar to thatwhen incorporated in its pIgRprecursor, because
steric interference with components on the cell membrane will
be limited.
The seven Asn residues that constitute the attachment
points for carbohydrate residues mostly appear on the same
side of SC, implying that the glycans are clustered within a
restricted part of the SC structure (Fig. 9B). The curve fits
showed a preference for modeling the seven oligosaccharide
chains in conformations extending away from the protein sur-
face (middle panels of Fig. 8). Although their precise spatial
locations remain unassigned by constrained scattering model-
ing, a preferential distribution of oligosaccharides on one face
of SC is not ruled out. If this is so, this can contribute to tether
free and/or IgA-bound SC efficiently to antigenic structures
found at the surface of microorganisms (12).
In the context of the interaction between SC and pIgA, the
location of the oligosaccharides on one face of SC leave uncov-
ered, and thus accessible, the three CDR-like motifs present in
D1, as well as Cys502 in D5 (Fig. 9D). These constitute two
critical elements for the interaction with pIgA (35, 36). Indeed,
the oligosaccharides of SC are not involved in the interaction
with pIgA but are nonetheless important for its resistance to
proteases and its correct anchoring within the mucus laying on
the epithelium (7). Studies comparing deglycosylated and
partly glycosylated D1 revealed nearly equal binding affinities
for pIgA (17). Recovery of the Fd fragment after digestion of
pIgA with proteases from intestinal fluids indicates that the Fc
portion is particularly sensitive in the absence of bound SC (6).
The determined length of SC fits very well with its likely asso-
ciation with pIgA without affecting the F(ab)2 and the hinge
region. This is supported by the observation that pIgA and SIgA
of the same specificity show the same affinity for their cognate
antigen (37). Additionally, the labile link between D3 and D4 of
SC is likely to be concealed within pIgA, thus providing an
explanation for the mutual protection previously observed
between the two partners (6). This translates into the genera-
tion of a complex molecule optimally designed to operate at
mucosal surfaces.
Although not covalent, the interaction between the C-termi-
nal part of the J chain in pIgA and SC is a critical step for
transport of the pIgR complex tomucosal surfaces (4). Pentam-
eric IgM and pIgA are both transported by pIgR, but it is known
that D1 can discriminate among Ig subclasses in favor of IgA
(35), and that D1–D2 and D1–D3 bind pIgA, but not mIgA nor
IgG (38), explaining the predominance of SIgA in secretions. As
far as pIgA is concerned, the integrity of D2 andD3 is necessary
for a covalent interaction to take place (28), yet without estab-
lishing close contact with the pIgA backbone (39, 28). This
argues in favor of the “zipper effect” model initiated by the
interaction of D1with one C chain of pIgA, progression to the
J chain, and establishment of the disulfide bond betweenCys311
of the C2 domain of IgA andCys502 of D5 (36). In the J-shaped
structure model, D1 remains appropriately exposed to initiate
this “zipper” binding interaction.
Several unsolved issues remain, such as the identification
of the residues in SC that are involved in the interactions
with the J chain and with the residues 402–410 of the C3
domain in the Fc fragment of pIgA (40). Likewise, even
though the CDR-like motifs of D1 have been extensively
described, their ligands on the pIgA molecule remain uni-
dentified. In this respect, based on electron micrographs of
human pIgA displaying a partly bent tail-to-tail arrangement
(41), one can envisage that the Fc domain spacing is suitable
for the binding of at least one SC molecule. Whether the
compact conformation of SC opens up upon binding to pIgA
is another issue. Moreover, structural differences between
human IgA1 and IgA2 exist (22, 23) that are consistent with
recent findings showing distinct bindingmodes of human SC
to pIgA1 and pIgA2 (42). Future experiments aimed at
unraveling the contribution of SC in terms of the architec-
ture of the whole SIgA molecule are now being planned.
Knowledge of the three-dimensional structure of SC repre-
sents a mandatory first step toward the resolution of the
complete structure of SIgA. If we assume that the model of
SC is not that different from the extracellular portion of
pIgR, it might also be helpful per se to map binding site(s) to
FIGURE 9. Best-fit models for SC. The domains D1–D5 are colored from blue (N terminus) to red (C terminus). A, the ten best-fitmodels I to X are shown with
D1–D3 in the sameorientation.Model I is thebest-fitmodel fromFig. 8A.B, stereo viewof thebest-fitmodel of Fig. 8A. Oligosaccharideshere and inD are shown
in light blue.C, electrostatic viewsof the continuousprotein surfaces seen in theD1–D3andD4–D5models. Thenumbering corresponds to theoligosaccharide
chains (Fig. 1B). Red, acidic; blue, basic.D, the best-fit model of Fig. 8A is rotated by 180° to show the CDR I, II, and III peptides in D1 (in pink) and Cys502 in D5 (in
yellow).
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permit epithelial drug targeting through specific interaction
with pIgR itself (43, 44, 45).
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